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QUILL ON SCALPEL
This section provides a medium through which Canadian
surgeons can declare themselves, briefly and informally, on
the day-to-day affairs of surgery.

Percutaneous Transluminal Angioplasty:
Under- or Overused?
In 1964, Dotter and Judkins1 reported a
novel approach to the treatment of arterio
sclerotic lesions of peripheral arteries.
Arterial stenosis or occlusion was dilated
percutaneously using a series of coaxial
catheters. In 1968, Dotter and col
leagues2 reported their experience with
this technique in 155 patients. The suc
cess rate was 80% in patients with focal
stenosis of the femoropopliteal system but
only 29% in patients who had complete
ly occluded segments. In 1969,3 we re
ported our experience of percutaneous
transluminal dilatation in 15 patients with
segmental stenoses of the femoral or
popliteal arteries, using Dotter’s tech
nique, with early success in 14 patients.
In spite of these encouraging results, the
procedure did not gain widespread accep
tance because of its limited application.
It was not until Griintzig and Hopff4
developed the double-lumen catheter that
the principle of percutaneous translumi
nal dilatation was accepted. Now the
technique is widely used. Although there
have been numerous reports on the proce
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dure, its role in the management of
patients with peripheral vascular disease
has not been clearly defined.
In the March 1985 issue of this Jour
nal (pages 150 to 152), Jones and her col
leagues reported on their results of trans
luminal angioplasty in a high-risk
population — those with either rest pain,
pregangrene or gangrene. Presumably,
such a group, without any intervention,
would require amputation in a relatively
short time. Of their 85 patients, techni
cal failure occurred in 16. Of the remain
ing 69, symptomatic improvement was
obtained in 40 patients. Nine patients
required repeat dilatation from 2 to 51
months after the initial procedure; in five
of them, the repeat procedure was unsuc
cessful. Consequently, of the 85 patients,
only 35 (41 %) had a successful result for
even a short period. The authors’ cri
terion for success, namely avoiding sur
gery, does not appear to be appropriate,
since seven of the patients in whom
angioplasty was a technical failure main
tained their limbs without surgery. One
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Instructions to Contributors

can only postulate how a similar group
of high-risk patients operated on by
experienced vascular surgeons, using local
or regional anesthesia and both anatomic
and extra-anatomic techniques, would
have fared.
In our vascular unit we have learned,
as have others, that patients with iliac
lesions have higher success rates with
transluminal dilatation than do patients
with femoral or popliteal lesions; that
patients who have stenoses have a higher
success rate than do patients with com 
plete occlusions; and that the shorter the
segment to be dilated and the better the
distal runoff, the better is the result.
Since patients who have advanced
ischemia generally have multiple levels
of disease with poor runoff, in our ex
perience such patients are not generally
candidates for transluminal dilatation. In
our unit, most patients who have limbthreatening ischemia have been managed
surgically rather than by angioplasty.
However, in some patients transluminal
dilatation of a proximal stenosis has been
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combined with distal revascularization.
The best results with transluminal dilata
tion have been in patients with intermit
tent claudication.
The advantages of transluminal dilata
tion are that the cost is low and when per
formed by an expert it is associated with
low morbidity and mortality. In the care
fully selected patient the results can be
excellent. In the patient with advanced
disease a more favourable result may be
achieved with an appropriately selected
operative procedure performed under
local or regional anesthesia. There is no
doubt that transluminal dilatation is

underused in some centres and overused
in others. The right place for translumi
nal dilatation in the spectrum of therapeu
tic options for vascular disease remains
to be determined.
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W hat Should the Practising Surgeon Do With Precancerous
and High-Risk Breast Lesions?

Segmental mastectomy or local tumour
resection, with or without postoperative
radiotherapy, is becoming increasingly
accepted as an approach to stage I and
stage II cancers of the breast. The con
tributors to the symposium on precancer
ous and high-risk breast lesions, which
appears in this issue of the Journal (pages
242 to 267), recommend a more aggres
sive approach to these lesions than that
practised by many surgeons today. There
fore, I must ask myself whether I am
comfortable carrying out total breast
removal, either conventionally or sub
cutaneously, in order to avoid cancer.
Moreover, I must question whether any
of these precancerous entities, which are
so repeatedly referred to in the literature,
have ever been proven to develop into
invasive cancer.
Certainly there are high-risk lesions and
high-risk patients. The risks relate to the
epidemiologic, historical and clinical
characteristics and to the microscopic
interpretation of biopsied material. These
factors must be considered when the deci
sion is made, first, whether to biopsy and,
second, whether to repeat the biopsy, fol
low up conservatively or recommend fur
ther surgery.
At one extreme is the case of an obese
woman who has never experienced a fullterm pregnancy; she has a 40-year-old sisPresented as part o f a symposium on
precancerous and high-risk lesions o f the
breast by the Royal College o f Physicians
and Surgeons o f Canada, in cooperation
with the Canadian Association o f General
Surgeons, the Canadian Oncology Society
and the Canadian Society o f Plastic Sur
geons, Montreal, PQ, Sept. 11, 1984
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ter with breast cancer and now, because
a precancerous breast condition is diag
nosed, total mastectomy is recommended.
Whether the same recommendation
would be made if the only clinical highrisk factor was diffuse mammographic
change is questionable and would seldom
be a determining factor in my judgement.
The confusion is further promoted by
what I like to call the pathologic indeci
siveness of the multiple diagnoses offered
on biopsy material. Seven different
categories of breast lesions are noted by
the symposium panelists. What is the cli
nician to understand when he hears the
words carcinoma in situ, intraductal car
cinoma, noninvasive ductal carcinoma,
diffuse atypical hyperplasia, papilloma
tosis, adenomatosis, sclerosing adenosis,
lobular dysplasia, lobular carcinoma in
situ or diffuse cystic hyperplasia with
atypism? These confusing interpretations
of biopsy specimens may not mean the
same to pathologists and to clinicians.
I do not recommend, in the under
standing, intelligent patient who can be
followed up regularly, that, based upon
the above diagnoses alone, she have
prophylactic removal of her breast.
However, some recommendation for
management must be made. The patient
must understand that there is no cook
book answer to this dilemma and if she
is not willing to assist us in finding the
answer by being followed up conserva
tively, then she should be encouraged to
undergo definitive surgery. While con
troversy exists as to what is, or is not, a
precancerous condition of the breast, the
patient must be aware of this dilemma

and assume some of the decision-making
responsibility for her management.
Subcutaneous mastectomy should not
be used to treat infiltrating breast cancer.
Selectively, it may have a role in the
management of severely atypical lesions
as determined by clinical, mammographic
or microscopic interpretation. Unfor
tunately, the usual subcutaneous mastec
tomy leaves a “ padded” layer of sub
cutaneous tissue beneath the skin,
particularly beneath the nipple, which
contains isolated glandular and ductal ele
ments of the breast. Whether 5%, 10%
or 15% is left after subcutaneous mastec
tomy, there still remains a risk of cancer,
for that portion of remaining breast is at
the same risk as was the entire breast. The
more breast tissue removed, the less likely
the patient is to get cancer, but also the
less likely one is to achieve a satisfactory
cosmetic result. With the placement of the
implants beneath the pectoralis muscle,
the plastic surgeon can often do what he
calls a total mastectomy, leaving only a
small amount of glandular tissue beneath
the nipple-areolar complex, but breast tis
sue is left unless, possibly, the nipple
is transplanted. Under those circum
stances, in order for the transplanted
nipple to remain viable, essentially a full
thickness or sometimes a split-thickness
graft remains after debridement of all the
tissue beneath the areola and the nipple.
It has been my experience, however, that
few patients are satisfied with the cos
metic results of subcutaneous mastectomy
or immediate implant after what I call a
99% breast removal, leaving skin and nip
ple intact. I recommend that if removal
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of breast tissue is indicated because of
cancer or the high risk of cancer, then the
breast tissue should be removed in its
entirety and reconstruction undertaken
immediately, or after a suitable interval.
I find that cosmetic success is achieved
more readily if the reconstruction is
undertaken 6 to 10 weeks after breast
removal. There are, of course, exceptions.
When the patient and her husband
express strong interests in preserving the
original breast, skin, nipple and contour,
we will agree to subcutaneous mastec
tomy with multiple biopsies being care
fully analysed, especially in those cases in
which the breast is diffusely nodular, virginally firm or difficult to evaluate.
When such prophylaxis is decided
upon, there is the controversy over how
the opposite breast should be handled.
Both glands have the same embryologic
origin and should therefore carry the
same risk of tumour development. The
opposite breast is not considered for sur
gery unless it is biopsied for diagnostic
reasons based upon the pathological find
ings in the affected breast. If total mastec
tomy is decided upon for the premalignant lesion, then the opposite breast
should presumably be left intact except
for biopsy. Further intervention would be
indicated by the biopsy findings. Cos
metic symmetry is difficult to obtain and
as long as the contralateral breast remains
clinically normal or minimally abnormal,
it should be preserved.
Only with tim e, careful patient
monitoring by cooperative group studies
and appropriate interpretation and
follow-up of the many pathologic entities
will we know what to do with the breast
containing “ precancerous” lesions. The
intelligent, cooperative, understanding
patient should be offered conservative
treatment with regular follow-up and
repeat biopsies at regular intervals. The
biopsy can be done by needle, trocar or
open technique. Semiannual low-dose
mammography might be helpful. It is
essential that these patients become
meticulous self-breast examiners and with
the help of their husbands carry out a
conscientious weekly breast examination.
I recognize that cancer of the breast
remains one of the more frequent causes
of death in women. In spite of this, it is
difficult to recommend aggressive surgery
for a disease that has yet to be proven to
be truly a precursor of cancer.
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Human Bite Injuries
of the Hand

and, in the long run, a saving of health
care resources.
G. A lla n T a y l o r ,

To the editors.—My experience with
human bite injuries of the hand at the
Ottawa Civic Hospital over the past few
years prompts me to respond to Dr. Bite’s
article (Can J Surg 1984; 27: 616-8).
Through this experience we have
adopted a policy whereby all these inju
ries are referred to the plastic surgery
service, whether the patient presents early
or late after injury. All bites that have
penetrated the full thickness of the dermis
are extended and explored under local
anesthesia to determine, as early as pos
sible, whether or not the integrity of the
underlying joint or tendon has been vio
lated. Leaving the wound open and
prescribing antibiotics orally is simply not
adequate treatment in our experience. All
patients with open joints who present with
cellulitis or suppuration should, in our
view, be admitted to hospital for paren
teral administration of antibiotics. It is
essential that the integrity of underlying
joint and tendon be established as early
as possible and this can only be done by
exploring and visualizing the structures.
Dr. Bite makes no mention of this as a
policy although he does allude to the need
for copious irrigation of wounds. Treat
ing patients with active infection expec
tantly as outpatients and giving antibiotics
orally has almost always resulted in
advanced complicated infections with
severe morbidity and permanent disabil
ity of the involved hand. To rely on clin
ical evidence of septic arthritis will
inevitably give a false sense of security to
the surgeons dealing with these injuries.
The time to establish joint integrity is as
soon after injury as possible and before
active septic arthritis supervenes.
I would, therefore, make a plea to all
surgeons involved in the management of
human bites to adopt this more aggres
sive approach in the interests of superior
results, lower morbidity and disability,

m d , frcsc

Chief, Division of Plastic Surgery,
Ottawa Civic Hospital,
Ottawa, Ont.
K1Y 4E9

To the editors.—Dr. Taylor raises some
important points about the management
of human bite injuries of the hand. I cer
tainly agree with him that the wound
should be examined under local anesthe
sia at the time of initial assessment when
irrigating it. If penetration of the joint
capsule or tendon sheath is discovered,
more aggressive management with parenterally administered antibiotics, hospital
admission and possibly formal operative
exploration is warranted. However, in the
absence of such findings, when the clini
cal findings are minimal and the patient
is seen within 24 hours of injury, I dis
agree with Dr. Taylor. Statistical analy
sis of my results showed no significant
difference in outcome (as measured by
duration of hospitalization, duration of
outpatient follow-up required and com
plication rate) between patients seen
within 24 hours of injury, those assessed
from 1 to 7 days following injury and
those initially seen more than 7 days fol
lowing injury. Furthermore, Malinowski
and colleagues1 prospectively studied 265
patients with human bite injuries o f the
hand and concluded that there was no
difference in outcome and complication
rates between 131 hospitalized patients
treated parenterally with antibiotics and
134 similar patients treated as outpatients
and given antibiotics orally. All had
minimal clinical findings at the time of
initial assessment and, in fact, the highest
complication rate (4.7%) occurred in the
hospitalized group. Thus, if all patients
with human bite injuries were admitted
to hospital, at least 50% would be admit
ted unnecessarily. I stress that I only

recommend outpatient management for
those patients with minimal clinical find
ings (no septic arthritis, no purulent
drainage and no cellulitis) who are seen
within 24 hours of injury. If such a course
of management is adopted, the patient
should be re-examined within 24 hours,
preferably by the same physician. To
admit all such patients to hospital is
unjustified and an unnecessary expense
on the basis of the available data.
U ld is B it e , m d , fr csc
Apt. C20,
2015 - 41st Street NW,
Rochester, MN 55901
USA
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Head Injuries
To the editors.—I read with great interest
the excellent article “ Head injuries: a
prospective, computerized study” , by
Parkinson, Stephenson and Phillips (Can
J Surg 1985; 28: 79-83). The article is full
of valuable information that will make it
widely read and cited. Nevertheless, the
authors make two controversial state
ments that can likely be buttressed by
information collected in their study but
which are made without reference to sup
porting data.
The first deals with the effect of “ inten
sive” therapy that includes “ intracranial
pressure monitoring, paralysis, ventila
tion and barbiturates” . When compared
with that of patients treated by simply
“ maintaining an airway and giving man
nitol, based on clinical indications...,
patients treated more intensively... did
less well as a group than might have been
expected” , the authors claim. One may
surmise that among the 323 patients
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reported to have had cerebral contusion
or intracranial hematomas, or both, there
might have been approximately 100
patients who had raised intracranial pres
sure, as intracranial hypertension may be
expected to develop in roughly one third
o f patients with severe head injuries.1
One hundred patients carefully studied
would suffice to support or refute the
contention that “ intensive” therapy is not
effective. I should like to know how many
patients were monitored, whether the
patients who died did so because o f
intractable intracranial hypertension,
whether the intensive and the nonintensive groups were comparable with respect
to coma scale, associated injuries, and so
on. It is well known that random assign
ment, even when formally done, may
produce groups with significant differ
ences in important features that make
comparisons more difficult.
The second concept that I consider con
troversial is the implication that with “ no
history of a lucid interval” patients “were
unlikely to have been saved had they
arrived in hospital earlier” . Dr. Parkin
son and his colleagues do not cite the arti

FUCIDIN for INTRAVENOUS INFUSION
Vial 1 - diethanolamine fusidate BPC dry powder 580 mg (equiv
alent to 500 mg sodium fusidate B.P.)

cle by Seelig and associates2 who
presented data suggesting that early treat
ment o f acute subdural hematomas was
more likely to produce a favourable out
come. At the very least, I should like to
know how many patients died before
arrival at the Health Sciences Centre in
Winnipeg and, of those, how many were
hospitalized at smaller hospitals before
they were transferred.

M ichael Schwartz, md , m sc , frcsc
Department of Neurosurgery,
Sunnybrook Medical Centre,
2075 Bayview Ave.,
Toronto, Ont.
M4N 3M5
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118.

Patients with major injury o f the liver associated with hemorrhage

(A)

frequently require hepatic lobectomy

(B)

require T-tube drainage o f the biliary tract

(C)

can usually be managed by local hemostasis and
debridement

(D)

rarely die with current management techniques

(E)

often require ligation o f the hepatic artery for control of
bleeding
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What's new in surgery is the subject of this column. The short items are designed to let readers know
who's doing what and why. Surgeons are interested in what other surgeons are doing in
research, education, practice and administration. Surgery is a vibrant specialty, and, as
its practitioners, you must be the source as well as the readers of this column.

Portrait of the Canadian Surgeon: Not a Young Man
Compared with other specialists in Cana
da, surgeons and their colleagues in
anesthesia are an aging group — of
men — according to statistics emerging
from the Canadian Medical Association’s
data bank on practising physicians.
The figures show that almost 60% of
surgeons are older than 45 years and, in
the next 10 years, almost 30% will be 65
years of age or older. In fact, in the next
5 years, 20% will have reached or sur
passed the age of retirement. The category
“ surgery” encompasses cardiovascular,
thoracic, orthopedic, plastic and vascu
lar surgery as well as urology and neu
rosurgery.
The statistics are part of an extensive
report coauthored by Orvill Adams,
CMA’s Director of Economics, and
scheduled to appear in the Canadian
Medical Association Journal this month.
The report marks the first release of in
formation compiled from 41 599 replies
to a questionnaire sent out by the CMA
in 1982 to all physicians residing in Can
ada; 87.4% of them responded, indicat
ing that the figures accurately reflect the
medical profession in Canada.
According to the data, just over 9% of
Canada’s physicians are surgeons; 85%
work full-time and almost all the rest are
semiretired. Although women account for
about 14% of all physicians, they
represent only 1.8% of surgeons, possi
bly as much a reflection of the age distri
bution of surgeons as any other reason,
since women have only recently entered
the medical profession in large numbers.
The data leave no question about who
is practising surgery in Canada; the im
plications of what they portray are less
clear. Whether the rate of attrition cur
rently being experienced will put surgical
Contributions to this column are welcome.
Please send your material to: Mrs. Amy
Chouinard, Canadian Journal o f Surgery, PO
Box 8650, Ottawa, Ont. K1G 0G8.

services at a premium is particularly
nebulous because the data do not show
how much time surgeons now spend in
primary practice. What they do show is
how much time general practitioners
spend performing surgical interventions.
Of the 12 276 general practitioners who
stated that the word “ general” best
described their practices, 46.3% spend at
least 4 hours each week in the operating
room. Of the 2411 who noted that their
practice was not general, 3.1% catego
rized their work as general surgery.

Shortage of Surgeons Offset
by Oversupply of GPs
The Federal/Provincial Advisory Com
mittee on Health Manpower has forecast
a shortage of surgeons by the year 2000
but apparently expects general practition
ers and other medical specialists to meet
the demand for services. Not yet formal
ly released, that committee’s findings
were circulated internally in a preliminary
report last fall and recently attracted me
dia attention because it predicted an 18%
surplus of general practitioners and med
ical specialists.
The committee recognized the inade
quacy of its data but believed they were
sufficient to indicate overall trends
towards an oversupply. Allowing for
shortages in surgical and laboratory
specialties, the committee forecasts a to
tal surplus of 12%. The methods the com
mittee used to calculate future require
ments for physicians have been criticized,
since they were based primarily on
physician-to-population ratios and past
supplies.
“ The ratio is so crude... I prefer not
to use it,” commented Adams who went
on to explain that his department shies
away from the use of physician-to-popu
lation ratios mainly because they have
become the sole measure and “ they don’t
really show what you need to know. You

Adams: “ physician-to-population ratios
crude” .

need to know what resources you have in
an area and the population you are try
ing to serve. But you also need to know
what type of health system you are work
ing toward.” The big question is: What
does one compare the figures to? Com
paring them to those of the past assumes
that the system was perfect previously,
and comparing them to those in other
countries is probably even less useful.
Said Adams, “ It’s ridiculous to compare
physician-to-population ratios in Canada
with those in the US. The countries
deliver health care in a different way.”
Nevertheless, based on its figures, the
committee recommended measures to
avert the future oversupply of physicians
by curbing increments from every source.
It called for cutbacks in annual immigra
tion of physicians recruited to fill posi
tions for which no Canadian can be
found, in licences being given to foreigntrained graduates (including Canadian
citizens), in postgraduate training in
medicine and in medical school enrol
ment. The committee also recommended
that postgraduate training be rationalized
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to fill the ranks of specialties in which
shortages are perceived.
If implemented, the across-board
reductions will likely affect some
provinces more than others. In the past,
Saskatchewan and Newfoundland have
been particularly dependent on immigrant
physicians. For example, according to
Adams’s figures, more than half of sur
geons in the age group 55 to 65 years who
are practising in Saskatchewan received
their education outside Canada, and the
percentage for all surgeons in Saskatche
wan is 46%. The latter compares with
26% for surgeons country-wide and 28%
for all physicians. As might be expected,
the United Kingdom was the source of
almost half the surgeons aged 55 to 65
years and, together with India, account
ed for nearly half of all surgeons trained
outside Canada.
These figures suggest that, in the nottoo-distant future, surgeons will be scarce
in some areas of the country. Trends in
the popularity of different fields of medi
cine may be partly responsible for the cur
rent picture, although the number of sur
gical residents trained annually has not
changed much over the past 10 years.
According to data from the Royal Col
lege of Physicians and Surgeons of
Canada, an average 190 residents have
gained certification yearly for the past
decade in the specialties constituting the
surgical category referred to by the
federal/provincial committee.
Overall, fluctuations have been offset
from year to year, but the tendency has
been away from general surgery towards
greater specialization. In 1975, 94 general
surgeons gained certification, whereas the
figure for 1984 was 60, reflecting a rela
tively steady decline over the years. In
other words, the supply of surgeons is
likely dwindling, and the ones being
trained differ in focus and skills from
those trained in the past.

University, said the approach to patients
is “ microscopic and fractionated” , and
the effects on teaching and research have
probably been compounded by the efforts
of medical faculties to seek out renowned
experts in particular fields. The result is
an absence of generalists as role models
and an increase in the costs of care.
The high costs of subspecialization
came up again and again at the meeting,
with speakers focusing on the large sums
of money involved even in the develop
ment of an examination for certification
in a new specialty. The questionable costeffectiveness of a pulmonologist’s doing
general medicine 85% of the time was
raised as an example.
The consensus seemed to be that sub
specialization is inevitable as a response
to scientific advances in knowledge and
equipment, but that public needs should
be a major criterion in the creation of a
subspecialty.
No one argued that specialization was
not just a response but often a source of
technical and scientific advances. Univer
sity staff with narrowly specialized skills
often attract funds for research and de
velopment.

Two University-Affiliated
Centres Get Funds
for Research and Development
Both University Hospital, London,
Ont., and Sunnybrook Medical Centre,
Toronto, have recently announced invest
ments from nongovernment groups to
develop sophisticated techniques and
equipment. Scientists at University Hospi
tal will be collaborating with Biomedical
Instrumentation Inc. to produce a cardiac
mapping device that will simplify surgi

cal management of patients with heart
rhythm disorders. The computer-assisted
device will be used in the operating room
to identify the location of malfunctions
causing cardiac arrhythmias.
In Toronto, Sunnybrook Medical
Centre has obtained funds from a major
European foundation to develop a
biomechanical laboratory in which
biomaterials for bone surgery, joint
replacement and fracture fixation will
receive special atten tio n . Joseph
Schatzker, MD, FRCSC, who has
recently been appointed head of ortho
pedic surgery at the centre, will direct the
work, drawing on his expertise in joint
reconstruction and musculoskeletal
trauma.
Schatzker replaces Marvin Tile, MD,
FRCSC, who has been promoted to
deputy head of surgery at Sunnybrook
Medical Centre.

Other Appointments
and Honours
S.J. Peerless recently became the first
appointee to the C.G. Drake Professor
ship in Neurosurgery at the University of
Western Ontario; the position is for 5
years and was established to honour
Drake for his achievements in brain
surgery.
Clement McCulloch, MD, FRCSC,
was the 1985 recipient of the medical
achievement award, given out annually
since 1979 by the Canadian Association
of manufacturers of Medical Devices.
The award, presented at the association’s
annual general meeting on Apr. 15, 1985,
was recognition for McCulloch’s work in
ophthalmological research.
A my C houinard

Couture: “Strengthen
Broad-Based Specialties”
It is this change in the shape of speciali
zation that was the focus of discussions
in mid-March when the medical special
ties’ boards of the United States and
Canada met in Chicago.
Speaking to the group during a plenary
session of the day-long meeting, Royal
College President Jean G. Couture said
that the move towards increasing sub
specialization was taxing the resources of
the medical schools and undermining the
schools’ mission to produce well-rounded
physicians.
He noted that the number of operat
ing procedures done by general surgeons
has decreased and he called for a strength
ening of the broad-based specialties. Cou
ture, who is head of surgery at Laval
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Drs. Drake (left) and Peerless honoured at Western.
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Syme’s Amputation in Adults: a Long-Term Review
A retrospective study was undertaken in
two patient populations to establish the
failure rate of Syme's amputation. Failure
was defined as an amputation requiring
revision to a more proximal level. For
traumatic lesions of the foot the failure
rate was 29% and for dysvascular
lesions it was 41 %.
The long-term functional results in 55
patients who underwent Syme's amputa
tion for traumatic, dysvascular or conge
nital lesions were studied. Overall, 73%
had good function. The ideal Syme's
stump, where the fat pad is centred
securely over the distal tibia, was noted
in only 22% of patients. The authors
conclude that, in the past, technical
details may have been overemphasized,
because in this study the functional
results of Syme's amputation were more
dependent on prosthetic fitting. This
type of amputation is not recommended
for patients with dysvascular lesions
because of the high failure rate.
Une etude retrospective a ete faite au
sein de deux populations de patients
dans le but d'etablir le taux d'echec de
la technique d'amputation de Syme.
L'echec a et6 defini d'apres la necessite
de proceder a une revision a un niveau
plus proximal. Le pourcentage d'echec
fut de 29% dans les cas de lesions traumatiques du pied et de 41% pour les
problemes d'origine vasculaire.
On a etudie les resultats fonctionnels a
long terme de 55 amputations de Syme
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pour lesions traumatiques, dysvasculaires
ou congenitales. Dans I'ensemble, de
bons resultats ont ete obtenus dans
73% des cas. Le moignon ideal dans la
technique de Syme est obtenu quand le
tissu adipeux est bien centre autour de la
partie distale du tibia; un moignon ideal
n'a ete observe que chez 22% des
patients. Les auteurs concluent que,
dans le passe, les details techniques de
I'operation ont possiblement ete exageres puisque, dans cette etude, les resul
tats fonctionnels de I'amputation de
Syme ont ete davantage relies a I'ajustement de la prothese. Ce type d'amputa
tion n'est pas indique pour les patients
souffrant de lesions dysvasculaires, vu le
haut taux d'echec.

holing the skin and preventing migration
of the fat pad in the early postoperative
period. Emphasis on surgical technique
has been reported by others,1112 con
firming that the success of this procedure
depends on meticulous attention to tech
nical detail.
Over the years, dissatisfaction and the
revision rate have increased among
patients with traumatic amputations
attending the W orkers’ Compensation
Board Rehabilitation Centre of Ontario.
In this retrospective review, patients who
underwent Syme’s am putation for trau
matic and nontraumatic lesions were stu
died to establish the overall revision rate
and to evaluate long-term function.
Patients

The continuing role of Syme’s amputa
tion in treating traumatic injuries to the
foot, peripheral vascular disease, diabetes
mellitus, and congenital and neurologic
problems is still debated in the literature.
Despite its advantages, it has not gained
total acceptance or popularity since it was
first introduced by Syme' in 1843.
Many2'5 have found that long-term func
tion is satisfactory in most amputees,
except those in whom the amputation is
performed for peripheral vascular disease
and diabetes mellitus. In these circum
stances the high revision rate is unac
ceptable.6
The success of Syme’s amputation in
children is well documented.7'9 It has
unique end-bearing characteristics, it per
mits continued growth of the tibia so that
the patient may walk with or without a
prosthesis and the stump has proved
durable, enabling the patient to lead a
normal life.
Because of the study of H arris,10
Syme’s amputation has enjoyed consider
able popularity in North America.
Reviewing the history of the amputation
and the various modifications, he out
lined the importance of attention to tech
nical detail, which includes disarticulation
through the ankle, preserving the blood
supply to the flap, transecting the tibia
parallel to the floor and not perpendicu
lar to the tibial shaft, avoiding button

The medical records of 132 patients
attending The W orkers’ Compensation
Board Rehabilitation Centre in Toronto
and 56 patients attending Sunnybrook
Medical Centre who underwent Syme’s
amputation were reviewed. The factors
considered were the number of surgical
procedures performed before the defini
tive Syme’s amputation, the number of
amputations revised to a more proximal
level, the time of revision (early or late)
and the reason for revision. If the revi
sion was undertaken within 3 months of
amputation it was considered early, the
reafter it was regarded as late.
A total of 54 patients with 55 am puta
tions were personally reviewed (J.McE.).
These form the basis for much of this
report. Four were women, the remainder
were men. Of the 55 amputations, 35 were
for injury, 6 for congenital or neurologic
lesions and the remaining 14 were for
peripheral vascular disease and diabetes
mellitus. The average follow-up was 29
years (range from 1.5 to 65 years) for the
patients with trauma, 6.5 years (1.5 to 10
years) for the dysvascular patients and 31
years for those with congenital and neu
rologic lesions. The average age at follow
up was 56 years, patients with dysvascu
lar limbs being on average 8 years older.
One patient had a bilateral Syme’s
amputation. Eleven had contralateral
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amputations (7 below-knee, 1 GrittiStokes, 1 ray resection, 1 transmetatar
sal amputation and 1 toe resection). All
patients were assessed with regard to pain,
use of a prosthesis, size, shape, position
and mobility of the stump, employment
and overall function, including recrea
tional activities. The need for further sur
gical procedures was also recorded. We
used a modification of the Hornby and
Harris13 functional rating system. For a
good result, the patient had to be fully
employed at his original occupation or a
similar one, wearing a prosthesis full-time
with no restriction of social activities.
Minor stump pain, not necessitating regu
lar prosthetic adjustments, was tolerated
in this group. Change of occupation to
a more sedentary job, pain necessitating
regular prosthetic changes and restriction
of social and recreational activities were
considered a fair result only. Poor results
were those in which the patient com
plained of persistent pain and discomfort,
did not wear the prosthesis full time and
was unemployed or retired prematurely
as a direct result of the amputation.
Modifications in this rating system were
made for patients who had retired
because of old age.
The shape of the stump was described
as either conical, round, bulbous or flat.
The mobility of the stump was classified
using the criteria outlined by Murdoch,5
as follows: grade 1 — the heel pad was
securely fixed to the tibia; grade 2 — the
substance of the pad could be moved
from side to side without uncovering the
peripheral bone; grade 3 — the heel pad
could be displaced in all directions, leav
ing part of the peripheral bone unpro
tected; grade 4 — the heel pad was grossly
mobile and permanently displaced (Figs.
1 to 4). Bone irregularities of the lower
tibia were assessed by standard antero
posterior and lateral roentgenograms.
Results (Table I)

Dysvascular Group
All but 1 of the 14 patients in this group
wore a prosthesis full time. This includes
four patients with contralateral amputa
tions requiring prostheses. Only two
patients could weight bear at the end of
the stump. All but three patients had
retired, either because of old age or gene
ralized systemic disease.
Three patients could walk an unlimited
distance while the remainder were res
tricted by intermittent claudication.
Twelve of the 14 patients thought they
bore more weight at the knee.
Congenital Group

End weight bearing on the stump without
the prosthesis was possible in four
patients but not by the two who have
retired. None of the patients had an ideal
Syme’s stump, but all were functional.
Every patient was satisfied with the end
result. No further surgical procedures
were performed in this group.
Failure Rate
This was defined as the number of
Syme’s amputations requiring a revision
to a more proximal level. Of 132 trau
matic amputees, 38 (29%) amputations
were revised either to a standard belowknee or a long below-knee amputation.
Approximately 60% of the revisions were
performed for stump pain, the remainder
for prosthetic problems and stump infec
tion. The interval between the initial
amputation and revision ranged from 2
months to 61 years. In this group of
failures, the average number of operative
procedures before the elective Syme’s

Three patients suffered stump pain, but
it did not compromise their activity. All
six in this group had worked at some
stage, although two have now retired.

FIG. 3—Grade 3 mobility. Heel pad is dis
placed laterally, leaving medial side un
protected.
FIG. 1—Grade 1 mobility. Heel pad is
securely fixed to tibia.

Trauma Group
Twenty-two of the 35 patients com
plained of pain in the stump, but it was
severe in only 10. Eighty-two percent of
the amputees returned to their original
jobs, 31 % of them doing heavy labour
ing work such as underground mining.
Walking supports were used by eight
patients because of old age. Patients with
contralateral amputations tended to use
supports when walking long distances; 20
patients could walk an unlimited distance.
Only 17% of patients considered that they
were end weight bearing on the stump
while wearing the prosthesis; the re
mainder bore more weight proximally.
Further minor surgical procedures were
necessary in 17% of the patients in this
group. Technically, 22% of patients had
good stumps and 3% had poor stumps.
204

The remaining stumps, although func
tional in most cases, tended to migrate,
predominantly to the medial side of the
tibia. The major long-term complication,
as related by the patient, was migration
of the fat pad.

V_
_- j
FIG. 2—Grade 2 mobility. Substance of heel
pad can be moved anteriorly without uncover
ing peripheral bone.

FIG. 4—Grade 4 mobility. Heel pad is per
manently displaced anteromedially.
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operation was 5 (ranging from 2 to 14)
compared with an average of 3.3 proce
dures for the whole group of traumarelated amputations.
Of the 56 amputations for dysvascular
lesions, 23 (41%) were converted to a
higher level (20 below the knee, 2 above
the knee and 1 through the knee). All but
three were performed within 3 months of
the original procedure for infection and
wound breakdown. Of patients in this
group, 22 (40%) died within 6 months of
the revision; 12 of them had a two-stage
procedure carried out before failure
occurred.
Discussion
The failure rate of Syme’s amputation
in this series for both traumatic and dys
vascular lesions was high. Many of the
failures have been ascribed to poor sur
gical technique and patient selec
tion.2’10'12 It is understandable that infec
tion in the dysvascular limb predisposes
to failure, and the clinical diagnosis of tis
sue viability in this group is not reliable.
Because this study is retrospective, we
cannot comment on the condition of the
stump at the time of revision. We do
know from the clinical results that a tech
nically inferior Syme’s stump is compat
ible with good function when the prosthe
sis is modified. Because pain was the
major reason for revision in the traumatic
group, and because each patient had had
an average of five operations before their
elective Syme’s amputation, it is possible
that these patients fit into a special
chronic pain category, for example,
mania operativa.14 If one could identify
these difficult patients, it may be prudent
to proceed with an early elective ampu
tation in preference to multiple proce

dures to preserve a severely injured foot.
Good clinical results were recorded in
73% of the entire series of patients. Pain
was a predominant reason for poor func
tion. If modifications in the prosthesis
had not been made, it is possible that an
even greater number of patients would
have been in this category because of the
condition of their stumps.
The ideal Syme’s amputation accord
ing to the literature consists of securely
fixing the fat pad to the broadest area of
the cut end of the tibia — the cut end
being parallel to the floor and not perpen
dicular to the tibial shaft. Centrally posi
tioned fat pads on weight bearing were
recorded in only 22% of amputations in
the entire series; all gave good function.
Medial, lateral and posterior migration of
the fat pad predominated in the re
mainder but did not preclude a good
functional result. End weight bearing,
with or without the prosthesis, was pos
sible only in a minority of these patients,
suggesting that good prosthetic fitting was
probably the reason why these amputees
functioned so well.
Modern Syme’s amputation involves
disarticulation of the ankle joint com
bined with excision of both malleoli, as
a one- or two-stage procedure.15 The
articular cartilage is not removed and con
sequently because of the shape of the dis
tal tibia its surface is not parallel to the
ground in both the anteroposterior and
transverse planes. How securely the fat
pad can be centred over the cartilaginous
distal tibia is questionable. It appears to
us that both these modifications account
for the frequent migration of the fat pad.
In the presence of infection, two-stage
amputations have been advised.15'16 Of
the 17 such procedures performed for
infection in dysvascular limbs in this ser

Table I—Clinical Results of Syme's Amputation
Amputation group, no. of patients
Finding
Stump pain
Phantom pain
Prosthetic users (full time)
End weight bearing (without prosthesis)
Shape of stump
Bulbous
Round
Conical
Flat
Mobility of stump
Grade 1
2
3
4
Functional result
Good
Fair
Poor
*11 amputations.

Traumatic
(n - 35)

Dysvascular
(n - 14)

Congenital
(n -= 6)

22
24
35
18

8
11
13
2

3
3
6
4

30
3

10
2
2

4
1

-

2

-

-

1

7
16
11
1

5
4
4
1

0
2
3
1

24
6
5

10*
2
1

5
1
0

ies, only 5 were successful. This success
rate was considerably lower than in other
reported series. It has been our policy in
the past to try and preserve as much of
the foot as possible, and the elected site
of amputation was based on clinical
grounds only. We are now using the Dop
pler ischemic index15 in an effort to
evaluate the most suitable level for ampu
tation, and select suitable patients for
ankle disarticulation.
Undoubtedly, the best results for
Syme’s amputation were for the congen
ital lesions. These patients are younger,
well motivated and adapt to the prosthe
sis quickly. They do not regard their
amputation as a handicap and often par
ticipate in contact sports.
Conclusions
Our findings suggest that a functional
Syme’s amputation depends more o r
good prosthetic fitting than on meticulous
technical detail. Poor technique is inex
cusable, but we think too much empha
sis has been placed on technical imperfec
tions as the cause of failure.
In patients with dysvascular limbs,
Syme’s amputation cannot be recom
mended because of the high failure rate.
Better preoperative assessment may help
to predict the probability of success in
these patients. For traumatic lesions of
the foot, consideration should be given
to early elective Syme’s amputation in
preference to multiple procedures to
preserve it. The risk of a more proximal
amputation increases with the number of
foot procedures performed.
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Neuropathology of Chronic Pancreatitis in Humans
Various abnormalities of the pancreatic
ducts are recognized in chronic pancrea
titis.8 Painless pancreatitis occurs with
gross dilatation of the ducts, while severe
pain may accompany chronic pancreati
tis without dilatation. The severity of the
pain does not correlate with duct dilata
tion, strictures or obstruction.9-12
Bradley13 reported elevated pressures
in dilated ducts studied during surgery for
chronic pancreatitis. He suggested that
the pain correlated with increased
hydrostatic pressure. However, normal
pressures have been recorded in patients
with chronic pancreatitis with dilated
ducts, and manometric values in patients
with chronic pancreatitis equalled those
in normal patients.14’15 Pancreatic stimu
lation tests do not increase pancreatic
pain in many subjects with chronic pan
creatitis.16
Painful pancreatitis occurs without cal
cification in up to 50% of patients.
Ammann and colleagues17 described
decreased severity of pain with accom
panying increased calcification during
long-term follow-up of patients with
s ig n ifica tive . Le m om e n t de la prise
chronic pancreatitis. It is doubtful that
d 'a lc o o l a aussi m ontre une correlation
im p o rta n te avec le pourcentage des in fil
calcification alone causes pancreatic pain.
tra tio n s eosinophiles.
Sensory afferent fibres leaving the pan
P uisqu'on sa it que les eosinophiles
creas follow the sympathetic nerves,
so n t cy to to x iq u e s et lesent les tissu s par
which pass through the celiac ganglia and
une liberation d 'en zym e s co n se cutive a
splanchnic nerves. Celiac ganglionectomy
un processus de degranulation, les resuiand anesthetic nerve blocks abolish pan
ta ts de ce tte etude m o n tre n t que les
creatic pain.6’7 Apparently, neural com
eosinophiles perineuraux so n t susceptiponents are involved in transmitting pain
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the histopathology of chronic pancreati
tis, with particular reference to the neu
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To investigate the pathogenesis o f pain
in chronic pancreatitis, tissue resected
fro m 50 patients w ith th is c o n d itio n was
exam ined by lig h t m icro sco p y. An
exam iner, blinded to clinical and p a tho 
logical data, graded perineural fibrosis,
inflam m a tio n and the c o m p o sitio n o f
in fla m m a to ry in filtra te in 2 1 3 2 separate
perineural fields.
C orrelation o f perineural fib ro sis and
inflam m a tio n grading w ith alcohol inges
tio n and pain severity w as in sig nifica n t.
Pain se ve rity did correlate w ith th e tim 
ing o f alcohol co n su m p tio n . A lth o u g h
ca lcifica tio n s ig n ific a n tly a ffe cte d pain
se ve rity, the status o f d u c t d ila ta tio n
w as n o t significant.
Eosinophils w ere observed in d is
prop o rtion a te num bers in the perineural
in filtra te . The correlation o f percentage
eosinophilic in filtra te and pain severity
w a s highly significant. Tim ing o f alcohol
co nsum ption also correlated sig n ifica n tly
w ith the percentage eosinophilic
in filtra tio n .
A s eosinophils are k n o w n to be c y to 
to x ic and injurious to tissue by liberation
o f enzym es th rough d egranulation, the
fin d in g s o f this stu d y suggest th a t the
pain o f chronic p ancreatitis m ay be medi
ated by perineural eosinophils, th ro u g h a
ch e m o ta c tic m echanism in vo lvin g
alcohol.

A fin de rechercher la pathogenese de la
douleur dans la pan cre a tite chronique, on
a exam ine au m icroscope optique les tissus reseques de 50 p a tien ts a fflige s de
ce tte maladie. Ignorant des donnees cliniques et p athologiques, un e xam inateur
a evalue la fib ro se perineurale, I'in fla m m ation e t la co m p o sitio n de I'in filtra t
in flam m a to ire dans 2 1 3 2 cham ps perineuraux.
La co rre la tion entre la fibrose p e rin e u 
rale et I'in fla m m a tio n d 'u n e part, e t
I'in g e stio n d 'a lco o l et l'in te n site de la
d ouleur d 'a u tre part, s 'e s t averee sans
im po rta n ce. L 'in te n site de la douleur
s 'e s t m ontree to u te fo is reliee au m o m e n t
de la prise d 'a lco o l. Si la ca lcifica tio n
a va it une in flue n ce sig n ifica tive sur
l'in te n s ite de la douleur, le degre de la
d ila ta tio n du canal pancr£atique e ta it
sans im po rta n ce.
Des eosinophiles o n t ete observes
dans un nom bre d isp roportionne d 'in filtra ts perineuraux. La correlation e n tre le
pourcentage des in filtra ts eosinophiles e t
l'in te n s ite de la douleur e ta it h a u te m e n t

a single observer, blinded to clinical and
gross pathological data. In all, 2132
separate perineural fields were examined.
One perineural field was represented by
a x 150 magnification surrounding at
least one nerve fibril within the pancreatic
tissue (Fig. 1). Recordings were made of
the distribution and grading of fibrosis
and the distribution, grading and cell
composition of the inflammatory infil
trate and the findings were compared with
those of control tissue made of histori
cally normal pancreatic tissue and pan
creas obtained at autopsy from trauma
victims.
Gross pathologic data was previously
recorded for each patient, based on
preoperative radiologic examination,
operative examination and gross patho
logical examination. Documentation in
each case included tissue sample sites,
pancreatic duct status and the presence of
calcification. These data were withheld
from the histologic examiner.
Fibrosis was graded as follows: grade
1 — a minimal excess of loosely arranged
fibrous tissue in direct contact with the
perineurium; grade 2 — more densely
arranged fibrous tissue surrounding the
nerve fibril, usually associated with an
increased inflammatory component (Fig.
2); grade 3 — excessive perineural
proliferation of fibrous tissue, widely
separating the acinar lobules (Fig. 3).
The perineural inflammatory infiltrate
was graded according to the cellular den
sity of the inflammation: grade 1 —
minimal infiltration by occasional lym
phocytes and histiocytes in the perineu
ral region; grade 2 — moderate density
of cellular infiltration (Fig. 2); grade 3 —
marked infiltration of the perineural field
(Fig. 3); grade 4 — infiltration of the
entire perineural field.
Clinical information was previously
recorded for each patient. Pain was
graded according to outpatient records,
pharmaceutical prescription review and
inhospital records. Grading of pain was
tabulated as the mean number of 30-mg
codeine equivalents required every 24
hours. Alcohol intake was recorded from
the patient history, referring physician
history and history by family members.
Intake of alcohol greater than 50 g/d was
considered significant. The length of
abstinence before tissue sampling was
used to compute an alcohol grading score.
Total abstinence was graded 0, recent
alcohol intake was given a maximum
grade of 30. Grading between 30 and 0
depended on quantity consumed and
duration of abstinence before operation.
The score was biased towards the dura
tion of abstinence preoperatively, with
each month of abstinence lowering the
score by one point.
The status of the pancreatic duct was
compared to the mean grading of pain
severity and to the composition of the
208

inflammatory infiltrate using the paired
Student’s f-test. The presence or absence
of calcification was similarly compared.
Fibrosis grading and inflammatory infil
trate grading were compared separately
to grading of severity of pain by calcu
lating correlation coefficients; the signi
ficance of each r value was determined
from probability tables. Similarly, corre
lation coefficients were determined com
paring alcohol scoring with severity of
pain, composition of inflammatory infil
trate with severity of pain and composi
tion of infiltrate with alcohol scoring.
Where correlation coefficients were

found to be significant, a linear relation
ship was plotted by calculating the slope
and intercept values for the data under
consideration. The linear relationship was
illustrated graphically.
Findings

The histopathologic features were
equivalent in the same subject, regardless
of the sites from which the tissue samples
were obtained. Consistently, all histologic
examinations showed that the fibrosis and
inflammation were distributed in the
interlobular planes. There was minimal

FIG. 1—Photomicrograph of normal pancreas illustrating one perineural field around nerve
fibril (arrow) (hematoxylin and eosin, reduced by 29% from x 150).

FIG. 2—Perineural field illustrating grade 2 fibrosis (large arrow) and grade 2 inflamma
tion (small arrows) (hematoxylin and eosin, reduced by 32% from x 150).
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dilated ducts, the difference was not sig
nificant (mean 30-mg codeine equivalents
daily, 3.9 and 4.4, respectively, p > 0.2).
There was a significant correlation
(r = 0.34, p < 0.02) between alcohol
scores and the severity of pain. The linear
relation between these two features was
plotted (Fig. 4). Alcohol scores were well
distributed with 13 abstainers and 13 sub
jects consuming more than 50 g of alco
hol daily, within 6 months of operation.
Eleven subjects had painless pancreatitis,
while the remainder required from 2 to
20 codeine equivalents daily.
Calcification of the pancreas was noted
in the parenchyma and within ducts by
pancreatography, operative observation

intralobular fibrosis or inflammation
within preserved acinar tissue (Figs. 2 and
3). No inflammation or fibrosis was noted
around intralobular ducts. Fibrosis was
continuous in the interlobular plane, sur
rounding neural and vascular structures.
However, inflammatory infiltrate was
precisely restricted to perineural locations
(Fig. 3).
The pancreatic duct was considered to
be dilated when preoperative pancreato
graphy, operative pancreatography or
gross pathological examination revealed
a duct diameter greater than 1.0 cm.
When the mean grading of pain severity
was compared between 19 subjects with
dilated pancreatic ducts and 31 with non-
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or pathological examination. The mean
severity of pain was compared between
24 patients of the sample group of 50 who
did not have calcification (2.83 ± 3.4
[standard error] codeine equivalents) and
the remainder who had documented cal
cification of the gland (5.52 ± 4.0
codeine equivalents). The difference was
significant (p < 0.02).
Fibrosis was abnormal in all cases com
pared with controls. Fibrosis was graded
for each perineural field and was consis
tent throughout all samples for each case;
thus, median fibrosis grading could be
recorded for each subject. Grade 3 fibro
sis was recorded in the majority of exami
nations (64%), grade 1 in 8% and grade
2 in 28%. Correlation between grading of
fibrosis and mean grading of pain severity
was not significant (r = 0.123, p > 0.1).
As was observed with fibrosis, the
grading of the perineural inflammatory
infiltrate remained consistent in all sam
ples from the same patient. It was only
found around nerve fibrils in the inter
lobular plane; no infiltrate was noted in
the acinar or periductular tissues (Figs. 2,
3, 5 and 6).
The majority o f patients (76%) had
grade 2 inflammation (Table I). None of
the perineural fields examined showed
grade 4 inflam m ation. C orrelation
between the grading of inflammation and
the severity of pain was not significant
(r = 0.179, p > 0.1).
When the composition of the inflam
matory infiltrate was analysed for each

FIG. 3—Perineural field illustrating grade 3 inflammation restricted to perineural region
(arrows) and grade 3 fibrosis (hematoxylin and eosin, reduced by 32% from x 60).
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FIG. 4—Significant correlation (r = 0.34,
p < 0.02) between alcohol score and pain
severity.
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FIG. 5—Perineural infiltrates were composed of lymphocytes, histiocytes, occasional plasma
cells and neutrophils (hematoxylin and eosin, reduced by 32% from X 250).

Table I— Grading of Perineural
Inflammatory Infiltrate
% of samples
Description
Grade
10
Minimal
1
76
Moderate
2
14
Marked
3
0
Severe
4
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perineural field, the chronic infiltrate was
noted to be composed predominantly of
lymphocytes, histiocytes with occasional
plasma cells and neutrophils (Fig. 5). A
startling observation was the dispropor
tionate numbers of eosinophils present in
the perineural infiltrate (Fig. 6). This has
not been reported before. With higher
grades of inflammation, a correspond
ingly greater number of eosinophils was
observed. The presence of the eosinophils
bore no relation to the size of the nerve
fibril, or to the number of fibrils in each
perineural field. The eosinophils were dis
tributed close to the nerve fibril and on
several examinations the cells were noted
within the perineurium. Several scattered
observations were recorded, suggesting
degranulation of the eosinophils (Fig. 7).
For each subject, the eosinophilic com
ponent of the infiltrate was analysed in
two ways. Percentage eosinophilic con
centration documented the total number
of perineural fields with eosinophils com
pared with the total number of perineural
fields examined. The eosinophil density
was the total number of eosinophils per
total number of perineural fields with an
eosinophilic component. The density
number and the percentage eosinophilic
infiltration were similar for each subject;
the percentage eosinophilic infiltration
was the index chosen for analysis.
On analysis of the mean grading of
pain severity and percentage eosinophilic
infiltration, the correlation coefficient
was highly significant (r = 0.56, p <
0.001). The slope and intercept were cal
culated for the data and the linear rela
tion was illustrated graphically (Fig. 8).
Similarly, the relation between the alco
hol score and the percentage eosinophilic
infiltration was calculated. The correla
tion coefficient was again significant
(r = 0.44, p < 0.01) (Fig. 9).
The relation between the pancreatic
duct status and the eosinophilic compo
sition of the perineural infiltrate was ana
lysed by comparing percentage eosino
philic infiltration between the 19 patients
with dilated and 31 with nondilated ducts.
There was no significant difference (mean
eosinophilic infiltration 30% versus
43.2%, p > 0.1).
When the 26 subjects with pancreatic
calcification were compared with the 24
patients without, no significant difference
was noted in the mean percentage
eosinophilic infiltration (46.4% versus
31.6%, p > 0.1).

FIG. 6—Disproportionate numbers of eosinophils were observed in perineural infiltrate
(arrows) (hematoxylin and eosin, reduced by 32% from X 250).

FIG. 7—Degranulation of eosinophils (arrows) (hematoxylin and eosin, reduced by 32%
from x 500).

Discussion

Changes in pancreatic secretion and
ultrastructure due to long-term consump
tion of alcohol are well recognized. Vari
able patterns of duct dilatation and stric
ture have been described in chronic
alcoholic pancreatitis.810 Chronic fibros
ing pancreatitis does not always pro210

FIG. 8—Significant correlation (r = 0.56,
p < 0.001) between percentage eosinophilic
infiltration and pain severity.

FIG. 9—Significant correlation (r = 0.44,
p < 0.01) between alcohol score and percen
tage eosinophilic infiltration.
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duce duct dilatation. Noronha and co
workers18 have described progressive
perilobular fibrosis and variable acinar
atrophy in association with long-term
alcohol consumption. Calculus formation
in chronic calcific pancreatitis has been
extensively investigated by Sahel and
Sarles,19 since changes in pancreatic pro
tein secretion were identified in man and
experimental animals, following long
term alcohol intake. The recent identifi
cation of the pancreatic stone protein has
consolidated the theory that abnormal
pancreatic secretion leads to calculus for
mation in chronic calcific pancreati
tis.20'21 These morphologic and secretory
abnormalities are accepted sequelae of
long-term alcohol ingestion. Our study
confirmed universal interlobular fibrosis
in all specimens examined. However, it
failed to document any correlation of
pain severity with the grading of peri
neural fibrosis. Similarly, it did not
differentiate grading of pain based on
pancreatic duct dilatation or stricture.
Pancreatic calcification was present in
only half our cases. Although pain
increased substantially with calcific pan
creatitis, whether calcification alone can
produce pain is controversial. From our
study, it is important to recognize the lack
of significant difference in eosinophilic
composition of the perineural infiltrate
comparing calcific pancreatitis to noncalcific pancreatitis. This suggests that the
eosinophil is not responsible for increased
pain associated with calcification.
The specific perineural location of the
chronic inflammatory infiltrate observed
in all specimens has not been documented
previously. The chemotactic factors
responsible for this localization are
unknown. Grading of the inflammatory
infiltrate (cellular density) did not corre
late significantly with the grading of pain
severity. Discovery of the previously
unrecognized eosinophilic composition of
the infiltrate prompted a measurement of
percentage eosinophilic infiltration for
each perineural field. Correlation of
previously graded clinical features of pain
severity and alcohol score was found to
be significant (Fig. 4), as it was also
between the eosinophilic infiltrate and
pain severity. Moreover, the eosinophilic
infiltration correlated significantly with
the alcohol score, which was biased
towards the timing of recent alcohol con
sumption. There was no significant rela
tion between eosinophilic infiltration and
pancreatic duct morphology.
From analysis of our data, the
eosinophilic component of the perineural
infiltrate appears to be involved in the
pathogenesis of pain in chronic pancrea
titis.
Although the role of the eosinophil is
poorly understood, it is believed to have
a physiologic and pathologic role in col

lagen degradation.22 An eosinophilic
chemotactic factor has been identified
that will attract and enhance the action
o f the eosinophil.23 Its subsequent
cytotoxicity depends upon antibody bind
ing.24 The surface-binding proteins of
the eosinophil likely combine with the
im m unoglobulins.25 Cell and tissue
injury are mediated by eosinophilic
release of eosinophil cationic protein and
major basic protein. Recent investigations
have suggested that new proteins are
released from the eosinophil, with vary
ing enzyme action.26 Pertinent to this
study is a recent description of an
eosinophilic protein that is injurious to
nerve tissue, the eosinophil-derived neu
rotoxin.27
Although the main area of interest in
the cytotoxic action of the eosinophil con
cerns parasitology, spontaneous lung
parenchymal cell and collagen matrix
damage by eosinophils has recently been
reported.28 Our study may suggest that
chemotactic factors in the interlobular
spaces, specifically near nerve fibrils,
attract an eosinophil-rich inflammatory
infiltrate. It is also suggested by the sig
nificant clinical correlation that such a
mechanism is alcohol-related. Degranu
lation of the eosinophil (Fig. 7) results in
enzyme activation that may be responsi
ble for the nerve-mediated pain mechan
ism in chronic pancreatitis.
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Influence of Splenectomy on Lethal Effects
of Pneumococcal Infection
To determine whether the splenectomized host is more sensitive to the
toxic effects of pneumococcal infection
and whether the known clearance defect
accounts for the early, increased mortal
ity seen in postsplenectomy infection,
the authors studied 8-week-old C57B1
mice. They were divided into two
groups: seven control nonsplenectomized
mice and six splenectomized mice. All
animals were inoculated intravenously
with 103 colony forming units of Strep
tococcus pneumoniae. Microaliquots of
blood were drawn from the tail of all
mice into sterile, heparinized, capillary
tubes at 1, 4, 8 and 16 hours. Blood
bacteria were quantitated using a drop
dilution method. The time to death was
recorded. A form of survival analysis
using the Cox proportional hazards
model was performed on the data.
The infection was uniformly fatal. An
early decrease in the numbers of blood
bacteria was seen in nonsplenectomized
mice followed by a logarithmic linear
increase. In splenectomized mice, there
was early rapid bacterial growth greater
than that in control mice. Splenec
tomized mice died earlier than control
mice (p < 0.05 at 24 hours, Fisher's
exact test). The bacterial count had a
highly significant effect upon mortality
overall (p = 0.0017). A function
describing the risk of dying versus bac-

terial numbers was generated and was
the same for both groups.
The splenectomized host does not
appear to be more susceptible to the
toxic effects of pneumococcal infection.
Early mortality in bacteremic pneumococ
cal infection can be attributed to
impaired bacterial clearance alone.

cique. La mortality precoce rattachee a la
bacterie pneumococcique peut etre attri
bute au seul defaut de la clairance bac
terienne.

The syndrome of overwhelming post
splenectomy infection has been based
predominantly on case reports of severe
pneumococcal infections occurring in
Cette etude a ete realisee afin de verifier
splenectomized patients. The patients are
si le sujet splenectomise est davantage
often young and in apparent good health
sensible aux effets toxiques de I’infecwhen mild prodromes develop that
tion pneumococcique et si le defaut de
progress rapidly to severe illness and early
clairance que Ton connaTt, explique
death.' Features of the illness include
^augmentation de la mortality precoce
the Waterhouse-Friderichsen syndrome
post-splenectomie. Des souris C57B1
(bilateral adrenal hemorrhage), which has
agees de 8 semaines ont ete reparties en
frequently been described, often in associ
deux groupes, soit sept souris temoins
ation with disseminated intravascular
non splenectomisees et six souris sple
coagulation.2-4 These lesions have
nectomisees. Tous les animaux ont recu
usually been attributed to infections
par voie intraveineuse 103 unites for
caused by gram-negative endotoxinmant des colonies de Streptococcus
producing organisms such as menin
pneumoniae. Des micro-aliquotes de
gococci. Pneumococci are gram-positive
sang ont ete prelevees de la veine cau
organisms and by definition do not
date des souris a ('aide de tubes capilproduce endotoxin.
laires heparinSs steriles apres 1, 4, 8 et
Experimental studies have shown that
16 heures. La numeration des bact£ries
after splenectomy, bacterial clearance is
du sang a ete faite par la methode de la
impaired.5 We have hypothesized that,
dilution de la goutte. Le temps du deces
in addition to the known defect of bac
a ete enregistre. Une forme d'analyse de
terial clearance, the clearance of toxins or
survie reposant sur le modele des risques
bacterial degradation products may also
proportionnels de Cox a ete effectuee
be impaired. Theoretically, such a defect
sur les donnees.
could synergistically contribute to the
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bacteremic pneumococcal infections, it
may be possible to determine whether an
increased susceptibility to the lethal
effects of pneumococcal infection exists.
We have used a mouse model to examine
our hypothesis.
Methods
Bacteria
Streptococcus pneumoniae, type III,
smooth (ATCC), were maintained in
frozen liquid subculture containing 20%
glycerol. A vial was thawed and plated
onto blood agar overnight (at 37°C in 5%
carbon dioxide). Sidearm flasks contain
ing sterile Todd-Hewitt broth were inocu
lated with fresh colonies and incubated
in a standing rack. Growth was assessed
by following changes in optical density at
600 nm. Organisms were harvested in the
logarithmic growth phase and diluted in
Hanks’ balanced salt solution before
inoculating the animals. The inoculum
dose was confirmed by quantitative cul
ture. Optimal virulence was assured by
this technique as measured by the ability
of small inocula to cause death after
intraperitoneal injection as well by
microscopic examination using India-ink
counterstain, which demonstrated uni
form encapsulation and chain-length.
Mice
Age-matched 8-week-old C57B1 mice
were randomly assigned to two groups:
seven control nonsplenectomized and six
splenectomized mice. Splenectomies had
been performed 3 weeks before inocula
tion and the mice had regained the weight
lost postoperatively. All mice were inocu
lated intravenously with 1.6 x 103
colony forming units of S. pneumoniae.
At 1,4, 8 and 16 hours, microaliquots of
blood were drawn from the tail vein of
each mouse and placed into heparinized,
precalibrated, sterile, glass capillary
tubes. Serial dilutions in duplicate were

FIG. 1—Cumulative mortality versus time.
Dashed line = splenectomized animals, solid
line = nonsplenectomized animals. Difference
in mortality is statistically significant (p < 0.05
at 24 hours, using Fisher’s exact test).
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plated to quantitate blood bacterial num
bers accurately. The time to death was
noted for each animal.
Statistical Analysis
Statistical differences were measured by
Fisher’s exact test for overall survival at
24 hours and Cox’s proportional hazards
regression analysis. The hazard function,
the probability of dying at a certain time,
conditional upon survival until that time,
was first calculated using bacterial count
as a covariate.

of the splenectomized group, we added
the group factor to the model containing
the bacterial count factor. The effect of
this was insignificant, indicating that
nothing other than bacterial clearance
appears to distinguish between the groups
with respect to mortality. Moreover, there
was no significant interaction between
group and bacterial count, suggesting that
the bacterial count affects the mortality
of control and splenectomized animals in
a similar fashion. Differences in bacterial
clearance rates are sufficient to account
for the difference in blood bacterial num-

Results
By 24 hours, all splenectomized mice
were dead, but only 29% of the non
splenectomized mice (Fig. 1). This differ
ence is statistically significant, p < 0.05
by Fisher’s exact test.
When the course of infection in
individual animals is correlated with the
time to death (Fig. 2), the slope is steeper
for splenectomized than for nonsplenec
tomized mice. The spectrum of bacterial
clearance can be seen, showing that the
earlier times of death in splenectomized
mice correlate with the slopes of the bac
terial counts.
The survival characteristics of the two
groups were examined using Cox’s
proportional hazards model of regression
analysis. The bacterial count had a highly
significant effect upon the probability of
death overall (p = 0.0017). When
attempting to verify whether a factor
other than the bacterial clearance defect
could contribute to the earlier mortality

FIG. 3—Risk of death versus bacterial num
ber. Using information from Fig. 2, risk of
death was calculated for both groups, using
Cox’s proportional hazards model for survival
analysis. Comparison of curves revealed no sig
nificant difference. Result of combined anal
ysis is shown and demonstrates no inherent
difference in risk of death, based on blood bac
terial numbers between nonsplenectomized and
splenectomized animals.

FIG. 2—Numbers of bacteria in fatal bacteremic infection and corresponding times to
death. Logarithmic bacterial numbers (cfu/mL of blood, assay limit [ ^ ] 7.53) have been plotted
versus time (h). Arrow on ordinate indicates initial bacterial inoculum corrected for circulating
mouse blood volume. Each line represents single animal: dotted lines = splenectomized mice,
solid lines = nonsplenectomized mice. Also included are approximate times to death (t), grou
ped according to whether animal was dead by less than or equal to 16, 24, 36 or 48 hours after
inoculation. TNC = too numerous to count.
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bers with time seen between the two
groups. The risk of dying, plotted against
bacterial numbers (Fig. 3), gave a curve
that climbed exponentially and was iden
tical for nonsplenectomized and splenectomized animals. This suggests that no
inherent difference in susceptibility to the
lethal effects of pneumococcal infection
exists after splenectomy.
Discussion
That exotoxins and bacterial degrada
tion products must play a role in the
pathophysiology of pneumococcal infec
tion seems certain but remains unproven.
The pathophysiology of pneumococcal
infection, especially those events leading
to the death of the host, are poorly under
stood.6 It has been shown clinically that
death from pneumococcal infection can
still occur after sterility has been achieved
through the use of appropriate antibi
otics. This fact has been attributed to cir
culating pneumococcal polysaccharide.3
Acute anemia has been reported infre
quently,3,7 and it is not known whether
this is due to elaboration of the hemolytic
toxin, pneumolysin, or is related to some
thing else.

In this study, fatally infected splenectomized mice died earlier and demon
strated a more rapid increase in numbers
of bacteria than fatally infected non
splenectomized animals. The risk of dying
was determined solely by bacterial num
ber and the calculated curve of relative
risk for death was the same for both
groups. This indicates that the fatal bac
terial load was similar for both.
It is of interest that the introduction of
antibiotics has not been shown to have a
significant effect on early mortality from
bacteremic pneumococcal infection.8
Mortality remains high from pneumococ
cal infections in both the predisposed and
the unpredisposed host. In a recent Cana
dian study,9 there was a 41% mortality
in adult patients without pre-existing
underlying conditions and 43% in
patients with known predisposing factors
such as splenectomy. Our experimental
findings are in keeping with these clini
cal observations since they suggest that
outcome in the presence of an established
infection is based on bacterial number
and not on the presence or absence of
splenectomy.
We conclude that the splenectomized
host is not more susceptible to the lethal

effects of pneumococcal infection. It
seems, at least in the context of these
experiments, that early mortality can be
attributed to impaired pneumococcal
clearance alone.
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Reliability of the Total Lymphocyte Count
as a Parameter of Nutrition
To evaluate the total lymphocyte count
as a means of nutritional assessment,
body composition studies (a proven
method of nutritional assessment) and
total lymphocyte determinations were
performed simultaneously in 153
patients. The total lymphocyte count
correlated poorly with both the body cell
mass and the nutritional state measured
by the Nae to Ke ratio. For diagnosing
malnutrition, the total lymphocyte count
had a false-positive rate of 34% and a
false-negative rate of 50% . In a group of
78 patients who received total parenteral
nutrition for 2 weeks, the total lympho
cyte count did not accurately reflect the
nutritional changes. Due to its poor sen
sitivity and specificity, the total lympho
cyte count is of no value as a measure
of the nutritional state.

de faux negatifs. Chez un groupe de 78
patients qui ont recu une alimentation
parenterale totale pendant 2 semaines, la
numeration lymphocytaire totale n'a pas
bien reflete les changements nutritionnels. Vu sa faible sensibilite et sa mauvaise specificite, la numeration
lymphocytaire totale n'a aucune valeur
comme mesure de I'etat nutritionnel.

Presented at the 7th annual meeting o f the
Canadian Association o f General Surgeons,
Montreal, PQ, Sept. 11, 1984, held in con
junction with the 53rd annual meeting o f
the Royal College o f Physicians and Sur
geons o f Canada

An accurate assessment of a patient’s
nutritional status is important in both the
application and evaluation of nutritional
support. The association between mal
nutrition and an altered immune system
is supported by a number of population
surveys.1,2 As a result, various parame
ters of the immune system have been
employed as measures of nutrition in the
hospitalized patient. One such application
has been skin testing with recall antigens.
This immune test has been used widely for
nutritional assessment. We have recently
reviewed this parameter and found that
although the results of skin testing cor
related well with malnutrition, the meth
od did not have the sensitivity to meas
ure the nutritional state of the individual
patient.3
The total lymphocyte count has also
been used clinically for nutritional assess
ment of the individual patient. This was
based on earlier studies, showing that
malnutrition caused a decrease in the total
lymphocyte count and that nutritional
support returned the count to normal.4
Recent studies have not shown that the
association between the nutritional state
and the lymphocyte count is absolute.5,6
Despite this, the lymphocyte count is still
widely used and recommended for nutri
tional assessment in hospitalized pa
tients.7 This study was undertaken to
determine the validity of using the total
lymphocyte count as a measure of
nutrition.

Accepted fo r publication Dec. 27, 1984

Patients and Methods
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S6.24, Department o f Surgery, Royal
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Montreal, P Q H 3A 1A1

On 313 separate occasions, data were
collected from 153 patients (64 men, 89
women, mean age 53.9 ± 0.9 years),

Afin d'evaluer I'interet de la numeration
lymphocytaire totale comme moyen
d'etablir I'etat nutritionnel des patients,
les auteurs ont pratique simultanement
chez 153 d'entre-eux une etude de la
composition corporelle (une methode
eprouvee pour etablir I'etat nutritionnel)
et une numeration lymphocytaire totale.
Une faible correlation a ete observee
entre la numeration lymphocytaire totale
et la masse cellulaire corporelle, de
meme qu'avec I'etat nutritionnel mesure
par le rapport Nae/Ke. Dans le diagnostic
de la malnutrition, la numeration
lymphocytaire totale a eu un taux de
faux resultats positifs de 34% , et 50%

From the Department o f Surgery, Royal
Victoria Hospital and McGill University,
Montreal, PQ
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most of whom were malnourished. The
measurements were made before and dur
ing a course of total parenteral nutrition.
Measurements were also made on a group
of morbidly obese patients at varying
intervals following weight-reduction sur
gery. The nutritional state of these
patients was determined by measuring the
various components of body composi
tion. A multiple-isotope dilution tech
nique was used to determine the body
composition.8 The patients were injected
with 500 pC\ of tritiated water and 8 pCi
of sodium 22. Blood samples were drawn
before and at 4 and 24 hours after injec
tion. Plasma tritium concentration at 24
hours corrected for urine loss was used
to calculate the total body water (TBW).
The plasma 22Na activity, also corrected
for urine loss, was used to calculate the
exchangeable sodium (Nae). An indirect
method was used to calculate the total
exchangeable potassium (Ke),8 according
to the following equation: Ke =
R(TBW) - Nae, where R is the ratio of
the sum of sodium and potassium divided
by the water content, as measured in an
aliquot of whole blood.8 This technique
has been established experimentally in
both animals and man.8 To correct for
body size, these data are expressed as a
function of total body water, which is
more accurate than body weight, since it
is linearly related to the lean body mass
and the resulting measurement is thus
independent of the degree of adiposity.
Additional measurements of body com
position were obtained by the following
calculations: LBM = TBW/0.73, BF =
body weight - LBM, BCM = 0.00833
Ke and ECM = LBM - BCM, where
LBM = lean body mass, BF = body fat,
BCM = body cell mass and ECM =
extracellular mass.
The total lymphocyte counts were
determined either by manual counting of
a Wright’s smear or automated counting
with a Coulter counter. The lymphocyte
count was correlated with the nutritional
state, as measured by the body composi
tion parameters, by a standard linear
regression.9 All means are listed with the
standard error of the mean. Differences
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R esults

The total lymphocyte count was cor
related with the body cell mass (Fig. 1).
The body cell mass is represented by the
total exchangeable potassium divided by
total body water to normalize for body

FIG. 1—Correlation between lymphocyte
count and body cell mass (i.e., total exchange
able potassium/total body water [Ke/TBW ]),
313 measurements. Correlation was significant
(p < 0.01, r = 0.12); 95% confidence limits
for correlation are included.

size (Ke/TBW) which in 25 normal
volunteers was 80.0 ± 1 . 0 mmol/L with
95% confidence limits of 69.9 to 90.1
mmol/L.2 The study patients had a
mean Ke/TBW of 64.4 ± 0.7 mmol/L
(ranging from 39.0 to 89.8 mmol/L),
indicating that a large proportion had a
depleted body cell mass. The total lym
phocyte count was 1.807 ± 0.66 X
109/L (normal range in our laboratory
1.5 to 3.0 x 109/L). The regression was
significant (p < 0.05), but the regression
coefficient of r = 0.12 was poor.
Moreover, the data were very scattered,
resulting in wide 95% confidence limits.
Consequently, for a normal Ke/TBW of
80.0 mmol/L, regression indicated a lym
phocyte count of from 0, abnormally low,
to 4.26 x 109/L, abnormally high. In
Fig. 2, the lymphocyte count is correlated
with the Nae to Ke ratio. In malnutrition,
the extracellular mass expands as the body
cell mass is depleted. Consequently, the
Nae to Ke ratio is a sensitive index of the
nutritional state. In the 25 healthy volun
teers, the mean ratio was 0.98 ± 0.02,
with 95% confidence limits of 0.74 ±
200
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between the two sets of measurements,
which were made twice in the same
patient at different times, were analysed
by the paired Student’s /-test. A p value
of less than 0.05 indicated a significant
difference.

FIG. 2—Correlation between lymphocyte
count and nutritional state measured by ratio
of total exchangeable sodium to total exchan
geable potassium (Nae/K e), 313 measure
ments. Correlation was not significant (r =
-0.09); 95% confidence limits are included.

Measurement

FIG. 3—One hundred and forty-seven meas
urements for patients who were nutritionally
normal and 166 measurements for patients w ho
were malnourished are represented in this histo
gram. Dotted area represents normal lympho
cyte counts. Lymphocyte count in 50 o f 147
measurements incorrectly indicated that nor
mal patients were malnourished, for false
positive rate of 34%. Lymphocyte count incor
rectly indicated in 83 of 166 measurements that
malnourished patients were normal, for false
negative rate of 50%.

1.22.2 Malnutrition is thus defined as a
Nae to Ke ratio greater than 1.22. In this
group of patients, the mean ratio was 1.45
± 0.04, indicating that a large propor
tion of patients in our study were mal
nourished. The regression between the
Nae to Ke ratio and the lymphocyte
count was not significant (r = -0.09). This
lack of correlation was supported by the
wide scatter of data about the regression
line.
The patients were divided into those
with a normal nutritional state and those
with malnutrition based on their body
composition (Fig. 3). The lymphocyte
count correctly identified a normal nutri
tional state in 97 of 147 measurements
(66%) but incorrectly indicated that mal
nourished patients were normal in 83 of
166 measurements, for a false-negative
rate of 50%. Malnourished patients were
correctly identified by the lymphocyte
count in 83 measurements but in 50 meas
urements in which the patients had nor
mal nutritional state, the measurement
incorrectly identified the patients as mal
nourished, for a false-positive rate of
34% (50 of 147).
Seventy-eight patients with 97 pairs of
measurements separated by a substantial
time interval were divided into three
groups based on the observed changes in
their nutritional state (Table I). This per
mitted a comparison of changes in body
composition, and thus the nutritional
state, with changes in the lymphocyte
count. There was nutritional improve
ment in 54 measurements. The body cell
mass significantly (p < 0.001) increased
from 15.4 ± 0.6 kg to 18.0 ± 0.8 kg, as
reflected by the significant (p < 0.001)
increase in Ke/TBW. This nutritional
improvement was accompanied by a sig
nificant (p < 0.01) decrease in the extra
cellular mass and a significant (p < 0.001)
decrease in the Nae/TBW from 92.6 ±
1.0 mmol/L to 86.0 ±1. 1 mmol/L. The
significant (p < 0.001) decrease in the
Nae to Ke ratio from 1.71 ± 0.06 to 1.39
± 0.04 reflects the nutritional changes in
body composition. The lymphocyte count
increased from 1.6 ± 0.12 x 109/L to

Table -B ody Composition and Total Lymphocyte Count for 78 Patients With 97 Sequential Studies
Normal deteriorated
Malnourished deteriorated
Malnourished improved
(n = 15)
(n - 28)
(n - 54)
M2
Ml
M2
M1
M2
Ml

68.1
67.3 ± 3.0
Weight, kg
22.2
21.6 ± 2.1
Body fat, kg
45 .9
45.7 ± 1.7
Lean body mass, kg
15.4 ± 0.6
18.0
Body cell mass, kg
27.9
Extracellular mass, kg
30.3 ± 1.3
86.0
92.6 ± 1.0
Nae)TBW, mmol/L
64.1
55.8 ± 1.1
Ke/TBW, mmol/L
1.39
1.71 ± 0.06
Nas : Ke
1.88
1.60 ± 0.12
Total lymphocytes, X 10 9/L
M - measurement, Nae - total exchangeable sodium, Ke “Significant difference (p < 0.05) from M L

±
±
±
±
±
±
±
±
±

2.9
1.9
1.6
0.8 *
1.0*
1.1*
1.3*
0 .0 4 *
0.17

60.2
16.4
46.9
16.5
30.3
90.9
58.2
1.60
1.99

±
±
±
±
±
±
±
±
±

3.4
3.5
2.2
0.8
1.6
1.6
1.4
0.07
0.25

6 2 .4
16.1
4 9 .3
15.0
3 4 .3
9 7 .5
5 1 .2
2 .0 0
2.01

± 3.7
± 3.6
± 2.5
± 0 .7 *
± 2.1*
± 1.7*
± 1.7*
±0.11*
± 0.19

77.7
30.1
4 7 .6
20 .7
2 6 .9
77 .8
70.2
1.12
1.60

±
±
±
±
±
±
±
±
±

9.4
6.2
3.7
2.1
1.7
1.0
1.7
0.03
0.22

73.7
28 .5
4 5 .2
16.3
28 .9
87.8
59 .6
1.50
1.58

±
±
±
±
±
±
±
±
±

7.4
5.4
2.6
1.0 *
1.9 *
1.3*
1.7 *
0 .0 7 *
0.18

total exchangeable potassium, TBW = total body water.
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Symptoms: No toxic effects have been reported.
Treatment: In case of accidental ingestion, perform gastic
lavage.

1.88 ± 0.17 x 109/L , but not signifi
cantly. Also, both the initial and final
mean lymphocyte counts were within the
normal range.
In the second group, 28 pairs of meas
urements were obtained from mal
nourished patients in which the nutri
tional state deteriorated. There was a
significant (p < 0.01) decrease of the
body cell mass with the mean Ke/TBW
decreasing from 58.2 ± 1.4 mmol/L to
51.2 ± 1.7 mmol/L (p < 0.001). This
was associated with a significant (p <
0.01) increase in the extracellular mass
and the Nae/TBW from 90.9 ± 1.6
m m ol/L to 97.5 ± 1.7 mmol/L (p <
0.001). The mean N ae to Ke ratio
increased significantly (p < 0.001) from
1.60 ± 0.07 to 2.0 ± 0.11, indicating the
deterioration. Again, the lymphocyte
count did not change: both the initial lym
phocyte count of 1.99 ± 0.25 x 109/L
and the final mean of 2.01 ± 0.19 x
109/L were within the normal range.
In the last group of initially normal
patients who subsequently became mal
nourished, there were 15 pairs of meas
urements. The deterioration was indicated
by the significant (p < 0.001) increase in
the Nae to Ke ratio from a normal value
of 1.12 ± 0.03 to a ratio of 1.50 ± 0.07.
There was a significant (p < 0.001)
decrease in the Ke/TBW and a signifi
cant (p < 0.001) increase in the
Nae/TBW. The lymphocyte count again
remained basically unchanged with both
the initial mean of 1.6 ± 0.22 X 109/L
and the final mean of 1.58 ± 0.18 x
109/L being within normal limits.

DOSAGE
Administer in the morning and again at bedtime, and after
each evacuation. Continue this treatment until the acute
phase of pain and discomfort passes and the inflammation
subsides. Treatment with ANUCAINE-HC should be
followed by maintenance management with regular
ANUCAINE as required.
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insert one suppository into the rectum. Suppositories
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indicate that the total lymphocyte count
is not affected by malnutrition in these
hospitalized patients. This indication was
further supported by the sequential
studies in which, despite significant
changes in the nutritional state, the lym
phocyte count did not change signifi
cantly. As a result of this poor associa
tion between the nutritional state and the
total lymphocyte count, there was a false
positive rate of 34% and a false-negative
rate of 50% when the lymphocyte count
was used to detect malnutrition.
The results of this study indicate that
the total lymphocyte is not affected by
malnutrition. This does not mean that the
immune response is not affected, since the
total lymphocyte count is a poor meas
ure of immunity. In previous studies of
this type, the immune response was evalu
ated in terms of nutritional assessment of
a population as well as the individual
patient.3 The lack of good correlation of
the total lymphocyte count to the body
composition, the wide confidence limits
and the poor results of sequential studies
indicate that the total lymphocyte count
is of no value in assessing the nutritional
state of an individual patient.
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Blunt Liver Trauma at the Sunnybrook Regional Trauma Unit
Between June 1, 1976 and Mar. 31,
19 83 , the Sunnybrook Medical Centre
Regional Trauma Unit in Toronto, Ont.,
admitted 145 patients with liver trauma;
of these, 141 (97% ) had sustained blunt
liver trauma. Of 113 patients who under
went open peritoneal lavage, 112 had a
true-positive lavage.
Resuscitation was successful in 137
patients and 134 of these underwent
laparotomy. Seventy-nine (59%) of the
134 patients required only minor surgical
treatment; the other 55 (41%) required
major surgical procedures.
The overall mortality was 32% (47 of
145). Eight patients died during resusci
tation but only one of them died of liver
hemorrhage. Of the 39 patients who
died after admission, the cause of death
was head injury in 22, while 6 died of
liver hemorrhage and 11 of other causes.
Overall, liver hemorrhage was the cause
of death in 15% of cases (7 of 47).

Entre le 1er juin 1976 et le 31 mars
19 83 , 145 patients victimes de traumatismes hepatiques sont entres a I'Unite
regionale de soins pour traumatises du
Sunnybrook Medical Centre a Toronto.
Parmi ceux-ci, 141 (97% ) avaient subi
des contusions hdpatiques. Sur 113
patients chez qui on pratiqua un lavage
peritoneal, 112 eurent un resultat positif
certain.
Cent trente-sept patients furent reanimes et 134 subirent une laparotomie.
De ce dernier groupe, 79 (59% ) ne

From the Department o f Surgery, Division
o f General Surgery, Sunnybrook Medical
Centre and University o f Toronto,
Toronto, Ont.
Presented at the 7th annual meeting o f the
Canadian Association o f General Surgeons,
Montreal, PQ, Sept. 12, 1984, held in con
junction with the 53rd annual meeting o f
the Royal College o f Physicians and Sur
geons o f Canada
Accepted for publication Feb. 4, 1985
Reprint requests to: Dr. S.S. Hanna,
Department o f Surgery, Rm. 1A-1034,
Sunnybrook Hospital, 2075 Bayview Ave.,
Toronto, Ont. M4N 3M5

220

necessiterent qu'une chirurgie mineure
alors que les 55 (41% ) autres devaient
subir une intervention chirurgicale
majeure.
La mortalite globale fut de 32% (47
sur 145). Huit patients sont decedes
pendant les tentatives de reanimation
mais un seul d'entre-eux est mort
d'hemorragie hepatique. Des 39 patients
qui sont decedes apres leur hospitalisa
tion, 22 sont decedes des suites d'un
traumatisme cranien, 6 d'hemorragie
hepatique et 11 d'autres causes. Dans
I'ensemble, I'hemorragie hepatique fut la
cause de deeds dans 15% des cas (7 sui
47).

Patients with liver injuries who could
not be successfully resuscitated and died
in the emergency room were included. All
patients who were treated elsewhere for
liver injury but were transferred to Sun
nybrook Medical Centre for postopera
tive care or care of associated injuries
were excluded.
Open peritoneal lavage was considered
positive when the fluid was either grossly
bloody or the erythrocyte count was
greater than 10.0 x 109/L.* All patients
with a positive peritoneal lavage were
operated upon to treat the intra
abdominal hemorrhage. Liver-related
mortality was calculated by reviewing the
cause of death. An abbreviated injury
severity score (ISS 1980 version) for each
patient was calculated according to the
rules of the American Association for
Automotive Medicine.4 Injury severity
scores were compared by Student’s /-test.

Motor vehicle accidents are the major
cause of blunt abdominal trauma in
Canada and, as such, constitute a serious
health-care problem.1 After the spleen,
the liver is the most commonly injured
organ and is associated with multiple
organ injuries in about 50% of pa
tients.2,3 Although the prognosis for
these critically injured patients has
improved markedly, considerable dis
agreement still exists among experienced
trauma surgeons as to the preferred
method of management after blunt
hepatic injury.
The purpose of this communication is
to review our experience with liver trauma
at Sunnybrook Medical Centre Regional
Trauma Unit, with emphasis on blunt
trauma, in order to evaluate current
methods of diagnosis and treatment, and
the complications and mortality of
hepatic trauma. We are the major trauma
centre for southern Ontario, with 85% of
our patients being referred from other
institutions.

Motor vehicle accidents were the cause
of injury in 127 (90%) of those with blunt
trauma. The other causes of blunt trauma
were accidental or suicidal falls, a kick by
a horse and a crush injury in a ferris
wheel. Of the 145 patients with liver
trauma, 79 (54%) were between 10 and
30 years old.

Methods

Lavage

The charts of all patients with liver
injuries admitted between June 1, 1976
and Mar. 31, 1983 were reviewed to deter
mine age, sex, length of hospital stay,
type of trauma, diagnosis, type of liver
injury, treatment, complications, asso
ciated injuries, injury severity scores and
cause of death.

Open peritoneal lavage was done in
113 patients, with a true-positive lavage in
112; 1 patient had a false-negative result.
This patient had signs of peritoneal injury

Findings

During the study period, Sunnybrook
Medical Centre Regional Trauma Unit
admitted 1173 trauma patients. Of these,
145 (101 males, 44 females) had sustained
liver trauma; 141 (97%) had blunt injury,
while 4 (3%) had sustained a penetrating
stab injury.
Cause o f Injury

’Currently, only lavage counts greater than
20.0 x 109/L erythrocytes are considered
positive.
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2 days after admission and the liver injury
was discovered at operation.
Diagnosis and Treatment
Of the 145 patients with liver trauma
who were brought to the emergency
room, 137 were successfully resuscitated.
Laparotomy was done in 134 of these,
while 3 patients in whom a diagnosis of
subcapsular hematoma was made clini
cally were treated conservatively. The lat
ter did well on follow-up. Sixteen of the
134 patients required im m ediate
laparotomy for obvious intra-abdominal
injuries (4 patients had penetrating inju
ries). Two had laparotom y after
laparoscopy. Three others with liver inju
ries who had laparotomy had incomplete
records as to how the diagnosis of
intraperitoneal bleeding was made.
Ninety-six (74%) of 130 patients who
underwent laparotomy were found to be
bleeding from their liver injury at opera
tion, whereas in 34 (26%) the bleeding
had already stopped. The records did not
elaborate on this point in the other four
patients. Liver injury was limited to the
right lobe in 65 patients (54%), to the left
lobe in 35 (29%), both lobes were injured
in 19 patients (16%) and 1 patient (0.8%)
had injury limited to the portal vein which
Table 1—Surgical Treatment
No. of
patients
(%)
22(16)

Type of treatment
No treatment
Minor surgical treatment
13(10)
Drainage only
20(15)
Hemostatic agents only
Hemostatic agents and drainage 24(18)
Major surgical treatment
36(27)
Suture and drainage
12(9)
Suture only
7(5)
Resectional debridement
134(100)
Totals

Table II—Causes of Death in Eight Patients
Who Died During Resuscitation
No. of
Cause
patients
Severe cardiopulmonaryinjuries
3
Head injury
2
Aortic - inferior venacaval tears
2
Liver hemorrhage
1

Table Ill-Miscellaneous Causes of Death
After Admission in 11 Patients
No. of
Cause
patients
Shock from nonhepatic causes
3
Expanding retroperitoneal hematoma
2
Lung injury and respiratory failure
2
Myocardial contusion
2
Pulmonary embolism
1
Ruptured thoracic aorta
1

was bleeding profusely. This was repaired
and the patient did well. The location of
injury was not noted in the other 14.
In 22 (16%) patients whose bleeding
was found to have ceased when
laparotomy was done, no definitive treat
ment was necessary. Minor surgical treat
ment, which consisted of peritoneal
drainage or use of hemostatic agents, or
both, was necessary in 57 patients (43%)
(Table I). Of 55 patients who needed
major intervention, the liver wound was
sutured and drained in 36. In 12 patients,
the liver was only sutured. The other
seven patients required resectional
debridement.
Deaths
The mortality for the series of 145
patients with liver injury was 32% (47
patients). Eight died during resuscitation
but in only one was death due to liver
hemorrhage (Table II). Of the 39 patients
who died after admission, head injury
was the cause in 22 and various other
causes in 11 (Table III). Six patients died
of liver hemorrhage (Table IV). Overall,
therefore, hepatic bleeding was the cause
of death in 7 of the 47 patients (15%).
The other 40 patients died of various
other causes, mostly head injuries (24
patients). The mean ISS for the 98 sur
vivors was 40 ± 11 (standard deviation)
which differed significantly (p < 0.0005)
from that for the 47 nonsurvivors, 57 ±
12 .

There were 45 complications in 29 of
the 98 surviving patients (Table V).
However, only five patients required
reoperation, two for subphrenic abscess,
one for a pancreatic pseudocyst, one for
gallbladder necrosis and one for abdomi
nal wall bleeding. All these patients did
well after reoperation.
Discussion
A t Sunnybrook M edical C entre
Regional Trauma Unit, 12% (145) of our
1173 trauma patients suffered a liver
injury; 97% a blunt liver injury and 3%

a penetrating stab wound. There were no
gunshot wounds to the liver. These
figures, although similar to those reported
from the United Kingdom,5 Sweden6 and
Malaysia,7 are in sharp contrast to the
figures reported from the U nited
States,8' 16 where penetrating injuries
form the majority of traumatic injuries
to the liver. The finding that 54% of our
patients were between 10 and 30 years of
age compares closely with other reported
series.17'20
Often the diagnosis of hepatic injury
is not made until laparotomy is per
formed, since the signs of liver injury,
which include shock, contusion over
lower chest and upper abdom en,
shoulder-tip pain and positive peritoneal
lavage, are all nonspecific. Open
peritoneal lavage is extremely useful in the
diagnosis of intra-abdominal bleeding.
We had true-positive findings in 112 of
113 patients in whom open peritoneal
lavage was perform ed. M oon and
Federle21 suggested that computerized
tomography combines the best features of
all available diagnostic techniques in
evaluating the patient with hepatic injury.
It is rapid, noninvasive, accurately defines
the extent of hepatic or other abdominal
injuries and quantifies the size of
associated hemoperitoneum. We have
recently begun a study using this tech
nique in the diagnosis of blunt abdomi
nal trauma.
The incidence of subcapsular hema
tom a following blunt abdominal traum a
has been reported to range from 0.33%
to 12% of all liver trauma. Conservative
treatment of subcapsular hematoma is
favoured by some,2,22,23 while others cau
tion against it for the fear of delayed rup
ture, infection or hemobilia.10 Our three
patients with subcapsular hematoma were
treated conservatively and all did well.
The surgical treatment of a patient with
hepatic trauma depends on the type of
wound encountered at operation.24 Some
minor lacerations that have stopped
bleeding may not require repair, but it is
impossible to select preoperatively
patients with minor injuries that will stop

Table IV-Surgical Procedures and Complications in Six Patients Who Died of
Liver Hemorrhage After Laparotomy

First procedure
Suture and drainage
Suture and drainage
Resectional debridement
Resectional debridement
Packing elsewhere
Packing elsewhere

Complication
Rebleeding and disseminated
intravascular coagulation
Rebleeding and disseminated
intravascular coagulation
Continued shock
Rebleeding and disseminated
intravascular coagulation
Rebleeding and disseminated
intravascular coagulation
Cirrhotic liver
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Second procedure
Suture and drainage

Injury
severity
score
59

None

66

None
Resectional debridement

59
59

Resectional debridement
at Sunnybrook
Suture and drainage
at Sunnybrook

33
34
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bleeding. Use o f hemostatic agents like
Avitene, Surgicel, Oxycel, liquid throm 
bin or packing were sufficient to control
bleeding in patients with minor injuries.
O f the patients who required m ajor sur
gical treatm ent, sutures had to be applied
to the liver in 87% and resectional
debridem ent was needed in 13%. Initial
management o f severe lacerations is aided
by digital or atraum atic clamp com pres
sion o f the hepatoduodenal ligament as
described by Pringle in 1908.25 This will
perm it ligation o f small vessels and
debridem ent.24
The role o f hepatic artery ligation in
controlling hem orrhage has frequently
been supported18’22’26'27 and disputed.9,10
W alt9 has suggested that we may be
trading short-term gains in hemostasis for
long-term hepatic sepsis with delayed
m ortality. We did not use hepatic artery
ligation in any of our patients; we believe
that although this method is occasionally
useful, it is overused.
The rate o f hepatic resectional debride
m ent, which consists of limited resection

Table V—Complications in the 98
Surviving Patients (n - 291
No. of
Complication
episodes
Sepsis
10*
Liver failure
6
Disseminated intravascular
coagulation
6
Biliary fistula
4
Renal failure
4
Pulmonary embolism
4
Other
11
‘ Includes 3 subphrenic abscesses.

o f devitalized tissue along the lines of
injury, has declined progressively from a
high of 46% 7 to as low as 3 % .28 It was
used in 5% o f our patients who under
went laparotomy for hepatic trauma. This
rate compares well with those o f other
series.
After bleeding has been controlled and
the wound debrided, adequate drainage
should be provided. Few communications
have questioned the value o f peritoneal
drainage,29,30 which was used in 60% of
our patients who underwent laparotomy.
Merendino and colleagues31 recom
mended drainage of the common bile duct
using a T tube in severe liver traum a to
decrease likelihood of biliary fistulas.
Lucas and Ledgerwood32 have shown a
striking increase in m orbidity following
T-tube drainage, and we agree that it
should not be used.
Shotgun wounds are the most lethal
liver injuries, followed in descending
order by blunt traum a and gunshot and
stab w ounds.6,9 Isolated hepatic injury
occurs in less than 10% of patients with
blunt traum a and is associated with a
mortality o f 5% which increases to over
55% when six or more organs are in
volved.13,14 O ur overall m ortality was
32% (47 o f 145). True liver-related m or
tality due to hemorrhage was seen in 15%
(7 o f 47) o f those who died. This was
mostly due to the development o f pro
found coagulopathy associated with long
standing shock that did not respond to
correction o f blood volume and clotting
factors.11,22 The other 40 who died could
be divided into two main groups: those
who died of severe head injuries either
before or after resuscitation (24 patients)
and those who died of miscellaneous

Table VI—Mortality for Blunt Liver Trauma Reported in Literature
Total
No. of
Mortality, %
Location
no. of
patients with
Authors
of study
patients
blunt trauma Overall Blunt trauma
Schrock and associates, 19688 San Francisco
61
20
24
65
Walt, 1969,12 19789
Detroit
436
50
11
30
—
Walt, 19789
Detroit
637
57
15
331
40
12
20
Balasegaram, 19767
179
Malaysia
90 (MVA 71)
17
14
Defore and associates, 197613 Houston
1590 240
13
30
Levin and associates, 197814 New Orleans
546
76 (MVA 75%) 10
28
Fischer and associates, 197829 Minnesota
303
22
“
29
Elerding and associates,
19 7 9 ,15 198020
Denver
225
66
15
20
—
Aldrete and associates, 197916 Alabama
108
48
17
_
Pachter and Spencer, 197928 New York
85
8
7
Miller and Bernstein, 198018
Irving (Calif)
34
56
9
Hasselgren and associates,
19816
Sweden
58
20 (MVA 9)
19
30
Caine and associates, 19825
Cambridge
__
(UK)
26
25 (MVA 25)
15
—
Thomas, 198334
Hamilton
82
17
?
—
Corica and Powers, 197533
Albany
75
33
?
Witte and Zokoski, 198319
—
Arizona
26
8
Current series
Toronto
145 141 (MVA 127) 32
32
MVA = motor vehicle accident.
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causes (16 patients). Our figures compare
well with blunt traum a mortality in other
series (Table VI).5'9’12' 16’18'20’28’29,33’34 At
Sunnybrook Medical Centre, approxi
mately 70% o f patients adm itted with
multiple injuries have a serious head
injury, which is an im portant cause of
m orbidity and death.35 In view o f the
severe type of blunt hepatic traum a at our
centre, it is not surprising that our over
all m ortality is higher than that of some
reported series in which penetrating liver
injury dominates and carries a mortality
o f less than 5%.

Conclusions
Most blunt hepatic traum a can be
managed adequately using a simple con
servative approach, based on wellestablished principles. Early diagnosis,
prom pt hemostasis, restoration of blood
volume and coagulation, prevention of
hypotherm ia, hypotension and acidosis
and treatm ent o f associated injuries are
crucial in saving the patient. Surgical
principles o f management include direct
control o f hem orrhage, debridement of
devitalized liver tissue and adequate
drainage.
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SESAP IV Critique
ITEM 118

In the management of severe hepatic injuries, enthusiasm for resection
has been replaced by the belief that persistence in local hemostasis and
debridement will control most hepatic bleeding. Routine T-tube
drainage of the common duct has been shown to be both unnecessary
and detrimental for these patients, most of whom have ducts of nor
mal size. If T-tube drainage is used, postoperative sepsis and gastroin
testinal bleeding are increased.
Major liver injury is associated with a mortality in excess of 15%.
Bleeding from liver parenchyma in some instances can arise from
branches of the hepatic artery. With local hemostatic measures, liga
tion of the hepatic artery should only rarely be required for the manage
ment of major liver injuries. If used, however, ligation has been shown
to be safe, with no significant long-term effect on liver function.
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1. Pilonidal Disease
Many procedures have been advocated
to treat pilonidal disease, suggesting that
no one method is highly efficacious. In
the office, the surgical approach is
directed towards three aspects of the
condition: pilonidal abscess, recurrent
pilonidal disease following surgery and
chronic pilonidal disease following spon
taneous rupture of an abscess or secon
dary to incision and drainage.
In managing the acute pilonidal
abscess, an intradermal injection is given
over the indurated, fluctuant area as well
as the midline orifice which can almost
always be identified. The midline orifice
is incised and the incision carried into
the abscess cavity. The edges of the
cavity are excised. Healing takes place
secondarily. A second procedure is rarely
needed.
Plusieurs operations ont ete proposees
pour traiter le kyste pilonidal, ce qui
laisse supposer qu'aucune n'est tres efficace. Dans le cabinet de consultation, la
chirurgie s'attaque a trois aspects de
cette affection: I'abces pilonidal, la recidive post-chirurgicale du kyste pilonidal
et le kyste pilonidal chronique consecutif
a la rupture d'un abces ou secondaire a
une incision avec drainage.
Devant un abces pilonidal aigu, on
administre une injection intradermale audessus de la zone induree mobile de
meme que de I'orifice median, lequel
peut presque toujours etre identifie. Une
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incision est pratiquee par I'orifice median
jusque dans I'abces. Les bords de la
cavite sont excises. La guerison se fait
par seconde intention. Une deuxieme
operation est rarement necessaire.

Pilonidal disease has posed a problem in
surgical management since Anderson1 in
1847 first described marsupialization of
the tract for cure. The etiology of the dis
ease remains obscure. It does not occur
before puberty and is rare in black peo
ple and in Asiatics. It is far more com
mon among hirsute individuals2 and
there is a definite association with
trauma. During World War II, soldiers
lost many man hours due to “jeep dis
ease” .3 The combination of poor per
sonal hygiene due to battlefield conditions
and the trauma of riding the hard seats
of jeeps over difficult terrain were the
main causative factors. The presence of
the midline pits very evenly placed over
the postsacral area suggests a congenital
origin.4 With the development of secon
dary sexual characteristics at puberty, the
hair becomes more profuse and coarse.
Shafts of exfoliated hair, particularly
from the scalp, then penetrate the pits or
theoretically can themselves cause pits
and, with poor personal hygiene and
trauma, a secondary infection develops.
Pathologically, hair follicles have never
been found in the sinus tracts, proving
that the hair is extraneous to the area.
Moreover, frequently no connection
between adjacent midline orifices can be
seen.

Treatment
Many procedures have been advocated
to treat pilonidal disease, which suggests
that no one method is highly efficacious.
Sebrechts5 in his bibliography of piloni
dal disease listed 936 separate papers, the
majority of which described its manage
ment. Excision and primary closure,6

marsupialization,7 split-thickness grafts,8
Z-plasty,9 injection of sclerosing solu
tions,10 excision and delayed closure,"
electrocoagulation,12 semiprimary clo
sure,13 gluteal fascioplasty14 and incision
and curettage15 have all been advocated.
The management of this condition in the
office has been suggested before and
therefore is not new.16-18 The office sur
gical approach revolves around three
aspects of the condition: pilonidal
abscess, recurrent pilonidal disease fol
lowing surgery and chronic pilonidal dis
ease following spontaneous rupture of an
abscess or secondary to previous incision
and drainage.
Acute Pilonidal Abscess
The acute pilonidal abscess presents as
a painful swelling in the postsacral area
cephalad to the coccyx and generally
presenting to the right or the left of the
midline. Induration or fluctuation, or
both, can be seen and palpated and nearly
always a midline orifice can be identified.
The skin overlying the abscess cavity is
injected with 1 to 2 mL of a solution of
0.25% bupivacaine with 1:200 000
epinephrine, using a 30-gauge dental nee
dle. It is important to inject the anesthetic
solution intradermally to achieve ade
quate anesthesia. The skin will blanch if
the injection is being given intradermally.
Injection into the abscess cavity should
be avoided since it will be painful and
anesthesia will be inadequate due to the
acid pH. A small probe is then inserted
through the midline orifice into the
abscess cavity. This midline pit can
usually be identified. The incision is
extended from the midline orifice the full
length of the abscess cavity. The edges of
the abscess cavity are excised to expose
the posterior wall completely. It may be
necessary to inject further local anesthetic
into the skin edges to accomplish this. If
a midline orifice cannot be identified, the
incision should still be made through the
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midline and then extended into the
abscess cavity. The posterior wall of the
abscess is not incised and the granulation
tissue is either cauterized with a silver
nitrate stick or curetted out. A gauze
dressing is placed into the wound, then
cotton and a V pad that is taped into
place. The patient should not remove the
dressing until the following day since that
may result in bleeding. Hot tub baths are
started the following day and continued
until the wound is healed. The healing
time is generally 2 weeks and the patient
experiences minimal discomfort. Recur
rence of the pilonidal cyst managed in this
way is unusual; thus, the treatment is
definitive.
Recurrent Pilonidal Disease
Management of a recurrent pilonidal
sinus after formal surgery can be adapted
to office surgery. The recurrence in most
cases develops in the caudal portion of the
scar. A blind cavity or sinus tract is fre
quently encountered through a midline
opening. A local anesthetic is adminis
tered and an incision made directly over
the probe, exposing the sinus tract or
cavity. The posterior wall of the tract is
left intact but is scraped free of granula
tion tissue and the edges of the tract are
debrided. Frequently, the posterior wall
is completely epithelialized and leaving it
intact shortens the healing period. A
dressing is applied as described and hot
baths are begun the following day. If the
wound is large, the patient is urged to use
a Water Pik once daily to keep the wound
clean as recommended by Hoexter.19
The patient is seen at weekly intervals
when the hair is shaved back from the
skin edges of the wound, the granulation
tissue removed and the wound cauterized
with 10% silver nitrate. The healing time
averages 3 to 4 weeks, depending on the
size of the wound.
Chronic Pilonidal Disease
The chronically draining pilonidal cyst
that develops after incision and drainage
of an abscess or spontaneous rupture of
a pilonidal abscess, can again, in most
instances, be managed in the office. The
anesthetic injection, however, is slightly
different. To a 50-mL vial of 0.25%
bupivacaine with 1:200 000 epinephrine,
2 mL of hyaluronidase (300 turbidity
reducing units) are added. The hyaluroni
dase breaks down the intracellular cement
and brings about rapid diffusion of the
solution with immediate anesthesia. The
hair about the cyst is first shaved and then
the anesthetic is administered, placing the
solution circumferentially about the cyst
as well as deep to the cyst between the cyst
and the postsacral fascia. With a no. 15
blade disposable scalpel, a midline inci
sion is made through all midline orifices,
226

exposing the cyst or sinus tract. The edges
of the wound are cut back and bevelled.
The posterior wall of the cyst is left intact,
but all granulation tissue is vigorously
removed. Hemostasis is secured by elec
trocautery. A piece of Surgicel followed
by cotton and several V pads are then
applied. The dressing is removed the fol
lowing day and hot baths are started. Fol
lowing each hot bath, a 4 x 4-inch gauze
soaked in 0.5% silver nitrate solution is
applied to the wound followed by a dry
gauze pad to hold it in place. The use of
the silver nitrate solution keeps the wound
clean and the granulation tissue down,
thus speeding up the healing process. In
the nervous, apprehensive patient, this
same procedure is carried out in the
hospital in a similar manner but with the
addition of diazepam intravenously in
increments of 2.5 mg up to 10 to 15 mg.
The patient is seen at weekly intervals and
is instructed to use a Water Pik if the
wounds are not clean. The hair is always
shaved back from the wound edges at
these weekly visits. In a personal
review20 of 126 patients treated in this
manner in the hospital for pilonidal dis
ease, the recurrence rate was 20.9% and
the average healing time was less than 2
months. The recurrences were treated by
office procedures in all but one instance.
Discussion
I agree with Hurst21 that pilonidal dis
ease is overtreated. Wide, radical excision
down to the postsacral fascia under a
major anesthetic leaving a wound that
may take 3 to 6 months to heal has no
place in the management of pilonidal dis
ease. The high recurrence rate appears to
be due to the development of new disease
rather than recurrence of the old since it
is difficult to believe that the surgeon
leaves any cysts or sinus tracts behind.
When healing time is prolonged and the
wound is not kept meticulously clean and
free of hair, new sinus tracts and cysts
may be formed by the inclusion of hair
deep in the wound with epithelializadon
over the enclosed hair. The object should
be to create as small a wound as possible
and get it healed as quickly as possible.
Cleanliness is the hallmark of success in
the proper management of pilonidal
disease.
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2. Lateral Internal Sphincterotomy:
Rationale, Technique and Anesthesia
To determine the role of lateral internal
sphincterotomy under local anesthesia in
patients with anal fissures, a retrospec
tive review of 133 patients (62 men, 71
women) was conducted. They ranged in
age from 19 to 79 years. The open tech
nique described by Sir Alan Parks was
adopted, except that the operation was
performed under local anesthesia as an
outpatient procedure. Associated opera
tions were performed in nine patients
(6.5% ). Complications, which occurred
in seven patients (5.3% ), included
difficulty controlling flatus, incomplete
wound healing and thrombosed external
and prolapsing internal hemorrhoids.
Relief of pain was prompt. The advan
tages of this operation are that hospitali
zation is not necessary, it can be per
formed under local anesthesia,
postoperative discomfort is of short
duration and wounds heal quickly. This
report supports the use of lateral internal
sphincterotomy for patients with a
chronic anal fissure.
Une etude retrospective portant sur 133
malades (62 hommes et 71 femmes) a
6te menee dans le but de preciser le role
de la sphincterotomie laterale interne
sous anesthesie locale dans le traitement
des fissures anales. Leur age allait de 19
a 79 ans. On a adopte la technique
ouverte decrite par Sir Alan Parks, a ceci
pres que I'operation a ete pratiquee sous
anesthesie locale en clinique externe.
Des operations associees ont ete faites
chez neuf patients (6.5% ). Des compli
cations, qui sont survenues chez sept
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patients (5.3% ), ont inclu difficulty a
controler les gaz intestinaux, cicatrisation
incomplete, thrombose des hemorroldes
externes et prolapsus des hemorroldes
internes. Le soulagement de la douleur
fut rapide. Les avantages de cette opera
tion resultent du fait que I’hospitalisation
n'est pas necessaire, qu elle peut etre
faite sous anesthesie locale, que la gene
postoperatoire est de courte duree et
que la plaie guerit rapidement. Cet article
soutient I'utilisation de la sphincteroto
mie laterale interne chez les patients
souffrant de fissure anale chronique.

In the development of a fissure in ano,
the initiating factor is generally consi
dered to be trauma to the anal canal, in
the form o f a hard stool.1 Usually the
acute fissure heals, but under certain con
ditions it persists. One perpetuating fac
tor that is important in the formation of
a chronic anal fissure is chronic consti
pation. This is more likely an associated
symptom but may continue to aggravate
the anal canal, perpetuating the fissure.
Inflammation has also been invoked as
a perpetuating factor but this is unlikely
because inflammation is no more florid
in patients with very long-standing anal
fissures than in those with fissures of
recent onset. An abnormality of the inter
nal anal sphincter is important. Studies
by Nothmann and Shuster2 demon
strated that, following rectal distension,
the normal reflex relaxation of the inter
nal sphincter is followed by an abnormal
“ overshoot contraction” in patients with
anal fissures. This phenomenon may
account for the sphincter spasm and
explain the pain that occurs during and
after defecation. They further demon
strated that following successful treat
ment o f the fissure, the abnormal reflex
contraction vanishes. This abnormality
should then be considered when trying to
arrive at a rationale treatment for the
problem.
In 1959, Eisenhammer3 recommended
lateral internal sphincterotomy to treat
patients with a chronic fissure in ano, a
procedure that was originally described by
Brodie4 in 1835. There are many varia

tions of Brodie’s procedure. It may be
performed under local or general anesthe
sia, through a radial or circumferential
incision, or using a subcutaneous tech
nique. The muscle may be divided from
medial to lateral or vice versa.
Patients
To determine the results obtained with
lateral internal sphincterotomy under
local anesthesia, we reviewed retrospec
tively 133 patients with anal fissure. There
were 62 men (47%) and 71 women (53%),
ranging in age from 19 to 79 years with
most being in the third or fourth decades
of life.
Technique
We adopted the technique described by
Sir Alan Parks.5 However, we perform
this operation under local anesthesia as
an outpatient procedure unless there are
extenuating circumstances such as an
allergy to the local anesthetic.
With the patient in the prone jackknife
position, the perianal region is prepared
with a disinfectant solution and draped
in the usual fashion. With a fine needle,
an anesthetic solution of 0.5% xylocaine
in 1:200 000 epinephrine or 0.25%
bupivacaine in 1:200 000 epinephrine is
infiltrated into the left lateral aspect near
the anal verge, ensuring that the solution
is directed to the level of the dentate line.
The area o f the fissure is then anesthe
tized. A Pratt bivalve is inserted into the
anal orifice. Should there still be some
discomfort, the entire perianal region may
be anesthetized. A short incision is made
just distal to the intersphincteric groove,
which can usually be palpated quite eas
ily. The anoderm is lifted o ff the under
lying internal sphincter to the level of the
dentate line and the intersphincteric plane
is developed. The full thickness o f the
internal sphincter is divided from its lower
edge to the level of the dentate line using
either a pair o f Metzenbaum scissors or
a scalpel. Hemostasis is obtained with
cautery and the wound can be closed with
a couple o f interrupted sutures of 3-0
chromic catgut.
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postoperatively; then she was lost to
follow-up. There were three patients
whose operative site did not heal. One
patient was re-examined under general
anesthesia and an unusual finding was
demonstrated. It was noted during re
exploration that the lowermost portion of
the internal sphincter had not been
divided at the original sphincterotomy,
consequently the wound did not heal
(Fig. 1). This problem was easily cor
rected by completing the incision.
Another wound did not heal because the
operation was performed on a patient
with Crohn’s disease. Although the
wound did not heal, the patient was
asymptomatic. One patient had persistent
pain and the fissure did not heal. Conse
quently, 1 month later a lateral internal
sphincterotomy was performed on the
opposite side, giving prompt relief of
symptoms and complete healing of the
fissure. One patient returned the day after
the procedure with a complete ring of
prolapsed, thrombosed internal hemor
rhoids as well as a ring of thrombosed
external hemorrhoids. Emergency hemor
rhoidectomy was performed and his post
operative course was smooth. Fortunate
ly, no patient suffered postoperatively
from hemorrhage, perianal abscesses or
fistula in ano. Urinary retention was not
encountered.

Results
The symptoms encountered in this ser
ies are shown in Table I.
Thirty-one patients had associated
problems: hemorrhoids in 24, anal steno
sis in 4, Crohn’s disease in 2 and syphilis
in 1 patient.
Associated operations were performed
in nine patients (6.8%). In four, a oneor two-quadrant hemorrhoidectomy was
performed and in one of these a hyper
trophied anal papilla was excised. In five
other patients, associated hypertrophied
anal papillae and sentinel piles were
excised. Another patient had his condylomata acuminata removed.
Complications occurred in seven
patients (5.3%). Three patients had
difficulty controlling flatus. In two, the
problem was temporary and resolved
spontaneously but one patient had uncon
trollable flatus for at least 1 year

Table 1-Symptoms in 133 Patients
With Anal Fissure
No. of
patients (%)

Symptom
Pain
Bright red rectal bleeding
Straining
Pruritus
Prolapse
Mucus

133(1001
74(55.6)
22(16.5)
11 (8.3)
10(7.5)
4(3.0)

Postoperative Care
Patients were discharged home on a
regular diet, advised to take sitz baths and
a psyllium seed preparation as a stool
softener; a non-constipating oral anal
gesic was prescribed. Originally, patients
were seen 1 week and again 1 month after
the procedure, but later in the review it
was deemed unnecessary to see them after
a week so they were seen only 1 month
following the procedure.
Although the exact duration of pain
postoperatively was not documented for
each patient, most had relief within 48
hours and many within 24 hours.

FIG. 1—Incomplete division of lower por
tion of internal sphincter.

Table II—Reported Results of Lateral Internal Sphincterotomy
% impaired
control of
Authors

No.

Hawley, 1969®
Hoffmann and Goligher, 19707
Notaras, 19718
Millar, 1971®
Hunter, 197510
Rudd, 1975”
Oh, 197812
Bailey and colleagues, 197813
Marby and colleagues, 197914
Rosenthal, 1979' s
Abcarian, 198016
Vafai and Mann, 198117
Current series, 1983

24
99
82
99
74
200
300
418
78
125
150
272
133

Flatus
-

6
2
2
27
0
1
1
0
Few
30
16
2.3

Feces
0
1
1
0
27
0
0.6
1.2
0
0
0
0
0.8

Fecal
soiling, %

Unhealed or
recurrence, %

0
7
6
1
34
0
2

0
3
10
0
12
0.5
1.6
1
29
0.8
1.3
3
1.5

-

0
0
0
12
0

Discussion
In recent years, lateral internal sphinc
terotomy has increasingly been the treat
ment of choice for patients with a chronic
anal fissure. In a poll of the members of
the American Society of Colon and Rec
tal Surgeons in 1979, most respondants
stated that their first or preferred opera
tion of choice for chronic fissure in ano
was the lateral internal sphincterotomy.
Recently, many authors6'17 have reported
their results with this operation (Table II).
With only one exception (Hunter10) all
reported satisfactory control of flatus and
feces. In the series reported by Rosen
th a l,15 A b c a ria n ,16 and Vafai and
M ann,17 all of the problems relating to
control of flatus and soiling were only
temporary. Fecal soiling was reported in
some series but varied in degree of con
cern in different series. Hoffmann and
Goligher7 studied three procedures —
posterior in ternal sphincterotom y,
sphincter stretch and lateral internal
sphincterotomy — and, when comparing
disturbances of anal continence follow
ing these operations, found that lateral
internal sphincterotomy fared the best.
In terms of the unhealed fissure or the
patient who suffers a recurrence, the
results of this operation are quite good.
A bcarian16 com pared the results of
lateral internal sphincterotomy with fissurectomy and midline sphincterotomy.
He found that lateral internal sphinc
terotomy offered rapid wound healing, a
low recurrence rate and no permanent
defect in continence, and concluded that
it was the treatment of choice. The highest
recurrence rates were reported by Marby
and associates14 and N otaras.8 In both
series, the lateral internal sphincteroto
mies were performed in a blind manner.
O h12 pointed out that in his series the
incidence of recurrence was slightly higher
in patients who had sphincterotomy per
formed in a subcutaneous blind manner
than in those who had it performed using
an open technique. This may explain the
higher recurrence rates in the two cited
series. The incidence of recurrence may
also be related to the amount of internal
sphincter divided.

Conclusions
Our experience, supported by that of
others in the literature, strongly suggests
that lateral internal sphincterotomy is a
good operation for patients with a chronic
fissure in ano. It has several definite
advantages. There is no need for the
patient to be hospitalized. The operation
can be performed under local anesthesia.
Postoperative discomfort is of short dura
tion and wounds heal quickly. Fecal
soiling is not a problem and recurrence
following this mode of therapy is uncom-
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mon. Thus, less time is lost from work
and fewer follow-up visits are required.
Because of excellent results, we believe
that lateral internal sphincterotomy is the
treatment of choice for patients with a
chronic anal fissure.

5. PARKS AG: The management of fissure-in-ano. Hosp
Med 1967; 1: 737-8

12. O h C: A modified technique for lateral internal sphinc
terotomy. Surg Gynecol Obstet 1978; 146: 623-5

6. H awley PR: The treatment of chronic fissure-in-ano.
A trial of methods. Br J Surg 1969; 56: 915-8

13. Bailey RV, RUBIN RJ, Salvati EP: Lateral internal
sphincterotomy. Dis Colon Rectum 1978; 21: 584-6

7. H offmann DC, G o lig h er JC: Lateral subcutaneous
internal sphincterotomy in treatment of anal fissure. Br
Med J 1970; 3: 673-5

14. M arby M, A lex and er -W illiams J, BUCHMANN p ,
A rabi Y, Kappa s A, M inervini S, G atehouse D,
KEIGHLEY MR: A randomized controlled trial to com
pare anal dilatation with lateral subcutaneous sphinc
terotomy for anal fissure. Dis Colon Rectum 1979; 22:
308-11

References
1. G oldberg SM, G ord on PH, N ivatvongs S: Essen
tials o f Anorectal Surgery, Lippincott, Philadelphia,
1980: 86-99

8. N otar AS MJ: The treatment o f anal fissure by lateral
subcutaneous internal sphincterotomy — a technique and
results. Br J Surg 1971; 58: 96-100

15. ROSENTHAL D: Fissure-in-ano management in the mili
tary community. Milit M ed 1979; 144: 505-8

2. NOTHMANN BJ, SHUSTER MM: Internal anal sphincter
derangement with anal fissures. Gastroenterology 1974;
67: 216-20

9. MILLAR DM: Subcutaneous lateral internal anal sphinc
terotomy for anal fissure. Ibid: 737-9

3. ElSENHAMMER S: The evaluation of internal anal sphinc
terotomy operation with special reference to anal fissure.
Surg Gynecol Obstet 1959; 109: 583-90

10. HUNTER A: Anorectal problems: lateral subcutaneous
anal sphincterotomy. Dis Colon Rectum 1975; 18: 665-8

16. A bcarian H: Surgical correction of chronic anal fissure:
results of lateral internal sphincterotomy vs. fissurectomy
— midline sphincterotomy. Dis Colon Rectum 1980; 23:
31-6

4. BRODIE BC: Lectures on diseases of the rectum. 111.
Preternatural contraction of the sphincter ani. LondM ed
Ga$ 1835; 16: 26-31

11. RUDD WW: Lateral subcutaneous internal sphinc
terotomy for chronic anal fissure, an outpatient proce
dure. Ibid: 319-23

17. Vafai M, Mann CV: Closed lateral internal anal sphinc
terotomy without removal of sentinel pile for fissure-inano. Coloproctology 1981; 3: 91-3

Z a n e C o h e n , m d , fr c sc

3. Alternatives to Surgical Hemorrhoidectomy
Hemorrhoids are an extremely common
affliction. The prevalence ranges from 1
in 25 to 1 in 30 individuals. There was a
20% decrease in the number of hemor
rhoidectomies performed between 1978
and 1982. Alternatives to formal hemor
rhoidectomy are injection sclerotherapy
and rubber-band ligation. High-fibre diets
and bulk laxatives are effective in reliev
ing the symptoms of hemorrhoids, eas
ing defecation and regulating bowel habit
and can be used liberally. Bleeding
hemorrhoids can be treated by diet
alone, or by injection or rubber-band liga
tion. Prolapsing hemorrhoids are best
treated by rubber-band ligation. The rela
tively few patients in whom these more
conservative measures fail can be consi
dered for hemorrhoidectomy.
Les hemorroides sont une affection tres
courante. La prevalence se situe entre 1
sur 25 individus et 1 sur 30. On a cons
tate une diminution de 20% du nombre
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des hemorroi'dectomies entre 1978 et
1982. La sclerotherapie par injection et
la ligature par bande eiastique sont des
alternatives a I'hemorroidectomie classique. Les regimes riches en fibres et les
laxatifs mucillagineux soulagent efficacement les symptomes des hemorroides,
facilitent la defecation et regularised les
selles; ils peuvent etre largement utilises.
Les saignements hemorroidaires peuvent
etre traites par le regime seul, par injec
tion ou par ligature par bande eiastique.
Le meilleur traitement des hemorroides
prolabees est la ligature par bande eias
tique. Les quelques patients pour qui ces
mesures conservatrices ne suffisent pas
sont candidats a I'hemorroidectomie.

Hemorrhoidal disease is extremely com
mon in westernized countries. In North
America it has been estimated that one
out of every two individuals over the age
of 40 years has some degree of hemor
rhoidal disease. In the third world
this prevalence ranges from 1 in 25 to 1
in 30.1 In the majority of cases the
hemorrhoids are asymptomatic. In a
study reported by Haas and associates,2
198 (82%) of 241 asymptomatic persons
were found to have hemorrhoids. For
comparison, in the symptomatic group of
594 patients, 522 (88%) had evidence of
hemorrhoids.
Asymptomatic hemorrhoids appear
with increasing age. The peak ages are
from 40 to 80 years. Symptomatic hemor
rhoids are similarly distributed although
there are a greater number with sympto

matic hemorrhoids under the age of 30
years.3 In Ontario, the prevalence of
hemorrhoids is the same as is mentioned
above; however, there has been a steady
decrease (20%) in the number of hemor
rhoidectomies performed from 1978 to
1982.4 In my own practice over a 6-year
period, I have seen 412 patients with
hemorrhoidal disease, only 26 of whom
required hemorrhoidectomy; 156 under
went rubber-band ligation, 21 injection
sclerotherapy and 213 were managed by
dietary manipulation alone.
Alternatives to Hemorrhoidectomy

The classifications that I use for hemor
rhoids are: first degree — maintained per
sistently at the proper level in the anal
canal; second degree — prolapse with
bowel movement but spontaneously
reduced when straining ceases; third
degree — prolapse out of the anal canal
requiring manual reduction; fourth
degree — prolapse, often thrombosis, and
cannot be reduced manually.
The usual symptoms consist of consti
pation, bleeding, discomfort, prolapse
and occasionally an associated discharge
with anal irritation. These symptoms can
often be resolved by office treatment of
the hemorrhoidal disease using a highfibre diet, and injection sclerotherapy or
rubber-band ligation, or both.
High-Fibre Diet

In 1978, Webster and associates5 corn-
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pared the effects of Fybogel and placebo
on patients with hemorrhoidal disease.
The end points were relief of symptoms,
ease of defecation and regular bowel
habits. For all of these end points, there
was a clear indication that the majority
of patients were improved with Fybogel
compared to placebo, particularly in
those who described greater ease of defe
cation and better bowel habit. In my own
experience, most patients who are com
pliant and who will agree to be placed on
a high-fibre diet supplemented by stool
softeners can often minimize their symp
toms, particularly if they are complain
ing of only small amounts of bright red
rectal bleeding and anal discomfort on
defecation.
Injection Sclerotherapy
The indications for injection sclerother
apy are first-degree hemorrhoids and
small second-degree hemorrhoids where
the major symptom is that of bleeding.
The rationale for injection sclerotherapy
is the use of an irritant solution that
produces an inflammatory reaction and
fibrosis with subsequent devasculariza
tion, thus minimizing rectal bleeding.6
The fibrosis increases the fixation of the
hemorrhoid to the underlying muscle
thereby also reducing prolapse. Injection
sclerotherapy is a simple and safe method
for decreasing hemorrhoidal bleeding.
The needle should be placed in the sub
mucosal layer well above the dentate mar
gin and 3 to 4 mL of 5% phenol in oil
can be used surrounding each of the
hemorrhoids. The contraindications are
external hemorrhoids, acute attacks of
hemorrhoidal disease and repeated injec
tion as well as associated anal lesions. The
complications include necrosis and injec
tion ulcers, submucosal abscess and
parathenomas.6 All these complications
are rare.
Injection sclerotherapy is more popu
lar in Great Britain than it is in North
America. However, in my practice I often
inject hemorrhoids when the major symp
tom is hemorrhoidal bleeding, as I have
found that rubber-band ligation can be
somewhat inaccurate when the exact site
of bleeding is difficult to identify.
Rubber-Band Ligation
Rubber-band ligations can be used for
second- and third-degree hemorrhoids,
and occasionally following reduction of
fourth-degree hemorrhoids. The tech
nique is relatively easy. The discomfort
that arises will be minimized if one per
forms the procedure well above the den
tate margin. I prefer to ligate only one or
at most two hemorrhoids at each sitting.
The ligation of three hemorrhoids will

produce substantial pain and discomfort.
Approximately 75% of patients in my
practice either have no further symptoms
or are greatly improved following one or
two rubber-band applications. In a study
performed at the Lahey Clinic in 1981 of
266 patients, 113 (43%) had no further
symptoms following rubber banding, 69
(26%) were greatly improved, 29 (11%)
were mildly improved and 20% were
unchanged or worse.7
The complications following rubberband ligation are mainly severe pain in
6% to 10% and hemorrhage in 1% to
2% of patients.6 Two of my patients
returned to hospital with major lower gas
trointestinal bleeding from the rubberband ligation site 10 to 14 days after the
procedure. The immediate treatment for
this is to place pressure over the area or
to insert a Foley catheter, inflate the bal
loon and pull back to tamponade the
bleeding until the bleeding site can be
identified and oversewn.

Summary
The treatment of bleeding hemorrhoi
dal disease is first injection sclerotherapy.
The failures are considered for rubberband ligation. When hemorrhoids are
large and protruding, rubber-band liga
tion is the procedure of choice.
For large prolapsing internal hemor
rhoids, an attempt is made to ligate these
using rubber bands. If this fails, hemor
rhoidectomy is performed.
With conservative measures and the
institution of a high-fibre diet and stool
softeners, the majority of hemorrhoids
can be treated nonsurgically with satisfac
tory results.
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4. Flexible Fiberoptic Sigmoidoscopy: an Office Procedure
Patients w h o had benign polyps and
cancers w ere studied retro sp e ctive ly to
define w h e th e r use o f the 6 0 -cm flexible
sigm oidoscope w o u ld m arkedly im prove
th e d iagnostic yield over the 2 5 -c m rigid
sigm oidoscope. O f the polyps fo u n d ,
4 8 % could have been seen by th e rigid
sigm oidoscope and 8 5 % by th e flexible
sigm oidoscope. Cancers were w ith in
reach o f digita l exam ination in 2 1 % , o f
th e rigid sigm oidoscope in 3 8 % and of
the fle xible sigm oidoscope in 6 0 % . This
ve rifie s th e greater diagnostic yie ld by
th e fle xible sigm oidoscope.
In 211 a sym p to m a tic patien ts w h o
u n d e rw e n t fle xible fib e ro p tic sig 
m oid o sco p y, th e scope reached to 25
cm in all and to 50 cm in 7 5 % . The
average tim e required fo r the exam ina
tio n w as 4 .9 m inutes. O f these patients,
w h o had also undergone rigid sig 
m oid o sco p y previously, 7 6 % preferred
th e fle xible scope, 18% preferred the
rigid scope and 6 % could tell no d iffe r
ence. The yield o f neoplasm s w a s 4 % in
the distal 2 5 cm o f th e colon and rec
tu m , but an additional 8% w ere fo u nd in
th e sigm oid colon.
T his review supports the need fo r fle x 
ible sigm oidoscopy in the o ffic e as a
screening to o l fo r detection o f polyps
and early diagnosis o f cancer in the
a sym p to m a tic p a tien t over 4 0 years of
age. T echnique, co sts and com plications
are discussed.
A fin de ve rifie r si, par rapport au sigm oi
doscope rigide de 2 5 cm, un sigm oidos-

From the Department o f Surgery, George
Washington University, Washington, DC
Presented as part o f a symposium on out
patient anorectal procedures by the Royal
College o f Physicians and Surgeons o f
Canada, in cooperation with the Canadian
Association o f General Surgeons, Calgary,
Alta., Sept. 21, 1983
Accepted fo r publication Nov. 19, 1984
Reprint requests to: Dr. Lee E. Smith,
Associate Professor, Department o f Sur
gery, George Washington University, 2150
Pennsylvania A ve. NW, Washington, DC
20037, USA
For prescribing information see page 241

cope fle xible de 60 cm e ta it capable
d 'a m e lio re r sensiblem ent I'e ffic a c ite diagnostiq u e , I'a u te u r a etudie en re tro s p e c 
tive une serie de patients porteurs de
polypes benins ou de cancers. De to u s
les polypes decouverts, 4 8 % auraient pu
etre tro u ve s avec le sigm oidoscope rigide
e t 8 5 % avec le sigm oidoscope fle xib le .
Les cancers eta ien t a la portee du to u c h e
recta l dans 2 1 % des cas, du sig m o id o s
cope rigide dans 3 8 % e t du sig m o id o s
cope fle xible dans 6 0 % . Ceci m et en e v i
dence la m eilleure e ffica cite d iagnostique
du sigm oidoscope flexible.
Parmi 211 patien ts a sym p to m a tiq u e s
soum is a une fibroscopie a I'aide du s ig 
m oidoscope flexible, ('in stru m e n t s 'e s t
rendu a 2 5 cm dans to u s les cas e t a
a tte in t 50 cm dans 7 5 % . Le tem ps
m oyen requis pour I'exam en fu t de 4 .9
m inutes. De ceux qui ava ie nt deja subi
un exam en au sigm oidoscope rigide,
7 6 % o n t prefere I'in s tru m e n t fle xible ,
1 8 % le sigm oidoscope rigide et 6 %
n 'a v a ie n t pas de preference. Le nom bre
de neoplasies decouvertes dans le 2 5 cm
d ista l du colon et du rectu m fu t de 4 %
m ais un 8 % s u p p le m e n ta l fu t decouv e rt dans le sigm oide.
C ette etude souligne la necessity d 'u tiliser le sigm oidoscope fle xib le dans le
ca b in et de con su lta tio n com m e m oyen
de depistage des polypes e t pour le d ia 
g n o stic precoce du cancer chez les
p a tien ts asym p to m a tiq u e s de plus de 4 0
ans. On co m m e n te la te chnique, ses
co u ts et ses co m plications.

One in 25 Americans suffers from cancer
of the colon at some time. There are
approximately 120 000 new cases of
colonic and rectal cancer each year, and
60 000 deaths.1 The number of deaths
annually is consistently about half the
incidence, reflecting the positive observa
tion that 50% may be cured. However,
cure is predicated upon detection of the
cancer while it is still localized. Effective
screening procedures are necessary to
unmask occult cancers.
Is there an effective means of prevent
ing colonic and rectal cancer? M orson2
demonstrated that there is a sequence of

degeneration of the benign, tubular ade
noma to cancer. Following this reason
ing, the detection and removal of benign
tubular or papillary adenomas is the only
known means of preventing carcinoma of
the colon or rectum. Evidence that this
action prevents cancer was provided by
Gilbertsen, at the Cancer Detection Clinic
of the University of M innesota.3 He
reported a marked decrease from the
predicted number of cancers as a result
of detection and removal of all polyps.
If a cancer is detected earlier, is the out
come of the disease influenced? As previ
ously noted, approximately 50% of the
patients in whom colonic or rectal cancer
is diagnosed can be cured by surgical exci
sion. The cure rates are greatest in those
cancers that are small and have not yet
metastasized. For example, cases of
colonic and rectal cancer recorded at the
National Naval Medical Center Tumor
Registry in Bethesda, Md., were grouped
by the Astler-Coller classification, a
modification of Dukes’ classification
(Table I).4 The 5-year survival for
patients in these groups was as follows:
A — 100%, B1 — 77%, B2 — 61% , Cl
— 66%, C2 — 30%, D — 1%. Clearly,
earlier detection of lesser stages of cancer
would positively influence the cure of this
disease.
In regard to cancer of the colon, the
American Cancer Society has recom
mended (a) annual digital rectal exami
nation in patients over 40 years of age,
(b) annual examination for occult blood
in patients over 50 years of age and (c)

Table I—Astler-Coller Classification of
Colonic and Rectal Cancer
Class
Description
A
Limited to mucosa.
B1
Extension into but not through
muscularis propria, negative nodes.
B2
Extension through muscularis propria,
negative nodes.
Extension into but not through
C1
muscularis propria, positive nodes.
C2
Extension through muscularis propria,
positive nodes.
D
Distant metastases.
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sigmoidoscopy every 3 to 5 years in
patients over age 50.
The rigid 25-cm sigmoidoscope is the
instrument that is referred to in the last
recommendation. If rigid sigmoidoscopy
offers diagnostic benefit, would more
benefit be provided by the flexible sig
moidoscope, which examines up to 60 cm
of colon?
This paper addresses the rationale,
indication and techniques for using
flexible fiberoptic sigmoidoscopy as a
primary screening tool in the physician’s
office.

examination, time required for examina
tion, numbers of lesions identified and
patient preference were gathered. Patient
preference is meaningful because all
patients had previously undergone rigid
sigmoidoscopy as part of an annual phys
ical examination. Time was kept by a stop
watch; as the scope touched the anus time
began, and as the scope was withdrawn
from the anus the watch was stopped.
Technique

The procedure is performed during an
office visit. Two small enemas are given

as preparation. The patient is placed on
the power table in the jackknife position
but is not tilted into a head-down posi
tion. No sedation is necessary. A twoglove technique is used, the outer glove
being worn only for digital examination
and introduction of the well-lubricated
sigmoidoscope. As a matter of personal
preference, the scope dial controls were
taken out of the locked mode so that the
tip would advance freely. The scope is
gently pushed blindly up to the 5- to
10-cm level. Under direct vision, the rec
tum can be traversed to the 15- to 20-cm
level easily. The right hand is used to

Method

At the National Naval Medical Center,
Bethesda, Md., 499 patients (336 men,
153 women) who had polyps removed
through either a rigid sigmoidoscope or
colonoscope between 1974 and 1981 had
their charts reviewed to determine the site
of the lesion. All patients had undergone
barium enema examination or colono
scopy as part of the investigation. Lesions
up to 25 cm from the anus were desig
nated to be within view of the rigid sig
moidoscope. The remainder were classi
fied as to site by barium enema or
colonoscopy. The polypoid lesions were
classified as simple tubular, mixed tubu
lar and papillary, papillary, simple tubu
lar with cancer, mixed with cancer, papil
lary with cancer, or metaplastic. The
metaplastic polyps are not believed to
have the potential to degenerate into
cancer, as opposed to the other polyps.
The charts of 448 patients with cancer
from 1970 to 1979 were reviewed to iden
tify the site of the cancer. Cancers within
10 cm were considered reachable by digi
tal examination. Those from 10 to 25 cm
were potentially reached by the rigid sig
moidoscope. Those in the sigmoid were
potentially within reach of the flexible
fiberoptic sigmoidoscope.
In 1979, a subset of 211 asymptomatic
patients at the United States Capitol
Colon and Rectal Clinic, Washington,
DC, were evaluated by flexible fiberop
tic sigmoidoscopy. Prospective data
regarding level reached in the colon at

Table Ill-Colon and Rectal Cancers in 448 Patients,
1970 to 1979
Potential
detection by

No. (%|

Cumulative gain,
no. (%)

Digit
Rigid scope
Flexible scope

92 (211
78(17)
99(22)

92 (21)
170 (38)
269(60)

Level
0-10 cm
11-25 cm
Sigmoid

Table IV—Level of Examination Achieved by
Flexible Fiberoptic Sigmoidoscopy in 211 Patients
Level, cm

No. (%|

10-19
20-29
30-39
40-49
50-59
> 60

0(0)
4(2)
14(6)
39(19)
86(41)
68(32)

Cumulative
reach, %
100
100
98
92
73
32

Table V-Site of Neoplasms Found by Flexible Fiberoptic Sigmoidoscopy
in Asymptomatic Patients
No. of
patients

Series
Bohlman and associates, 19775
Lipshutz and associates, 1979®
Marks and associates, 19797
Meyer and associates, 1979®
Wherry, 19819
Present study

120
200
203
122
417
211

Level, no. (%)
< 25 cm
8 (6.6)
—

9 (4.4)
3 (2.4)
38(9.1)
10(4)

> 25 cm
28(23.3)
-

16(7.8)
13(10.6)
35(8.4)
18(8.0)

Totals,
no. (%)
36(30)
- (9 .5 )
25(12.2)
16(13)
73(17.5)
14(12)

Table II—Polyps of the Colon and Rectum in 499 Patients, 1974 to 1981
Polyp type

Site
Rectum
Sigmoid
Descending colon
Splenic flexure
Transverse colon
Hepatic flexure
Ascending colon
Cecum
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Tubular

Tubular
with
carcinoma

109
83
15
1
5
2
10
3

8
6
0
0
0
0
0
0

Mixed

Mixed
with
carcinoma

Papillary

Papillary
with
carcinoma

32
35
2
0
2
2
1
0

17
8
1
1
1
0
2
2

16
3
0
0
1
0
3
5

5
3
0
1
0
2
0
3

Metaplastic

Totals

12

259
168
21
5
9
6
18
13

30
3
2
0
0
2
0
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folds for more complete examination.
Before the scope is removed, all air is suc
tioned out to decrease distension and the
feeling of bloating that the patient
experiences.

grasp the sigmoidoscope shaft near the
anus, to pull or push and to torque the
shaft of the scope. When the tip must be
deflected to find the correct direction up
the bowel lumen, the right hand is moved
to the dials. The left hand supports the
scope head, and the fingers are automat
ically in position to apply suction or
insufflation. Often the left thumb, cra
dling the scope head, is used to rotate a
dial, leaving the right hand free to apply
torque. Examination is performed as the
scope is withdrawn. The examiner leans
away from the patient, drawing the scope
out slowly. With this extracting action,
both hands are free for fine movements
of the dials to inspect the bowel wall.
Insufflation is important to flatten out

Results
Of the 499 patients who had polyps
removed at the National Naval Medical
Center between 1974 and 1981, 390 had
epithelial neoplasms (tubular, mixed or
papillary) and 109 had metaplastic polyps
(Table II). Because metaplastic polyps do
not degenerate into cancers, our attention
focused on the tubular and papillary
polyps. Of these neoplasms, 187 (48%)
were in the rectum and presumably could

T a b l e V I — L e v e l R e a c h e d b y F l e x ib le F i b e r o p t i c S i g m o i d o s c o p y
L e v e l, %

No. of
S e r ie s

p a tie n ts

<

2 5 cm

> 4 5 cm

_

B o h lm a n a n d a s s o c ia t e s , 1 9 7 7 s

139

M a n ie r , 1 9 7 8 12

140

C r e s p i a n d a s s o c ia t e s , 1 9 7 8 13

468

—

63

L a m b e r t a n d a s s o c ia t e s , 1 9 7 8 14

300

95

50

M a r k s a n d a s s o c ia t e s , 1 9 7 9 7

50

100

67

1012

99

66

108

94

46

W in n a n a n d a s s o c ia t e s , 1 9 8 0 16

342

99

52

P re s e n t s tu d y

211

98

73

W i n a w e r a n d a s s o c ia t e s , 1 9 7 9 15

be seen by the rigid sigmoidoscope. There
were 138 (35%) in the sigmoid, which
could have been reached by the flexible
fiberoptic sigmoidoscope.
The retrospective review o f the charts
of 448 patients with colonic and rectal
cancer seen between 1970 and 1979 re
vealed that 92 (21%) of the tumours were
within reach of digital examination, 170
(38%) within reach of the rigid sigmoido
scope and 269 (60%) within reach of the
flexible sigmoidoscope (Table III).
Of the 211 asymptomatic patients at the
United States Capitol Colon and Rectal
Clinic who underwent flexible sigmoid
oscopy, all were examined up to the
25-cm level, which could be examined by
the rigid sigmoidoscope (Table IV).
Seventy-seven percent were examined to
the 50-cm level and higher.
The average time required to complete
flexible fiberoptic sigmoidoscopy was 4.9
minutes (range from 3 to 10 minutes). The
patient preference for rigid sigmoid
oscopy was 38 (18%) and for flexible
sigmoidoscopy 160 (76%); 13 (6%) had
no preference. Twenty-eight of the
asymptomatic patients had neoplasms.
Only 10 of these were below the 25-cm
level, within reach of the rigid sigmoido
scope (Table V5'9).
Discussion

T a b l e V I I - M e a n L e v e l R e a c h e d b y R ig id S i g m o i d o s c o p y
No. of
S e r ie s

M e a n le v e l,

p a tie n ts

B o h lm a n a n d a s s o c ia t e s , 1 9 7 7 s
M a r k s a n d a s s o c ia t e s , 1 9 7 9 7
W in n a n a n d a s s o c ia t e s , 1 9 8 0 16
N i v a t v o n g s a n d F r y d , 1 9 8 0 17

cm

139

2 0 .4

1012

2 0 .0

243

2 0 .0

5 0 0 m en

> 2 0

500 wom en

18

T a b le V I I I — D e g re e o f D is c o m f o r t C a u s e d b y
F le x ib le F i b e r o p t i c S i g m o i d o s c o p y
P a in , %
M in im a l t o

No. of
p a tie n ts

S e r ie s
L a m b e r t a n d a s s o c ia t e s , 1 9 7 8 14
M a r k s a n d a s s o c ia t e s , 1 9 7 9 7
W in n a n a n d a s s o c ia t e s , 1 9 8 0 16
T r a u l a n d a s s o c ia t e s , 1 9 8 3 18

T a b le I X - T i m e

None
-

—

3 .6

1012

-

—

1 0 .8

-

8 0 .0

2 0 .0

31

6 8 .4

0 .6

342
5000

R e q u ir e d f o r F l e x ib le F i b e r o p t i c S i g m o i d o s c o p y
No. of

S e r ie s
B o h lm a n a n d a s s o c ia t e s , 1 9 7 7 s

S e v e re

m o d e ra te

300

p a tie n ts
139

M e a n t im e .
m in
9 .4

C r e s p i a n d a s s o c ia t e s , 1 9 7 8 13

468

6

L a m b e r t a n d a s s o c ia t e s , 1 9 7 8 14

300

5 .1 5

L i p s h u t z a n d a s s o c ia t e s , 1 9 7 9 6
M a r k s a n d a s s o c ia t e s , 1 9 7 9 7
P re s e n t s tu d y

200
1012
211

7 .5
5
4 .9

A longer sigmoidoscope for screening
has become necessary, because the loca
tion of cancers has gradually shifted to
sites higher in the colon.10’11 Formerly, it
was believed that the rigid sigmoidoscope
would detect over half of the cancers,
whereas today, that number is only one
third. The sigmoid colon now accounts
for 30% of colonic and rectal cancers, a
rate that previously was only 13%. A
review of the literature reveals that the
distal 25 cm of the rectum and colon are
examined with the flexible sigmoidoscope
in over 94% of cases (Table v i 5,7-12' 16).
The 45- to 50-cm level is achieved in 46%
to 79% of patients in the same series; that
doubles or triples the length of bowel exa
mined by the rigid sigmoidoscope.
The rigid sigmoidoscope has gained a
reputation as a torture instrument. Sel
dom is the full 25 cm of the rigid sig
moidoscope inserted, because patient
tolerance is poor. The mean level reached
has been reported by several authors
to be approximately 20 cm (Table
yjj5,7,i6,i7) However, Nivatvongs and
Fryd17 stated that the 20-cm level applies
to men, the mean level reached in females
being only 18 cm. A less painful proce
dure will allow a better examination.
Several authors have described severe
patient discomfort, requiring examination
with the flexible fiberoptic sigmoidoscope
to be stopped. Severely painful examina
tions range from 0.6% to 20% (Table
VIII7’14’16’18). This wide range reflects the
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difficulty in evaluating such a subjective
complaint as pain. A review of the liter
ature shows that the yield of neoplasms
when screening asymptomatic patients
with the longer, less-painful flexible sig
moidoscope is about 12% (Table V).
Many of the benign neoplasms are poten
tial cancers that have been prevented by
early detection and excision.
What is the cost in terms of time and
money? As experience is gained, the
endoscopist will be able to perform the
procedure quicker. For inexperienced
endoscopists, double the appointment
time must be allotted so that eye-hand
coordination can be practised and the
frustration of racing the clock can be
avoided. The literature suggests that when
the endoscopist is familiar with the proce
dure, the time required will average 5 to
6 minutes (Table IX5'7'13'14).
The initial cost of equipment is over
$2500 for a complete system, and if repair
is required, costs are high. However, the
flexible fiberoptic sigmoidoscopes have
proved to be quite durable. Over 600 uses
can be expected, and often up to 1000
examinations can be performed before
the equipment fails.
An additional cost is the need for an
assistant to set up the scope, to help
steady the scope during insertion and to
clean it.
The fee for flexible fiberoptic sig
moidoscopy, as for other procedures,
varies around the United States. It is
usually two to three times the cost of sig
moidoscopy with a rigid scope. Double
the cost of sigmoidoscopy is reasonable,
because twice as much bowel is examined,
twice as many lesions are found, twice as
much time is required and perhaps twice
the risk is incurred.
Complications have been rare. Hemor
rhage and perforation are the major pos
sible complications. Hemorrhage occurs
more easily in the presence of existing dis
ease with friable mucosa. Stretching a
loop of sigmoid can result in splitting the
bowel wall, causing hemorrhage or per
foration. This is prevented by avoiding
force on the scope. The culprit is often
the slide-by technique, which everyone
uses to some degree. This technique
results in entrapment of the tip against the
bowel wall, which is recognized as a “ red
out” by the endoscopist. Continued push
ing may cause a perforation. Such con
ditions as acute inflammatory bowel dis
ease and radiated or ischemic bowel cause
an abnormally weak colonic wall, and
very gentle handling of the scope is neces
sary. Fixed points in the sigmoid, such as
adhesions from previous pelvic surgery,
may tear easily.
The flexible sigmoidoscope is a diag
nostic instrument. Polypectomy should
not be attempted without complete bowel
preparation, as for colonoscopy, because
explosive gases such as methane and

hydrogen may be present and may
explode if a spark is generated.
The flexible fiberoptic sigmoidoscope
is not a substitute for the barium enema
or colonoscope. When a patient has
symptoms referable to the colon or is in
a high-risk group of persons, such as
those with polyposis syndromes or
chronic ulcerative colitis or having a
family history of cancer, complete exami
nation of the colon is indicated.
The ideal candidate for flexible
fiberoptic sigmoidoscopy as an office
screening procedure is the asymptomatic
person over 40 years of age who is not
expected to need colonoscopy.
I thank Lisa D. Miller, my research techni
cian, for compiling the data on cancers and
polyps.
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Chairman: P. B e l l iv ea u , m d , frcsc *
Panelists: Z. C o h e n , P .H . G o r d o n , E .P . Sa l v a t i , L .E . S mith

5. Panel Discussion
Dr. Belliveau: I would like to thank the
speakers for their excellent presentations
and would welcome questions from the
audience. While we are waiting, I would
ask Dr. Cohen, who spoke on alternatives
to hemorrhoidectomy, to tell us if he
would consider banding in cases of acute,
thrombosed, internal hemorrhoids.
Dr. Cohen: In such a case, I would be
conservative and would not use rubber
banding on the patient.
Question: When performing left internal
sphincterotomy, do you do anything
about the sentinel tag and the hyper
trophied papilla that we see in chronic
fissure in ano?
Dr. Gordon: For the most part I don’t.
I don’t believe that it is necessary for heal
ing of the fissure to excise the hyper
trophied anal papilla or the sentinel pile.
Occasionally if a patient has a very large
pile and complains that it is pushing out
and is very bothersome, I may excise it,
but in terms of the procedure being neces
sary to heal a fissure, no. I don’t remem
ber the exact number, but 1 don’t think
that in my 133 cases, I performed more
than six such excisions.
Question: Dr. Salvati, first, what do you
do with the chronically unhealed piloni
dal wound, especially one that is deep in
the interanal cleft near the anal verge?
Then a question for Dr. Cohen: I noticed
on your slides that you band the hemor
rhoid directly and I wonder how many of
the members of the panel actually band
the hemorrhoid or include the prolapsing
tissue and the mucosa above the hemor
rhoid.
Dr. Salvati: I think we all have problems
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with unhealed wounds, particularly if
they have been operated on a couple of
times. Most of these wounds will heal if
you are persistent and see that, first, you
make the wound flat, second, that you
have the patient use a Water Pik to keep
the wound really clean and third, that you
see them every week to shave the hair
back. If you pay close attention to these
points, you can eventually get the sinus
healed. The technique described by
Rosenberg of reverse strapping helps
occasionally. To reverse strap the but
tocks is to open the buttocks up. This will
sometimes help in difficult cases.
Dr. Cohen: To answer your question, yes,
I agree with you. I usually would try to
get the upper portion of the hemorrhoid
and the prolapsing tissue above it.
Question: May I ask the panel if anyone
uses a topical agent, such as Preparation
H, on the symptomatic hemorrhoid?
Dr. Salvati: No, if you are talking about
symptomatic hemorrhoids. Most of the
symptomatic hemorrhoids that we see are
thrombosed externally. For every patient
with bleeding and protrusion there are
many more with thrombosed exter
nal hemorrhoids. We ought to point out
that the classification Dr. Cohen gave us
is for internal hemorrhoids, which don’t
cause pain unless they are irreducibly
prolapsed. They give rise to bleeding and
protrusion; pain from hemorrhoidal dis
ease comes from thrombosed external
hemorrhoids and they must be excised.
Question: 1 sometimes have difficulty
with patient compliance when I advise a
high-fibre diet and I would like to poll the
panel and ask them (a) what do they tell
their patients and advise them to eat and
(b) how do they maintain them?
Dr. Cohen: First, I think it is important
to have some kind of dietary regimen to
give the patient and instructions about
various foods. If the patient has any
problem understanding what we are try
ing to say, we send them to our dietician
who works quite closely with us. She will
follow them up usually by seeing them
every week for the first few weeks to
ensure that they have adhered to their
diet. I see them within 3 or 4 weeks to
assess their progress, and 1 think by fre
quent follow-up you can maintain that

person not only on high-fibre diet but on
stool softeners if indicated.
Dr. Salvati: If you wish to give the patient
a high-fibre diet for hemorrhoids and af
ter 6 months or a year those hemorrhoids
are still bleeding, they will continue to
bleed. You can only keep them asympto
matic just so long; then they will give
trouble and you will have to either ligate
or inject them. If you prescribe a highfibre diet for constipation, you can moti
vate the patient just a little bit better.
Searle puts out a booklet of high-fibre
items that the patient should eat and you
can generally motivate them properly, but
it’s not easy.
Dr. Gordon: I had a dietician list a whole
series of foods and explain how much
fibre there was in each food in the
categories of various cereals (bran being
the best), fruits and vegetables, so that the
patients, by the end of the day, would
have an idea of how much fibre they were
consuming, depending upon what they
had eaten from each category. This didn’t
confine the patients to any one food or
any one category of foods but it gave
them an idea of which foods were highest
in fibre and I think that this has been
quite helpful.
Dr. Smith: In general, I tell the patient
to go to a health-food store and buy raw
unmilled bran. It costs about a dollar a
pound. It’s about the cheapest thing you
can buy. It isn’t really tasty, but they must
try to disguise it — add it to soups, to
salads, to yoghurt, add milk and sugar,
fruit, be innovative. They should use a
third of a cup a day, measure it out in the
morning and by the end of the day it
should be finished.
Dr. Belliveau: Dr. Gordon, if you do a
lateral sphincterotomy in the office, first
of all, I suppose, you don’t put any pack
ing in?
Dr. Gordon: None at all.
Dr. Belliveau: And what do you tell your
patients to do in the first 2 days if they
have pain?
Dr. Gordon: I suggest they take sitz
baths. Warm baths are helpful. I
prescribe a nonconstipating agent, that is
to say one that doesn’t have codeine in
it. Most of the pain is on the first day;
after that, there really is not a lot of dis-
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comfort. In fact, some patients who have
had a lot of problems with the fissure will
say that even their first bowel movement
after the operation hurt them less than
having the fissure itself.
Dr. Belliveau: Panelists, what do you do
if you have a patient who has a fissure
associated with hemorrhoids? Do you still
do your sphincterotomy in the office or
would you suggest something else?
Dr. Smith: Well, everyone has hemor
rhoids, it’s just a question of whether they
are symptomatic or not. I don’t do any
thing if they aren’t symptomatic. Depend
ing on the degree of prolapse of the inter
nal hemorrhoids, I will band some
subsequently or, if they are what I call
third degree hemorrhoids that require
manual reduction, I will do a hemor
rhoidectomy at the same time.
Dr. Salvati: I believe that if you have a
third degree hemorrhoid and a fissure,
then you should operate on that particu
lar patient because of what Dr. Gordon
has pointed out. After all, if a patient
comes to you in pain and you do a lateral
sphincterotomy and all the hemorrhoids
prolapse, you are going to end up oper
ating anyhow, so you are far better off
doing the hemorrhoidectomy for the third
and fourth degree hemorrhoids and the
lateral sphincterotomy at the same time.
Dr. Cohen: I agree with that, if you have

an active fissure and third or fourth
degree hemorrhoidal disease.
Question: Dr. Salvati, is there any place
left for primary excision of pilonidal dis
ease? And, secondly, when do you oper
ate on a mass as was shown with the
acutely prolapsed, thrombosed hemor
rhoid?
Dr. Salvati: I really don’t see any indica
tion for primary excision and closure.
That requires generally a week of
hospitalization. It’s just too costly and the
recurrence rate is high. As far as treating
the acute hemorrhoidal prolapse, we
described a method a number of years ago
in which, if you add 1 mL of hyaluronidase to 10 mL of marcaine or lidocaine,
and inject it directly into the edematous
mass, you can reduce the internal hemor
rhoids within 30 or 40 seconds; then you
must excise any external components that
are thrombosed. Then you can do multi
ple internal hemorrhoidal ligations, two,
three or four at the same sitting, so you
can very easily treat acute hemorrhoidal
disease (i.e., prolapsed, thrombosed, gan
grenous hemorrhoids) as an office proce
dure. We do it all the time.
Dr. Belliveau: I would like to summarize
briefly what was said this morning. It
seems that pilonidal disease can be treated
in the office by a simple laying-open
procedure under local anesthesia. Lateral

internal sphincterotomy should replace
anal dilatation for the treatment of anal
fissure and that also can be done in the
office. As alternatives to hemorrhoidec
tomy, rubber-band ligation seems to be
faring the best and may be followed by
injection sclerotherapy. Finally, flexible
sigmoidoscopy seems to be something to
be explored. I don’t think it’s the recom
mendation of Dr. Smith that we should
all run out and buy one; the rigid scope
still has a role to play, but if you are
screening asymptomatic patients, you
should consider adding this to your
armamentarium. I would like to thank the
panel and the audience for their partici
pation.

In the Next Issue
The July 1985 issue of the Journal will con
tain a number of papers presented at the
1984 annual meeting of the Canadian
Cardiovascular Society and at the 1984 an
nual meeting of the Canadian Association
of General Surgeons. Also included will be
two papers (one on the management of
pancreatic trauma and the other a report
from a community hospital on fatal sepsis
after splenectomy) originating from the
1984 annual meeting of the Trauma As
sociation of Canada.

The Canadian Association of General Surgeons wishes to announce the following postgraduate courses, to be held dur
ing the 1985 meeting of the Royal College of Surgeons, Vancouver, British Columbia.
Sunday, September 8, 1985
SURGICAL ENDOSCOPY
Course Chairman — Roger Keith, Toronto
(416) 480-4736
********************************************

Monday, September 9, 1985
PERIPHERAL VASCULAR SURGERY
Course Chairman — Wallace Chung, Vancouver
(604) 228-7219
********************************************

Registration: Delegates — $125; Residents — $75

For further information contact:

THE ROYAL COLLEGE OF PHYSICIANS AND SURGEONS
74 Stanley Street
Ottawa K1M 1P4

********************************************************************************
C.A.G.S. will sponsor additional symposia from September 10 — 12 inclusive, in association with the Royal Australasian Col
lege of Surgeons:
Unexpected Findings at Laparotomy
Skin Cancer — The Royal Australasian College of Surgeons
Surgical Infections
Problems for the Community Surgeon
Alternatives to Conventional Ileostomy
Management of Intra-Oral Malignancies
Transplantation — An Overview
Surgical Nutrition
3 Paper Sessions
Registration: No Charge
For further information contact the C.A.G.S. Program Co-Chairmen:
Joel B. Freeman, M.D., Ottawa (416) 595-4952 until June 30 — (613) 737-8537 after June 30, 1985
J. Trevor Sandy, M.D., Vancouver (604) 876-2268
The final C.A.G.S. program will be mailed to all C.A.G.S. members in May 1985.
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Symposium: Breast Cancer 1984, Precancerous
and High-Risk Lesions
Introduction
Every surgeon has, at some time, encoun
tered the clinical problem of a small focus
of abnormal, possibly precancerous tis
sue in a breast biopsy specimen that con
tains mainly benign fibrocystic disease.
These foci may be atypical hyperplasia,
lobular carcinoma in situ or intraductal
carcinoma. Traditionally, these diagnoses
are considered together and, until
recently, were treated quite aggressively
by surgical management.
The proper management of these
lesions is now questioned, especially
because of the evolving pattern of sur
gical treatment for frank, invasive car
cinoma. There has been a trend, based on
ongoing scientific evaluation, to abandon

the more radical operations and move
through a series of steps from radical
mastectomy to modified radical mastec
tomy to partial mastectomy for local con
trol of the breast tumour.
If, as may appear, partial mastectomy
is equivalent to total mastectomy for a
carcinoma, is it appropriate to consider
total mastectomy for precancerous
lesions?
In the symposium that follows, input
has been sought from epidemiology,
pathology and surgery. While there may
be some overlap in the statistics cited, the
differences in interpretation and in
recommendations will be largely because
our data base is not sufficiently complete

for us to draw definitive conclusions.
Therefore, the material presented here is
offered not as guidelines for clinical
management but as thoughtful and logi
cal appraisals of the available knowledge,
to help clinicians work towards better
patient management.
R ic h a r d G. M a r g o l e se , m d , frcsc
Symposium chairman
Department of Surgery,
Sir Mortimer B. DavisJewish General Hospital,
Montreal, PQ
H3T 1E2

M a r t in T. S c h e c h t e r , m d , m s c , p h d

1. Breast Cancer Risk Factors:
Can We Select Women for Prophylactic Mastectomy?
Prophylactic procedures to prevent dis
ease in women at high risk for breast
cancer should be considered only when
the benefits of prophylaxis outweigh its
costs. The rational prophylactic use of
mastectomy in these circumstances must
await answers to several questions.
First, accurate estimates of the true risk
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associated with these lesions must be
obtained, as current estimates are impre
cise and potentially biased. Second, large
ongoing trials of breast cancer screening
and treatment may provide effective
methods of distinguishing those women
at exceptionally high risk in whom such
procedures may be warranted. Finally,
the question of conservative surgery as
an acceptable treatment for breast
cancer must be settled; otherwise, the
prophylactic procedure may be more
invasive and disfiguring than the treat
ment of the disease it seeks to prevent.
Les interventions prophylactiques destinees a prevenir le cancer du sein chez
les femmes a haut risque ne devrait etre
envisagees que quand les benefices
escomptes I'emportent sur les couts.
[.'utilisation raisonnable de la mastectomie prophylactique dans ces circonstances doit attendre les reponses & plusieurs
questions. Tout d'abord, il faudra etablir
une evaluation precise des risques reels
rattaches a ces lesions puisque les esti

mations actuelles sont imprecises et possiblement partiaies. En second lieu, les
importants essais cliniques sur le depistage et le traitement du cancer du sein
feront peut-etre ressortir des methodes
efficaces permettant d'identifier les fem
mes a risque exceptionnellement eleve
chez qui de telles interventions pourraient etre justifiees. Finalement, on
devra regler la question de la chirurgie
conservatrice comme traitement accepta
ble du cancer du sein; autrement, I'intervention prophylactique est possiblement
plus invasive et mutilante que le traite
ment de la maladie qu'elle cherche a pre
venir.

There are several different aspects to the
selection of women who are at high risk
for breast cancer. One question is which
women are at highest risk? It is perhaps
on these women that preventive and
health-promotion measures could be con
centrated for optimum results.
A second question pertains to issues in
screening; which women are the most
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likely to have a breast cancer detected on
screening? If a strategy for identifying
such women was available, then the
resources for screening as well as the haz
ards of annual mammography could be
concentrated only on the identified sub
group of women at high risk. This would
make better use of resources, lower the
screening-related risk and, most impor
tant, annual screening would be more
widely accepted by healthy women and
physicians.
Finally, a third related question is
raised by this symposium. Which of the
women with certain “ precancerous”
lesions are at highest risk of subsequently
having invasive carcinoma? Can we
accurately estimate the risk in individual
patients so as to guide our management
better? Clearly, accurate estimates of risk
are necessary if we are to make intelligent
decisions regarding the use of such proce
dures as prophylactic mastectomy.
For purposes of review, let us recall
some of the characteristics necessary for
successful surgical prophylactic proce
dures, such as prophylactic mastectomy
or colectomy. First, the prophylactic
maneuver should effectively prevent the
disease. Second, the population at high
risk should be easily identifiable. Third,
the benefit of the prophylactic maneuver
should outweigh its cost in this high-risk
population.
Here, benefit and cost should be viewed
in their wider sense. Benefit refers to both
financial and health benefits, including
any morbidity and mortality avoided by

prophylaxis, while costs refer to both
financial and health cost, including any
morbidity and mortality, anxiety, label
ling effects, and so on, caused by the
maneuver.
Clearly, the more successful we are at
identifying the high-risk population, the
more likely it is that the cost-benefit equa
tion will be satisfied. This can be seen
most readily by the radical proposal that
all women undergo prophylactic mastec
tomy at the age of 30 years. This would
do wonders for breast cancer mortality in
our society but clearly cost would far out
weigh benefit.
It is also critical to remember that it is
the psychological and emotional profile
of the individual woman that decides the
utilities that are to be assigned to the var
ious management options. There are
patients who, for various reasons, will
choose to avoid mastectomy at all costs
no matter what the risk of subsequent
cancer is, while others find greater benefit
in eliminating the continuous anxiety and
fear associated with repeated biopsies.
Selection
With regard to selection strategies, I
would like to make three key points. First,
I would emphasize that the etiology of
breast cancer is exceptionally complex,
representing a poorly understood inter
play of reproductive, hormonal, genetic
and environmental factors. Second, most
risk factors have modest etiologic force;
that is, their relative risks are modest, in
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the neighbourhood of two to five times
the normal, and it is their combination
that determines overall risk. Haagensen1
called this the “ cumulative predisposi
tion” . Unlike cigarette smoking and its
relation to lung cancer, there is no
individual risk factor for breast cancer
that is so highly culpable. Third, simplis
tic approaches to selecting women at high
risk will not suffice; that is, simple
approaches to risk-factor information will
provide only simple answers and, given
the complexity of breast cancer, these will
probably not be satisfactory.
Family History
An excellent example of the insight
gained from a more complex analysis con
cerns the question of family history. Con
sider the example of a 31-year-old woman
whose mother and three maternal aunts
all have breast cancer. The question of
prophylactic mastectomy is raised. To
begin with, the overall cumulative lifetime
risk for the average 31-year-old woman
has been estimated to be about 7% to
8% .2 The simple approach in the past in
considering family history has been to
assign an overall relative risk, usually
around two, to women with a family his
tory of breast cancer. The cumulative life
time risk would therefore be around 15%
for such a woman. If we add some com
plexity, however, we find that the risk
differs if the familial cancer was unilateral
or bilateral and if it occurred before or
after the menopause (Table I).3 If the
familial cancer is premenopausal and
bilateral, the relative risk is estimated to
be almost nine and the cumulative risk is
45%. On the other hand, if the familial
cancer is postmenopausal and unilateral,
which represents most familial cancers,
there is virtually no increase in risk at all.
The same holds true for multiple familial
cancer. If two sisters have premenopausal
bilateral breast cancer, the cumulative risk
for another sister is estimated to be about
50%. But if the sisters both have post
menopausal, unilateral disease, there is
again virtually no increase in risk.
Returning to our example, we find that
all of our patient’s familial cancers were
in fact unilateral and postmenopausal.
From these data, she appears to be at very
little, if any, increased risk o f breast
cancer. This is so despite what appears to
be at first glance an extremely strong
family history.
What has occurred here is that a risk
factor, in this case family history, has
been found to interact with menopausal
status and laterality. As a result, instead
of implicating family history to a mild
degree in all women with family histories,
the risk can be concentrated on the
extremely small number of women with
familial histories of premenopausal,
bilateral disease, and the majority of
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women with family histories, that is those
with familial histories of postmenopausal
unilateral disease, are exonerated.
Risk Factors

There seem to be many risk factors for
breast cancer: increasing age, premeno
pausal bilateral breast cancer in a firstdegree relative, a history of breast cancer
in the contralateral breast and certain
precancerous or high-risk lesions are as
sociated with the largest relative risks.
Late age at first live birth, early age at
menarche, late age at menopause, a his
tory of fibrocystic disease, low parity,
radiation to the chest and obesity have
also been implicated (Table II4). In addi
tion, there are the emerging questions sur
rounding the role of dietary fat consump
tion, the possible role of smoking and a
possible positive effect of long-term use
of oral contraceptives in young women.
On another level, various pathological
diagnoses may be predictors. With regard
to fibrocystic disease, the specific diag
noses that are thought to be associated
with subsequent breast cancer are atypi
cal epithelial hyperplasia, atypical lobu
lar hyperplasia and diffuse papillomato
sis with atypia. However, it is important
to point out that the elevated risks
associated with these diagnoses have not
been demonstrated consistently and that
if such elevations exist, they are likely
only to be in the neighbourhood of a twoto fourfold increase. Clearly, this would
not justify a consideration of prophylac
tic mastectomy.
High-Risk Lesions

To approach the question of high-risk
lesions, consider the example of a 42-yearold premenopausal woman with three
children, whose first child was born when
she was 21 years of age, whose menarche
was at 14 years and who has just had
lobular carcinoma in situ found on breast
biopsy. Clearly, the question of manage
ment for this patient depends on the
underlying question of whether invasive
breast cancer will develop. We know that
this woman has a high-risk lesion and car
ries an increased risk of breast cancer
developing, but exactly how high is this
risk?
Data from past studies5 suggest she
has about a 35% chance of having inva
sive cancer within 20 years. Is the increase
in risk from 7% to 35% sufficient cause
to consider prophylactic mastectomy in
this patient? This study5 was retrospec
tive so that there are problems with the
cohort of women assembled for follow
up. For example, the age ranged from 27
to 55 years so it is difficult to know how
to apply the results to any given age
group. The most glaring deficiency is that
only 50 patients were considered in this
244

study. The use of such small numbers
results in a lack of statistical precision.
The key estimate of 35%, for example,
was based on only nine cases. In this
study, 31 women were lost to follow-up
so that after 10 years, only 15 women
were being followed up. If one were to
put 95% confidence limits around the
estimates, one would obtain a range of
from 12% to 57% for the average 20-year
risk of invasive carcinoma. The lower end
of this range is not much higher than the
8% cumulative risk applicable to the
general population. The results are fur
ther confounded by the fact that in 45 of
the 50 women biopsies were done because
of the clinical presence of fibrocystic dis
ease. Many of these criticisms hold as well
for most other studies in this area. Fur
thermore, we have no data on the
influence of other risk factors such as age
at first live birth, age at menarche, and
so on, and how these risks might be modi
fied. These data certainly suggest that
women with lobular carcinoma in situ are
at elevated risk for invasive breast cancer,
but precise estimates of how high the risk
is are lacking. However, ongoing clinical
trials of breast cancer screening and of
breast cancer therapies may provide more
sound estimates in the future.
If we accept these estimates, then of
100 women like our patient, 35 or so will
suffer invasive cancer within 20 years.
Just as a half-full glass is also half-empty,
it is important to note that 65 of those
women will not have invasive carcinoma.
These constitute a fascinating group of
women who have a known precursor and
yet, perhaps for hormonal, dietary,
reproductive or genetic reasons, invasive
disease does not develop. An analysis of
the factors that protect these women
could be important to our understanding
of breast cancer etiology.
Even among the unfortunate women
with lobular carcinoma in situ who sub
sequently have invasive cancer, the evi
dence suggests that the invasive cancer is
just as likely to occur in the contralateral
as in the ipsilateral breast. Moreover, the
invasive cancer that develops is more
likely to be intraductal than lobular and
is unlikely to be in the same site as the
original lesion. These facts suggest that
the hypothesis that the lobular carcinoma
in situ progresses in a stepwise fashion to
become the invasive cancer, is untenable.
More reasonable is the hypothesis that
lobular carcinoma in situ is a marker for
women at high risk, in much the same
way as a history of premenopausal
bilateral breast cancer in a first-degree
relative is.
Conclusions

Lobular Carcinoma in Situ
From these observations, there appear

to be some logical conclusions. First,
since both breasts are at equal risk, the
management of the contralateral breast
should be identical to that of the
ipsilateral one. Second, since lobular car
cinoma in situ should be viewed as a risk
factor or marker and not as a precursor,
any management policy for this lesion
should be applied as well to any risk fac
tor of equal magnitude, such as pre
menopausal bilateral breast cancer in a
first-degree relative. Since the risk of sub
sequent invasive cancer in women with
such a family history has been estimated
to be approximately of the same magni
tude as the risk for women with lobular
carcinoma in situ, then the management
policy for each of these situations should
be the same.
Does it logically follow from this that
a policy of bilateral mastectomy is justi
fied for lobular carcinoma in situ or any
other risk factor of equal magnitude?
Given the paucity of data and our current
inability accurately to assess risk, I do not
believe that such a policy can be justified.
Intraductal Carcinoma
The situation with regard to intraduc
tal carcinoma may be clearer. This is not
because the estimates of risk are any
sounder than for lobular carcinoma in
situ, since again the numbers of patients
followed in studies are woefully inade
quate. What is clearer is the observation
that subsequent invasive cancer, when it
occurs, tends to do so in the ipsilateral
breast only and the histologic type of the
subsequent cancer is usually ductal. These
observations support the hypothesis that
intraductal carcinoma is a precursor
lesion with malignant potential. For these
reasons, prophylactic mastectomy has
been far less controversial as treatment
for intraductal carcinoma than it has been
for lobular carcinoma in situ. However,
it is important to note that our knowledge
of the true risk associated with intraduc
tal lesions is imprecise. The methodologic
problems cited earlier apply also to the
follow-up studies of women with this type
of lesion. There is evidence to suggest that
in a significant proportion of women with
intraductal cancer, the disease does not
progress to invasive cancer.6
Prophylactic Mastectomy
Policies concerning prophylactic
mastectomy become even more difficult
in the light of recent changes in our atti
tude concerning the primary therapy of
breast cancer. If the recent trend towards
more breast-conserving surgery such as
lumpectomy continues, it may very well
violate the cost-benefit equation to advo
cate a prophylactic procedure that is far
more aggressive and disfiguring than the
eventual therapy of the disease that the

VOLUME 28, NO. 3, M A Y 1985 / THE CANADIAN JOURNAL OF SURGERY

ADMINISTRATION
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CEFOBID (cefoperazone sodium) should be administered by deep intramuscular injection into a large
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prophylactic procedure seeks to prevent.
The only way prophylactic mastectomy
might be applied rationally is if more
exact estimates of risk o f subsequent inva
sive cancer in women with these lesions
were available and if methods were deve
loped for identifying those women with
such lesions who are at exceptionally high
risk. Such methods are not yet available.
The National Breast Screening Study o f
Canada,7 a randomized controlled trial
currently being conducted across Canada,
is recruiting 90 000 women to assess the
benefits o f annual screening. Using data
from this study and a multivariate
biostatistical technique known as logistic
discriminant analysis, we were able to
combine risk factors such as age at first
live birth and family history, to discern
women at high risk. These methods
allowed us to identify 40% o f the popu
lation in whom 85% o f all breast cancers
occur. It is hoped that prospective data
arising from this study as well as from
ongoing clinical trials o f breast cancer
therapy will provide more accurate esti
mates o f risk for women with high-risk
lesions and similar discriminants to identify women at exceptionally high risk for
whom prophylactic procedures may be
warranted. Such discriminants may be
complex, combining the risk-factor infor
mation and histopathologic features o f
the original lesion. It is conceivable that
methods will exist for selecting out o f all
women with lobular carcinoma in situ,
40% to 50% in whom most o f the inva
sive cancers will occur. The cumulative
risk in such women might approach 70%
or beyond so that a prophylactic interven
tion could be more easily justified.
Moreover, it would reduce the number o f
women considered for prophylaxis by
50% or more. Until these methods exist,
however, and until the question o f breast
conservation as an acceptable therapy for
invasive cancer is settled, I do not believe
there is sound epidemiologic evidence to
support an overall policy o f prophylac
tic mastectomy.
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2. Definition of Precancerous and
High-Risk Mammary Lesions
Intraepithelial (noninvasive) neoplasia of
breast, the most potent precursor of
invasive carcinoma, comprises two
types: lobular carcinoma in situ and duc
tal carcinoma in situ. Their respective
morphologic character, biologic sig
nificance and natural history are dis
cussed. Borderline lesions, such as atypi
cal lobular hyperplasia and atypical
ductal hyperplasia, are defined and their
importance as risk factors for subse
quent carcinoma is emphasized. Analysis
of the concept of fibrocystic disease
recognizes a lack of both pathologic
specificity and predictive value as a risk
factor for malignant disease. Rather than
referring to fibrocystic disease, this com
plex should be stratified in specific histo
logic types to understand better its bio
logic significance.
Les neoplasies intraepitheliales (non invasives) du sein, qui representent les plus
serieux precurseurs d'un carcinome invasif, sont de deux types: les carcinomes
lobulaires in situ et les carcinomes canaliculaires in situ. On commente leurs
caracteres morphologiques respectifs,
leur importance biolologique et leur histoire naturelle. Les cas limites, tels que
I'hyperplasie lobulaire atypique et
I'hyperpiasie canaliculaire atypique, sont
definis, et leur importance en tant que
facteur de risque d'un cancer subsequent

est soulignee. A I'analyse, le concept de
maladie fibrokystique du sein n'offre ni
specificite pathologique, ni valeur previsionnelle comme facteur de risque. Plutot
que d'en referer a la maladie fibrokysti
que, il vaudrait mieux stratifier les cas
d'aprfes le type histologique specifique
afin de mieux comprendre Timportance
biologique de celui-ci.

It is well established that lobular carci
noma in situ and ductal carcinoma in situ
(intraductal carcinoma) are the most sig
nificant and potent precursors of invasive
breast cancer. Their distinctive natural
history has been elucidated through recent
retrospective studies.1-4 Both lesions have
been legitimately included in the concept
of minimal breast cancer.
Lobular Carcinoma in Situ

Lobular carcinoma in situ represents
28% to 37%5-6 of all cases of carcinoma
in situ. It is defined as involvement of a
variable number of terminal lobular units
by a proliferation of monotonous cells
that obliterate luminal spaces, with a vari

able degree of distension (Fig. 1). It is
usually an incidental finding on histologic
examination of a biopsy specimen for
such conditions as fibrocystic disease. A
high degree of alertness and adequate fix
ation of tissue are prerequisites for histo
logic recognition. Noninvasion is assumed
on the basis of insular groups of cells with
a smooth and spherical contour, centred
around the terminal ductule. There are
two cytologic subtypes, which may be
combined. The first is characterized by a
monotonous population of polygonal
cells with a pale or amphophilic cyto
plasm. Intracytoplasmic globules or lumina are frequently noted.7 Nuclei are
round, with little variation in size; they
often display a finely dispersed chroma
tin with inconspicuous nucleoli. Mitoses
are sparse or absent. The second subtype
is characterized by a population of morepleomorphic, less-cohesive cells with
anisocytosis that may display prominent
nucleoli. These two subtypes have been
designated types A and B respectively by
Haagensen and colleagues.8 Retrograde
ductal involvement is not unusual;
tumour cells may be insinuated between
the basement membrane, with or without
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FIG. 1—Lobular carcinoma in silu. Distension of terminal lobular unit by solid popula
tion of monotonous cells. Note frequent intracytoplasmic, clear globules (hematoxylin and eosin

x 400).
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outer budding and preservation of inner
lining epithelium.9'10 The pathologist
should not confuse this pattern with duc
tal carcinoma in situ (the clinging pat
tern), a disease of distinct biologic sig
nificance. The retrograde extension of
lobular carcinoma in situ has been
referred to as Pagetoid spread.9 On the
other hand, it is important to distinguish
between lobular carcinoma in situ and
intraductal carcinoma within the lobular
unit, since the latter may extend centrifugally and involve the terminal lobular
unit. This process has been termed lobu
lar canceration.9 Occasionally, this
phenomenon is the only detectable topo
graphic histologic pattern. A cribriform
pattern, a more pleomorphic tumour cell
population and cell necrosis are more

likely to indicate lobular canceration
(Fig. 2).
The retrospective study of Rosen and
colleagues1 has elucidated the biology of
lobular carcinoma in situ. They analysed
84 patients, treated by biopsy only and
followed up for an average of 24 years.
Subsequent invasive carcinoma developed
in 28 (33%) of the patients, in the
ipsilateral breast in 12, in the contralateral
breast in 9 and in both breasts in 7. In
regard to histiotype, there were 20 inva
sive ductal carcinomas, 13 invasive lobu
lar, 1 mucinous and 1 tubular carcinoma.
Interestingly, the majority of subsequent
carcinomas became evident 15 or more
years after the original biopsy and 38%
were not detected until 20 years later.1
Still unexplained is why, although 60%

of subsequently studied mastectomy
specimens harboured foci of residual
lobular carcinoma in situ, less than half
of the patients treated by biopsy only
would subsequently have ipsilateral car
cinom a.11 These findings suggest that
lobular carcinoma in situ is a tissue mar
ker for increased risk of subsequent inva
sive carcinoma of any histiotype, in the
whole bilateral mammary parenchyma.
Lobular carcinoma in situ is a potent,
anatomically defined risk factor for sub
sequent invasive carcinoma, carrying a
ninefold relative risk for the patient.1
Atypical Lobular Hyperplasia
Atypical lobular hyperplasia is best
defined as a histologic entity that does not
fulfil all the criteria for the definition of
lobular carcinoma in situ. There is no
detectable distension of the lobular unit
and residual lumina are present (Fig. 3).
Nuclei may appear partly ovoid and over
lap.9 It has been suggested that this
lesion could represent the “ early” or
incomplete form of lobular carcinoma in
situ.12 Recent studies have defined the
relative risk.13’14 A retrospective analysis
of 125 cases of atypical lobular hyperpla
sia revealed that in 14% of these patients
invasive carcinoma developed, represent
ing a relative risk of 4.4, in contrast to
the relative risk of 9 for lobular carci
noma in situ.14
Intraductal Carcinoma

FIG. 2—Lobular canceration by ductal carcinoma in situ. Lobular unit displays malignant
columnar cells surrounding well-formed holes. This should be distinguished from lobular car
cinoma in situ (hematoxylin and eosin, x 400).

FIG. 3—Atypical lobular hyperplasia. Proliferation of monotonous cells without signifi
cant lobular distension. Residual luminal spaces are present (hematoxylin and eosin, x 400).

Intraductal carcinoma has a distinctive
biologic and histologic character. Clini
cally, it appears as a discrete or question
able mass in about 75% of cases.15
Symptoms are also more likely before
invasion occurs if the lesion is central and
subareolar. A minimal tumour sampling
o f 6 to 10 blocks has been suggested as
basic requirement to rule out inva
sion.16,17 It is most important to ensure
a diagnosis o f pure (noninvasive)
intraductal carcinoma if the surgeon is
not going to perform a nodal dissection.
Intraductal proliferation of malignant
cells depicting a solid, papillary or cribri
form pattern of growth is characteristic
(Fig. 4). Tumour cells are usually more
pleomorphic than those found in lobular
carcinoma in situ and necrosis, referred
to as comedo-type, is frequently observed.
The histologic judgement of noninvasion
is based on a spherical ductal contour and
sharp epithelial-stromal demarcation. An
associated inflammatory cell response
may be present. In spite of the absence
of demonstrable stromal invasion, on rare
occasions nodal metastasis may occur.
This could be explained on the basis of
inadequate tumour sampling or early
escape of tumour cells from the basal
lamina. Indeed, Ozzello18 demonstrated
transgression of basal lamina by tumour

VOLUME 28, NO. 3, M A Y 1985 / THE CANADIAN JOURNAL OF SURGERY

249

cells at the ultrastructural level. Intraduc
tal carcinoma may occasionally depict the
so-called clinging pattern, defined as one
or a few layers of malignant cells lining
the ductal system.9 The diagnosis often
depends on the alertness of the patholo
gist and may easily be missed. Extension
to lobular unit (lobular canceration) or
epidermotropism (Paget’s disease) are
also possible pertinent findings on patho
logical examination.
The natural history of intraductal car
cinoma has been described in two major
series in which patients were treated by
biopsy only.3’4 In a series of 15 patients,
7 had ipsilateral invasive carcinoma
within 10 years.4 In a second series of 28
patients, with average follow-up of 16
years, 7 patients had ipsilateral invasive
carcinoma within an average of 6 years.
In none of these patients did cancer
develop contralaterally and the invasive
ductal carcinoma was of the conventional
ductal histiotype.3 Although the overall
risk for subsequent invasive carcinoma is
similar to that for lobular carcinoma in
situ, the ipsilateral localization and much
shorter interval to the development of
invasive cancer are quite distinct.

FIG. 4—Intraductal carcinoma. Intraductal proliferation of polygonal cells, displaying hyperchromasia. solid papillary tufting and necrosis (N) (hematoxylin and eosin, x 400).

Fibrocystic Disease Complex
Fibrocystic disease as a risk factor for
breast carcinoma is of dubious sig
nificance. The main reason is that this
lesion embraces a spectrum of hormonal,
stromal and epithelial changes. Indeed,
numerous histopathologic findings are
included in this complex. It has been sug
gested that the term fibrocystic disease be
characterized by more specific histologic
determinants in order to allow a better
histologic classification and prospective
analysis.19 Historically, it has been esti
mated that fibrocystic disease carries a
risk factor of no more than 1.5 to 2.5.9
We have characterized the fibrocystic dis
ease complex into specific histologic
categories (Table I). That without
epithelial hyperplasia is characterized by
cysts, fibrosis and apocrine metaplasia.
No significant risk for cancer develop
ment has been convincingly demon
strated. Fibrocystic disease with epithelial
hyperplasia (intraductal or intraductular
hyperplasia, or both, and epitheliosis) is
characterized by a multicentric, benign
proliferation of both epithelial and

Table I—Fibrocystic Disease Complex
__
__
of the Breast
Without epithelial hyperplasia
With epithelial hyperplasia
Not otherwise specified
Atypical
Radial scar
Blunt duct and sclerosing adenosis
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FIG. 5—Atypical ductal hyperplasia. Proliferation of monotonous cells with variable nuclear
hyperchromasia and without distinct myoepithelial differentiation. Irregular luminal spaces are
present. This represents minimal deviation from lobular carcinoma in situ (hematoxylin and
eosin, x 400).

FIG. 6—Radial scar. Presence of fibroelastotic scar (right side) with radiating tubular struc
tures (left side) (hematoxylin and eosin, x 160).
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myoepithelial cells. Most important in
this category is the recognition of the
atypical form of epithelial hyperplasia,
referred to as atypical ductal hyperplasia.
This condition is defined as a lesion dis
playing cytoarchitectural features in the
borderline zone between not-otherwisespecified epithelial hyperplasia and
intraductal carcinoma (Fig. 5). The histo
logic deviation from intraductal carci
noma may be minimal and in some cases
clear distinction is not feasible. The lesion
may meet some but not all of the criteria
for intraductal carcinoma.20 For exam
ple, luminal spaces are not clearly slit-like
or hole-like, the cell population is often
monotonous and nuclear hyperchromasia is inconstant. A recent retrospective
analysis of 149 such cases showed a 12%
incidence of subsequent invasive carci
noma and a relative risk factor of 4.2.14
In fact, this risk is not substantially differ
ent from that for atypical lobular hyper
plasia.14 The overall risk for atypical
proliferative lesions is about one half of
that for carcinomas in situ but comes
close to it if there is a positive family his
tory.14 If the atypical group of prolifer
ative lesions is excluded, there is no con
vincing evidence that blunt duct,
sclerosing adenosis and fibrocystic disease
complex without hyperplasia are impor
tant risk factors.
Radial scar is a lesion that has received
close attention from pathologists lately.
It is likely to be misinterpreted as a malig
nant lesion on both radiologic21 and
pathologic examination. Of unknown
etiology, the lesion measures from 3 to
16 mm in size and is frequently multicen
tric.22>23 It is characterized by a central,
fibroelastotic core from which radiate
tubular structures, with or without papil
lary proliferation (Fig. 6). A complex
pathologic nomenclature has been used to
describe this entity,22 but radial scar is
the simplest descriptive term. Postulated
to represent an early incipient tubular car
cinoma,24 no convincing demonstration
has been made. Its biologic significance
as a histologic risk factor for cancer is
controversial. In a retrospective study of
32 cases with a mean follow-up of 19.5
years, only one patient subsequently had
ipsilateral invasive carcinoma. This is not
significantly different from the expecta
tion in normal control subjects.22 On the
other hand, an autopsy study showed a
higher incidence and greater number of
radial scars in cancer-associated mam
mary parenchyma than in breast pre
sumed to be at low risk for development
of cancer.23 The latter findings suggest
that radial scar carries a risk factor for
cancer development.
Although lobular and ductal carci
nomas in situ are well understood in
regard to their pathological definition and
natural history, we await the emergence
of new studies that should clarify the bio

Bactrim “Roche
logic significance of fibrocystic disease.
Histologic stratification in such a complex
entity appears essential to delineate pre
cise diagnostic criteria and for an under
standing of biologic data.
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3. Minimal Breast Cancer: Advance or Anachronism?
in question. These prerequisites are not
fulfilled by the term “minimal breast
cancer” . This definition was introduced
L'auteur argum ente que le cancer cirin 1971 by Gallager and Martin1 to
conscrit du sein n 'e s t pas une entite disdescribe “breast carcinoma that is read
tincte m ais q u'il com prend plutot trois
ily curable by available means” . They
co m p o sa n te s discretes ayant chacune
characterized minimal breast cancer as
des caracteristiques uniques. L'histoire
comprising three distinct processes: (a)
naturelle du cancer lobulaire in situ et du
lobular carcinoma in situ, (b) noninvasive
cancer intracanaliculaire, deux des com 
intraductal carcinoma and (c) invasive
posantes du cancer circonscrit du sein,
adenocarcinoma having a maximum
est decrite. O n souligne les dangers de
diameter of 0.5 cm. They selected 0.5 cm
se fier a d e s d on nee s reposant sur des
as the upper limit for compliance from
inform ations anecdotiques retrospecti
their hypothetical estimation that the inci
ves. Le cancer lobulaire in situ a ten
dence of nodal metastasis for these
dance a devenir multicentrique et bilate
tumours would be less than 5% and that
ral. D an s 2 5 % d e s ca s de cancer
the predicted 10-year survival rate would
lobulaire in situ, un cancer invasif du
be about 90%.
sein se developpe subsequem m ent, et la
More recently, the upper limit of
majorite de ces tum eurs prendra naistumour size for the invasive process has
sance d a n s les ca n a u x galactophores.
been expanded to include tumours as
L'intervalle m oyen entre le diagnostic de
large as 1 cm in diameter,2 but of far
cancer lobulaire in situ et I'apparition
greater importance is whether the term
d 'u n cancer invasif est de plus de 1 5 ans
minimal breast cancer is one that defines
et chacun des se in s est egalement
a true entity. From a biologic standpoint,
menace. A partir de ceci, on ne peut justhe grouping together of intraductal car
tifier le recours a la m astectom ie bilate
cinoma, lobular carcinoma in situ and
rale prophylactique. A I'o p p o se du ca n
invasive cancer (regardless of diameter)
cer lobulaire in situ, 2 5 % a 5 0 % des
appears inappropriate. Clearly, these
patientes atteintes de cancer intracanali
three processes represent distinct diseases,
culaire developperont un cancer infiltrant
having unique biologic characteristics. A
dans les 1 0 a nn ^es qui suivront la bioppossible justification for maintaining a
sie initiale. Bien que I'incidence putative
definition that includes disparate compo
des ca n ce rs m ulticentriques soit de
nents might be to signify uniformity in
5 0 % , pratiquem ent tous les cancers
therapeutic management, but since the
en va h issa n ts su b se q u e n ts apparaissent
therapeutic aspects of minimal breast
non seulem ent d a n s le m eme sein mais,
cancer are more complex than the defi
encore, d a n s le quadrant qui avait ete
nition, it is unlikely that the term will sur
soum is a la biopsie initiale. Devant la
vive
on the strength of this aspect.
From the Department o f Surgery, School
popularity actueile des operations visant
In fairness to Gallager and Martin, the
of Medicine, University o f Pittsburgh,
a preserver le sein d a n s les cas de ca n
definition of minimal breast cancer was
Pittsburgh, Pa.
cers e n va h issan ts, il y aurait lieu de metformulated at a time when insufficient
Presented as part of a symposium on
tre sur pied des e ssa is cliniques destines
attention
was being paid to categories of
precancerous and high-risk lesions of the
a evaluer la ju ste sse d 'u n traitement conbreast cancer with favourable prognostic
breast by the Royal College o f Physicians
servateur avec ou s a n s radiotherapie
characteristics. Any criticism should be
and Surgeons o f Canada, in cooperation
chez les patientes souffrant de cancer
with the Canadian Association of General
directed towards current investigators
Surgeons, the Canadian Oncology Society
intracanaliculaire.
who have maintained the term in spite of
and the Canadian Society of Plastic Sur
a better understanding of the biology of
geons, Montreal, PQ, Sept. 11, 1984
The formulation and adoption of new the diseases. Accordingly, I shall empha
Accepted for publication Jan. 7, 1985
cancer terminology is associated with an size the individuality of the three compo
inherent obligation — that the new defi nents of minimal breast cancer rather
Reprint requests to: Dr. TV. Wolmark,
nition describes a meaningful clinical than attempt a collective analysis based
Department o f Surgery, School of Medi
entity, the study of which furthers the bio on an outmoded concept.
cine, University o f Pittsburgh, 3459 Fifth
Avenue, Pittsburgh, PA 15213, USA
logic understanding of the disease process
Even if one were to accept the term
252
VOLUME 28, NO. 3, M A Y 1985 / THE CANADIAN JOURNAL OF SURGERY
The author a rgu es that minimal breast
cancer d o e s not represent a distinct d is
ease entity but c o m p rise s three discrete
com p one nts, each w ith unique charac
teristics. The natural history of lobular
carcinom a in situ and intraductal cancer,
tw o of the c o m p o n e n ts of minimal
breast cancer, is described. The dangers
of relying on a data base established on
the strength of retrospective anecdotal
inform ation is underscored. Lobular carci
nom a in situ h a s a propensity for m ul
ticentricity and bilaterality. In 2 5 % of
patients with lobular carcinom a in situ,
in va sive breast cancer will develop su b 
sequently, and the majority of these
tu m o u rs will be of ductal origin. The
average interval from the d ia g n o sis of
lobular carcinom a in situ to the develop
m ent of su b se q u e n t invasive cancer is
over 1 5 years and both breasts are at
equal risk. Base d on this information, the
use of bilateral prophylactic m astectom y
is unjustified. In contrast to lobular carci
nom a in situ, 2 5 % to 5 0 % of patients
w ith intraductal carcinom a will s u b se 
quently have infiltrating cancer, at an
average of 10 years after the initial
biopsy. A lth o u g h the putative incidence
of m ulticentricity is 5 0 % , virtually all
su b se q u e n t in v a siv e cancers occur not
only in the sam e breast but in the sam e
q uadrant as the initial lesion. In light of
the m om entum for breast-preserving
op erations in inva sive cancer, clinical
trials shou ld be im plem ented to a ss e s s
the propriety o f con servative m anage-

ment w ith and w ithout radiotherapy in
patients w ith intraductal carcinoma.

minimal breast cancer, it has been argued
that the number of patients meeting the
specified criteria would be very small
indeed. D ata from well-established
tumour registries3'4 estimate that only
10% of all breast cancers diagnosed could
be considered as minimal breast cancer
(Table I). There is good reason to believe,
however, that the overall detection of the
three components of minimal breast
cancer is changing as a direct result of the
increasing popularity and implementation
of screening programs. Data from the
Breast Cancer Detection Demonstration
Projects (BCDDP) disclosed that minimal
breast cancer accounted for more than
40% of cancers detected at the first
screening.2 O f these, noninfiltrating
cancer constituted more than 25% of all
detected breast cancers. Of the nonin
filtrating cancers, 80% were intraductal
and 20% were lobular carcinomas in situ.
In-depth analysis of the individual
components of minimal breast cancer is
thus not only compelling, but necessary.
With the development of screening
modalities that can identify more patients
with minimal breast cancer, well-con
trolled prospective studies designed to as
sess the biologic behaviour of noninfil
trating breast cancer are essential.

treated this cancer by performing at least treated by mastectomy were obtained
an ipsilateral mastectomy. In the second from retrospective and anecdotal case
hypothesis, lobular carcinoma in situ is reports.
regarded simply as a marker of a popu
A review of four of the principal ser
lation at high risk for the development of ies dealing with patients who had lobu
subsequent invasive cancer which is not lar carcinoma in situ treated only by
related to the initial lobular carcinoma in biopsy7,14' 16 disclosed that the number of
situ. The therapy that the surgeon selects documented cases was inadequate, rang
invariably reflects his biologic under ing from 32 to 263; moreover, the mean
standing of the disease.
follow-up varied from 15 to 24 years
Before therapeutically relevant issues (Table II).
are considered, it is important to review
Clearly, the most critical property of
the behaviour and natural history of the lobular carcinoma in situ that will
disease. Since lobular carcinoma in situ influence the choice of therapy is the inci
was defined as a distinct entity in 1941 by dence of invasive cancer subsequently.
Foote and Stewart3 and independently Here, too, there is a wide variation rang
by Muir,4 it has been known that the ing from a 13% incidence of invasive
entity is inconspicuous, both on clinical cancer in the series of Wheeler and
and gross examinations. It occurs at an colleagues14 to a high of 31% in the ser
earlier age than ductal cancer, with 75% ies reported by Rosen and associates.7 It
of all cases being documented between the is interesting that the interval from diag
ages of 40 and 54 years.5,6 The entity was nosis of the lobular carcinoma to that of
observed predominantly, but not exclu invasive cancer ranged from 15 to 20
sively, in premenopausal women.7,8 A years. Perhaps, the most fascinating
property that has often been cited as a aspect of the subsequent infiltrating
justification for performing mastectomy cancer is that it is not restricted to the
is the propensity towards multicentricity. ipsilateral breast, but occurs with equal
Although noninfiltrating multicentric frequency in the contralateral breast.7,16
tumours were evident in 10% to 60% of Curiously, the histologic features of the
all women with lobular carcinoma in situ, subsequent invasive cancer in the majority
the incidence of multicentric infiltrating of instances is not lobular as one might
cancer was less than 5% .9'" In addition, expect if lobular carcinoma in situ had
Lobular Carcinoma in Situ
bilateral disease has been demonstrated progressed to the invasive form, but is
in approximately 35% of cases.12,13
ductal in approximately 60% of cases.
The therapeutic preferences for this
Because surgeons have generally Despite some interesting theories suggest
type of cancer have largely been deter regarded lobular carcinoma in situ as the ing that lobular and ductal cancer have
mined by how the disease was perceived progenitor of invasive cancer, mastec similar anatomic origins,17 the prepon
biologically. Two mutually exclusive tomy has been the most popular therapy. derance of infiltrating ductal cancer fol
hypotheses have been formulated to This has eliminated the opportunity to lowing lobular carcinoma in situ supports
describe the disease. Proponents of the study the consequences of the disease fol the hypothesis that lobular cancer is a
first and most popular hypothesis regard lowing biopsy only and thus an opportu high-risk marker, not a precursor.
lobular carcinoma in situ as the direct nity to understand the natural history of
In summary, lobular carcinoma in situ
progenitor of invasive cancer, given the disease has been lost. All the data de is a fascinating multicentric and bilateral
enough time. Consequently, they have rived for lobular carcinoma in situ not entity. Twenty-five percent of patients
with this type of cancer will have invasive
cancer subsequently and the majority of
Table 1—Minimal Breast Cancer as Percentage of All Diagnosed Cases
the invasive cancers will be of ductal type.
Study
On average, more than 15 years will pass
Type of cancer
SEER, 19 7825
ACS, 1 9 8 0 5
BCDDP, 1 9 7 9 2
before the development of invasive cancer
and the contralateral breast is at equal
Minimal
9
12
41
isk for such development. Because inva
Noninfiltrating
5
3
26
Infiltrating < 1 cm
4
9
15
sive cancer may develop bilaterally,
whatever treatment is advocated for the
SEER = Surveillance Epidemiology and End Results Reporting, ACS - American College of Surgeons,
ipsilateral breast should also be advocated
BCDDP = Breast Cancer Detection Demonstration Projects.
for the contralateral breast. Based on the
data, in the opinion of our group the risk
o f invasive cancer does not justify
bilateral prophylactic mastectomy; con
Table II--Risk of Invasive Cancer Following Lobular Carcinoma in Situ
sequently, a predefined follow-up regi
Series, yr
men is the preferred method of dealing
Wheeler and
Andersen,
Rosen and
Haagensen and
with this disease. At present, we perform
colleagues.
1 9 7 7 15
colleagues,
colleagues,
an adequate local excision of the lobular
1 9 7 4 ,4 (n - 32) In - 44)
1 9 7 9 7 In - 99)
1 9 8 1 16 In - 263)
carcinoma with no further operative treat
Mean follow up, yr
18
15
24
15
ment. Because of the very low incidence
Subsequent invasive
(about 1%) of regional node metastases
cancer risk
from this disease, we do not think that
Ipsilateral, %
4
20
18
11
axillary node dissection is warranted.
Contralateral, %
9
9
14
9
With respect to treatment of the con
Overall risk, %
13
25
31
17
tralateral breast, a random or mirrorimage biopsy is meddlesome in our opin-
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ion and has little place in our therapeutic
approach. The current reappraisal of the
therapy for invasive cancer will undoubt
edly be a major influence on the treat
ment of lobular carcinoma in situ.
Preliminary results indicate that for some
patients there is no disadvantage to
breast-preserving operations. If these
findings are substantiated, then the
proponents of mastectomy for lobular
carcinoma in situ will find themselves in
the difficult position of advocating
prophylactic therapy more severe than the
treatment of the disease they are trying
to prevent. Until a therapeutic regimen
can be evolved, based on reliable prospec
tive data, we recommend that patients
with lobular carcinoma in situ not be sub
jected to mastectomy but to local excision
with follow-up consisting of physical
examinations every 3 to 6 months and
mammography annually.
Intraductal Cancer
If the data on lobular carcinoma in situ
can be described as scanty, that on
intraductal cancer may be characterized
as seriously deficient. In the former case,
because the disease was not recognized by
all as a neoplastic entity until relatively
recently, and because several investigators
chose to regard the disease as a noncar
cinoma, cases were available in which the
patient had not undergone mastectomy.
The same considerations are not applica
ble to intraductal carcinoma. Patients
with a diagnosis of intraductal carcinoma
were invariably treated by mastectomy,
and the major point of contention was
not whether a mastectomy should be per
formed, but whether a concomitant axil
lary node dissection was necessary. As a
result, few patients could be identified
who had not had mastectomy; once
again, an opportunity to evaluate the
behaviour of the disease was lost. In spite
of the paucity of definitive studies explor
ing the natural history of intraductal car
cinoma, there are sufficient examples in
the literature to indicate that noninvasive
intraductal cancer of the breast possesses
biologic characteristics distinct from those
of lobular carcinoma in situ.
O f those patients with noninfiltrating
breast cancer, the ratio of intraductal car
cinoma to lobular carcinoma is approxi
mately 2 to 1. The diseases differ with
respect to age distribution: the greatest
number of patients with lobular carci
noma is found in the 45- to 54-year age
group with a rapid decrease in subsequent
years, while the number of patients with
intraductal cancer is fairly constant for
women 55 years of age and older.5
Whether this is a result of different etiologic mechanisms for the two diseases or
because lobular carcinoma is hormone
dependent and intraductal cancer is not
remains speculative. Irrespective of etio254

logic considerations, the differences
underscore the distinct behavioural
characteristics of the two conditions.
As with lobular cancer, the most
important therapeutic property is the inci
dence of invasive cancer following a diag
nostic biopsy. Examples of the available
data on this aspect of intraductal cancer
are shown in Table III.18-20 All three
studies were retrospective and suffered
from small sample sizes. Of patients in
whom a diagnosis of intraductal carci
noma is made, 25% to 50% will allegedly
have infiltrating cancer, on average 10
years from the time of initial biopsy.
Although this disease has a greater than
50% frequency of ipsilateral multicentric
ity, almost all the invasive cancers occur
not only in the same breast, but in the
same quadrant as the initial tum our.19’20
The histologic type of invasive cancer is
exclusively ductal.
In addition to the property of multicen
tricity, from 5% to 20% of patients with
intraductal cancer reportedly have
residual foci of invasive cancer on exami
nation of multiple histologic sections of
the ipsilateral breast; however, when the
criteria for intraductal carcinoma were
rigidly defined, this figure was closer to
5%.9 Finally, there have been docu
mented instances21,22 in which 1% to 5%
of patients with intraductal carcinoma
and no evidence of infiltration on
microscopy had ipsilateral axillary lymphnode metastases. A summary and con
trast of the properties of lobular carci
noma in situ and intraductal carcinoma
appears in Table IV. The retrospective
nature and methodologic weakness of the
studies available on intraductal carcinoma
emphasize the error of drawing firm con
clusions on the behaviour of this disease.

Nevertheless, some of these characteris
tics have been interpreted as suggesting
that intraductal carcinoma is merely a
precursor of invasive cancer and that,
given sufficient time, invasive cancer will
develop from a residual focus in a defined
percentage of patients.
On the basis of this biologic interpre
tation of the properties attributed to
intraductal cancer, an ipsilateral mastec
tomy with a low axillary dissection has
become the most popular therapy for this
disease. The lack of data documenting its
natural history does not justify a compla
cent attitude in accepting this therapeu
tic approach. The pivotal question in the
operative management concerns the role
of breast-preserving operations with or
without axillary node dissection. Several
retrospective analyses address the value
of breast-preserving operations in this dis
ease. The American College of Surgeons
National Breast Cancer Survey Study5
reported on 202 patients with intraduc
tal carcinoma treated according to the dic
tates and preferences of the individual
surgeon. Treatment failures were identi
cal in patients treated with mastectomy
(with and without axillary dissection) and
those treated with breast-preserving oper
ations, with 65% of the patients alive and
free of disease at 5 years in both groups.
In spite of these findings, indicating no
difference, the American College of Sur
geons group seems disinclined to accept
its own analysis and concluded that total
mastectomy with low axillary dissection
or modified radical mastectomy repre
sents the optimal therapy for intraductal
carcinoma.
Preliminary results of the MD Ander
son Hospital experience with intraductal
carcinoma warrant further comment. In

Table 111-Risk of Invasive Cancer Following Intraductal Carcinom a
Series, yr
Farrow , 1 9 7 0 18
(n - 2 5 !

Betsill and
colleagues, 1 9 7 8 19
In - 15 )

Page and
colleagues, 19 8 2 20
(n - 2 5 )

20
1 -8

22
53
10

15
28
6

Mean fo llow -u p, yr
Subsequent invasive cancer, %
Interval to subsequent cancer, yr

Table IV —Properties of Noninvasive Breast Cancer
Property
Initial lesion
M ulticentricity, %
Residual invasive cancer, %
Subsequent invasive cancer
Occurrence, %
la te ra lity
Approxim ate interval to occurrence, yr
Histologic type

Lobular carcinom a
in situ

Intraductal
carcinoma

60
5

60
5 -2 0

25
Bilateral
20
Ductal

2 5 -5 5
Ipsilateral
10
Ductal
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70 consecutive patients treated with local
excision and radiotherapy to the ipsilateral breast, there has been only one
recurrence in the untreated ipsilateral
axilla after a minimum of 3 years follow
up (Montague E: Personal communica
tion, 1985).
The most compelling justification for
performing mastectomy in women with
intraductal carcinoma comes from two
recently completed studies,23’24 assessing
quandrantectomy and segmental mastec
tomy in patients with invasive cancer. As
with lobular carcinoma in situ, the
increasing acceptance of breast-preserving
operations for invasive disease will make
prophylactic mastectomy considerably
more difficult to justify. To resolve the
therapeutic dilemma with respect to
intraductal carcinoma, a carefully con
trolled, prospective, randomized, clinical
trial, designed to determine the natural
history as well as the appropriate treat
ment intervention, must be carried out.
Such a trial has currently been proposed
for implementation at a national level by
the National Surgical Adjuvant Breast
Project (NSABP) (Fig. 1). The inclusion
of a group of patients treated by local
excision (with free margins) will identify
the role of putative prognostic dis
criminants in the occurrence of subse
quent invasive disease (such as tumour
size and multifocality). The second arm
will address the propriety of adjuvant
radiotherapy to the remaining breast and
determine whether this regimen represents
acceptable therapy.

than 17% of patients with tumours less
than 0.5 cm in diameter had axillary
nodes that were histologically positive for
cancer; this figure rose to more than 20%
in tumours less than 1 cm in diameter.
Although tumour size provides some indi
cation of the histologic status of the
axilla, it should not be used alone to
predict prognosis. The identification of
patients according to tumour size (small
or otherwise) without information on the
status of axillary nodes should be
avoided. The designation of patients with
tumours less than 1 cm in diameter as a
distinct subset and their inclusion in
minimal breast cancer is inappropriate
biologically. Therapeutically, it is equally
misguided to include small invasive
neoplasms in the same category as nonin
filtrating cancer. The value of breast
preserving operations for small invasive
cancers as well as invasive cancers 4 cm
in diameter or smaller will be defined by
the recently completed NSABP, protocol
B-06.24 In this study, a substantial
proportion of the patients entered had
invasive cancer 1 cm in diameter or
smaller. Over 2100 patients were ran
domized to three treatment arms: (a)
modified radical mastectomy , (b) segmen
tal mastectomy and axillary node dissec
tion or (c) segmental mastectomy, axillary
node dissection and radiotherapy to the
remaining ipsilateral breast. The prelimi
nary results from this study confirm that
to categorize tumours less than 1 cm in
diameter as a separate subset is specious.

Invasive Adenocarcinoma
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NOTICES
Cleft Palate and
Related Craniofacial Anomalies
The 5th International Congress on Cleft
Palate and Related Craniofacial Anoma
lies will be held Sept. 2-7, 1985 at the
Congress Center in Monte Carlo.
This congress will be of interest to all
practitioners concerned with this subject,
including plastic, dental, pediatric and
maxillofacial surgeons, orthodontists and
otorhinolaryngologists.
For further information contact Dr.
Rene Malek, Chairman, International
Congress on Cleft Palate and Related Cra
niofacial Anomalies, 6, rue Erlanger,
75016 Paris, France; or write SOCFI, 14,
rue Mandar, 75002 Paris, France.

Reflux Esophagitis
and the Angelchik Prosthesis
A medical and surgical review of reflux
esophagitis and the Angelchik prosthesis,
presented by the departments o f surgery
and continuing medical education at the
University of Wisconsin, is being held
June 14-15, 1985 at the Concourse Hotel
in Madison, Wisconsin. The conference
is accredited for 11 hours in AMA
Category 1.
For further information contact: Sarah
Z. Aslakson, Department of Continuing
Medical Education, 465B W arf Building,
610 Walnut St., Madjfon, WI 53705,
USA; (608) 263-2856.

Thoracic and Cardiovascular
Surgery
The 7th Asian Congress of Thoracic and
continued on page 267
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4. Surgical Management of the Patient
at High Risk for Breast Cancer
The most controversial aspect of breast
disease centres around the management
of patients who have either a strong fa
mily history of breast cancer or a biopsy
diagnosis of lobular carcinoma in situ or
ductal carcinoma in situ. The current al
ternatives for patients who have two or
more relatives with breast cancer consist
of close follow-up or prophylactic total
mastectomies and reconstruction.
Invasive breast cancer in patients with
lobular carcinoma in situ may occur in
either breast and may be as high as 3 0 %
at 20 to 30 years. In these women it is
reasonable to do a wide excision of the
lobular carcinoma; in those without a fa
mily history, close follow-up is adequate.
Intraductal cancer treated by biopsy only
is associated with a 4 0 % risk of cancer
in the ipsilateral breast. Therefore, the
usual management is total mastectomy.
However, the information to support this
therapy over a segmental resection has
limited scientific validity.
Because the cosmetic appearance after
total mastectomy and reconstruction is
not as good as that of the normal breast,
this procedure must be employed cau
tiously and only with the total support of
the patient and her husband or close fa
mily. Subcutaneous mastectomy for
prophylaxis leaves behind macroscopic
glandular tissue and, therefore, is not
considered by many to be optimal

From the Tom Baker Cancer Centre,
Calgary, Alta.
Presented as part o f a symposium on
precancerous and high-risk lesions o f the
breast by the Royal College o f Physicians
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with the Canadian Association o f General
Surgeons, the Canadian Oncology Society
and the Canadian Society o f Plastic Sur
geons, Montreal, PQ, Sept. 11, 1984
*Director o f Surgery, Tom Baker Cancer
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ogy, Department o f Surgery, Foothills
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Accepted fo r publication Feb. 4, 1985
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management. A total mastectomy,
preserving the skin and resecting all
macroscopic breast tissue and nipple, is
the treatment of choice if the procedure
is deemed appropriate.
L'aspect le plus discute des maladies
du sein tourne autour du traitement de la
patiente qui possede de solides antece
dents familiaux de cancer du sein ou de
cede chez qui on a diagnostique, a la
biopsie, un carcinome lobulaire in situ ou
un cancer canaliculaire in situ. Les choix
qui s'offrent actuellement aux patientes
qui comptent plus d'une victime du
cancer du sein dans leur famille sont la
surveillance etroite ou la mastectomie
prophylactique totale avec conservation
de la peau et reconstruction.
Chez la patiente atteinte d'un carci
nome lobulaire in situ, un cancer invasif
peut apparaftre dans un ou I'autre sein
et sa frequence peut atteindre 3 0 %
apres 20 a 30 ans. II est raisonnable
chez ces femmes de proceder a une
excision large du carcinome lobulaire;
chez cedes qui n'ont pas d'antecedents
familiaux, une surveillance etroite est
suffisante. Les cancers canaliculaires
traites par biopsie seulement sont relies
a un risque de 4 0 % de cancer dans le
sein ipsilateral. En consequence, le traite
ment habituel consiste a realiser une
mastectomie totale. Toutefois la prefe
rence pour cette intervention par rapport
6 la resection segmentaire repose sur
une preuve scientifique limitee.
Comme I'apparence cosmetique apres
mastectomie totale et reconstruction
n'est pas aussi bonne que cede d'un sein
normal, on doit recourir a cette operation
avec precaution et seulement apres avoir
obtenu I'appui complet de la patiente et
de son conjoint ou de sa famille imme
diate. La mastectomie sous-cutanee a
visees prophylactiques laisse du tissu
glandulaire macroscopique et ne peut
done etre consideree comme un traite
ment optimum. Une mastectomie totale
avec conservation de la peau et resec
tion de tout le tissu mammaire macro
scopique ainsi que du mamelon,
represente le traitement de choix quand
cette intervention semble appropriee.

The dilemma of how to treat the patient
at high risk for invasive breast cancer has
become increasingly apparent. As a result
of breast screening programs, the acces
sibility of mammography and, in general,
a heightened awareness of health issues,
the illness is now detected early in its
course. In fact, many women, especially
those with a family history of breast
cancer, now consult the physician about
the particular risk for breast cancer dis
ease and request alternative management.
Treatment at this stage continues to be an
insoluble problem because our predictive
ability for any one patient is far from per
fect and the solutions are still unsatisfac
tory. Nevertheless, a review of data cur
rently available helps to formulate a plan
for each situation.
Family History

Traditionally, we have considered the
patient with a previous history of breast
cancer as being at the highest risk for a
subsequent metachronous lesion. This
risk averages 1% per year or 15% in the
woman’s lifetime. It has not been our
practice to recommend prophylactic
mastectomy in these circumstances,
although its use has certainly been consi
dered by surgeons in the past. However,
it is now recognized that a particularly
high-risk group for the development of
a subsequent metachronous lesion are
those patients who also have a family his
tory of breast cancer.1 In a study of 198
such patients, the incidence of a second
cancer was three times that for patients
with no family history of breast cancer.
The projected cumulative risk at 20 years
in premenopausal patients was 46% while
the actual occurrence was 37% .’ In post
menopausal patients who had a much
shorter follow-up, the occurrence of
breast cancer was only 5.8% after 4 years.
Therefore, if one considers a prophylac
tic contralateral mastectomy and recon
struction as a reasonable form of manage
ment in this subset of patients, candidates
would certainly include premenopausal
women with stage I breast cancer or those
who have been followed up for at least
5 years.
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Patients with a family history of breast
cancer are also at risk for an initial
primary breast cancer.2'3 This group
comprises women with two or more firstdegree relatives, including paternal rela
tives, who have been affected by the dis
ease. It is not generally realized that
although men rarely have breast cancer,
they readily transmit this tendency to their
progeny. A family history results not only
in a higher incidence of bilateral disease,
as already discussed, but also a much
younger age at presentation. This trans
mission of risk is most potent (47-fold in
one report) if the family members were
premenopausal at the time of diagnosis
and both breasts were ultimately affected.
If the family members were post
menopausal with bilateral foci of cancer,
the risk was greater by a factor of four and
translated into an 11 % incidence of breast
cancer in the relatives.3 If only one
breast was involved in the affected family
member, the risk for the family was not
much greater than in the normal popula
tion. The study did not define the risk in
women who present with three or more
first-degree relatives with breast cancer.
The risk in these women is much greater
than 30%, probably approaching 100%
in some. In such situations, the risk must
be estimated more by clinical judgement
than by available data. It is in these
patients that one can make the strongest
case for prophylactic mastectomy and
reconstruction.
Fibrocystic Disease
The most frequent clinical problem that
we deal with is fibrocystic disease which
is reputed by some to be at high risk for
progression to invasive cancer. Although
fibrocystic disease has often been impli
cated as a predisposing factor, the avail
able data suggest that the increased risk
is probably conferred only on those with
a proliferative lesion who have required
a breast biopsy. There is much less infor
mation on the exact risk of other benign
lesions, such as papillomatosis or atypi
cal ductal hyperplasia. However, in the
study of Haagensen and colleagues4 who
had 51 patients with a follow-up ranging
from 13 to 32 years, multiple sites of duc
tal papillomatosis in the breast resulted
in a higher incidence of breast cancer of
approximately 10%. In general, when a
biopsy shows a benign condition, a pro
phylactic surgical procedure is not justi
fied unless there are other extenuating
circumstances.
Carcinomas in Situ
The most extensively documented
group of high-risk women are those with
carcinoma in situ. These women have
traditionally been categorized as having
minimal breast cancer and have included

patients with infiltrative cancers less than
0.5 cm to 1.0 cm in diameter. These
tumours should no longer be considered
minimal, because the incidence of lymphnode metastases ranges from 10% to
20% .5 The two in-situ lesions, ductal
and lobular, have a different natural his
tory. Ductal carcinoma in situ is the more
aggressive lesion. In five series of approx
imately 80 patients, a subsequent carci
nom a developed exclusively in the
ipsilateral breast in 39%. This occurred
in the first 10 years of follow-up.5,6 A
more careful histologic examination of
these lesions has revealed a microinfiltrative component in 20%. This also
explains why 5% of these patients will
have metastatic axillary lymph nodes. The
opposite breast is not at inordinate risk
for a second primary tumour.6
Lobular carcinoma in situ is a lessfrequent diagnosis; 90% of these patients
are younger than 55 years. A subsequent
cancer is found in only 20% of these
patients after 15 years of follow-up, with
each breast being equally at risk.4 This is
not surprising as a mirror-image biopsy
is positive in about one third of these
patients. Axillary involvement is found in
less than 1% of these women. A rational
management in these patients is particu
larly controversial with treatments vary
ing from the simple biopsy, to modified
radical mastectomy, to bilateral sub
cutaneous mastectomies. There is no con
sensus as to the best treatment but it is
fair to comment that there are two
rational choices. One is to treat the diag
nosis as an indication of future high risk
and provide close clinical follow-up. The
second option is to eliminate all subse
quent potential for breast cancer by per
forming bilateral total mastectomy.
Indications for Prophylactic Procedures
With these facts in hand, it is impor
tant to emphasize that prophylactic
mastectomies are only reasonable in very
selected circumstances. First, a gradation
of perceived risk exists for most of these
patients and its determination is more
often an educated guess than easily estab
lished scientific fact. Some patients, such
as those with a diagnosis of lobular car
cinoma in situ, will be terrified by the
prediction of a 20% risk of cancer, while
others with a family history suggesting a
50% risk or more will be comfortable
with close follow-up. Any discussion of
prophylactic surgery must be held with
this in mind. The procedure should not
be considered seriously unless the hus
band and family give their full support
and enough time has been taken to ensure
a rational decision. Until plastic surgical
reconstruction reliably mimics a real
breast, one has to be convinced of the
overall health benefits before doing a

procedure that may result in a cosmeti
cally unattractive appearance. At the
same time, one must realize that even in
patients with stage I disease, long-term
cure is only 54%, although at 10 years
70% to 80% are disease free.7 This is a
very reasonable risk at 60 to 70 years of
age but not so palatable at 40 to 50 years.
If prophylactic surgery is determined to
be the best course for a particular patient,
then it is important to do the right oper
ation. In women with multiple papilloma
tosis or intraductal carcinoma, a uni
lateral mastectomy is indicated. In the
latter group, an axillary dissection is also
reasonable.6 In patients with a high-risk
family history or with lobular carcinoma
in situ, a bilateral mastectomy is neces
sary for prophylaxis. One must recognize
that many surgical procedures have been
used to treat in-situ carcinoma, ranging
from biopsy to radical mastectomy for
the ductal type or to bilateral total
m astectom y for the lobular type.
Although the findings of a survey con
ducted by the American College of Sur
geons on minimal breast cancer do not
show an advantage for any approach, the
short follow-up of 5 years renders this
observation meaningless.8
Subcutaneous Mastectomy
The use of subcutaneous mastectomy
for these women with our present state
of knowledge is not optimal.913 This
operation leaves breast tissue behind skin
flaps, scars, nipples and probably in the
axilla. Many plastic surgeons have had
experience o f carcinoma developing in
one or two patients who had previous
ly undergone subcutaneous mastecto
m y.10,11 In the animal model, partial
excision of breast tissue does not lower
the propensity for subsequent breast
cancer.14 Therefore, a meticulous total
mastectomy is essential to eliminate
future worry of a subsequent cancer.
Even this is tempered by the knowledge
that, occasionally, microscopic rests in the
muscle or adjacent to the dermis may
remain.9 It has been suggested that injec
tion of the lactiferous ductal system with
methylene blue would provide a visual
assurance of complete removal of all
breast tissue. This should be examined
further.9 A prophylactic total mastec
tomy is, in fact, similar to a cancer oper
ation except that the entire skin covering
can be preserved. The best incision is a
radial one encircling the nipple and
extending laterally, as it is easily hidden
by the brassiere. It provides equal surgi
cal access to all parts of the breast, espe
cially to the axillary tail. This incision
does not diminish a subsequent satisfac
tory cosmetic result. The reconstruction
problems resulting from thin skin flaps
are largely overcome by submuscular
placement o f the prosthesis.
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should be employed and it is advisable to
monitor serum levels in patients with severe
impairment.
In adults with renal insufficiency, an initial
loading dose of 1 g to 2 g should be given.
A fte r a lo a d in g d o s e , th e fo llo w in g
recommendations for maintenance dosage
may be used as a guide:
RENAL
FUNCTION
Mild
im pairm ent
Moderate
im pairm ent
Severe
im pairm ent
Essentially
no function

CREATININE
CLEARANCE
m L/m in

DOSE

FREQUENCY

50-30

1-2 g

every 8-12 h

29-10

1-2 g

every 12-24 h

9-5

0.5-1 g

every 12-24 h

<5

0.5-1 g

every 24-48 h

In the patient undergoing hemodialysis, the
loading dose of 1 -2 g should be given after
each hemodialysis, and the maintenance dose
should be given as indicated in the Table
above.
Neonates (Including Premature Infants),
Infants and Children (See WARNINGS for
Neonates under ADMINISTRATION in the
complete monograph.)
Premature Infants
with Body Weights
20-40 mg/kg every 12 h I.V.
Above 1500 g
Neonates
01 week of 20-40
age mg/kg every 12 h I.V.
14 weeks of20-40
age mg/kg every 8 h I.V.
Infants
1 month to 2 years
of age

20-40 mg/kg every 6 h or
every 8 h I.M. or I.V.

Children

20-40 mg/kg every 6 h or
every 8 h I.M. or I.V.

In severe infections, the total daily dosage in
infants and children may be increased to
200 mg/kg, but not to exceed 12 g per day.
MEFOXIN* is not recommended for the ther
apy of meningitis. If meningitis is suspected,
an appropriate antibiotic should be used.
At present there is in s u ffic ie n t data to
recommend a specific dosage for children
with impaired renal function.However, if the
administration of MEFOXIN* is deemed to be
essential the dosage should be modified
consistent with the recommendations for
adults (see Table above).
PROPHYLACTIC USE
For prophylactic use, a three-dose regimen of
MEFOXIN4 is recommended as follows:
Vaginal or abdom inal hysterectom y and
abdominal surgery
2 g a d m in is te re d in tra m u s c u la r ly or
in tra v e n o u s ly ju s t p r io r to s u rg e ry
(approximately one-half to one hour before
initial incision).
The second and third 2g doses should be
administered at 2 -6 hour intervals after the
initial dose.
Cesarean Section
The first dose of 2 g should be administered
intravenously as soon as the umbilical cord
has been clamped. The second and third
2 g doses should be given intravenously or
intramuscularly four hours and eight hours
after the first dose.

AVAILABILITY
MEFOXIN* (sterile cefoxitin sodium, Frosst
Std.) is supplied as sterile powder in boxes of
10 vials:
No. 3356 1 g cefoxitin as sodium salt
No. 3357 2 g cefoxitin as sodium salt
Storage
MEFOXIN* in the dry state should be stored
below 30° C.

PRODUCT MONOGRAPH AVAILABLE
ON REQUEST

5-739
MEMBER
PMAC

| PAAB |

JlOMt

P.O. BOX 1005, POINTE-CLAIRE
DORVAL, QUEBEC H9R 4P8

Conclusions
The concept of prophylactic breast sur
gery is not new. It is used in certain
patients to prevent colonic cancer, cervi
cal cancer and thyroid cancer. Because of
the psychosexual importance of the breast
in our society and the fact that reconstruc
tion has not been perfected, the ideal
treatment for high-risk patients has not
evolved. The indications for such a proce
dure depend not only on the relative risk
of breast cancer developing but, more
importantly, on the patient’s feelings
about this risk and her and her husband’s
ability to cope with a potentially poor cos
metic result. Prophylactic mastectomy is
indicated, but only in very carefully
selected patients. If there is any doubt,
one’s bias should be towards careful,
close follow-up.
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BOOK REVIEWS
CARDIAC PATHOLOGY. An Integrated
Text and Colour Atlas. Anton E. Becker
and Robert H. Anderson. 248 pp. Illust.
Raven Press, New York, 1983. $80 (US).
ISBN 0-89004-972-6.
The 16 chapters of this book are equally
divided between acquired and congenital
cardiac lesions. One, on cardiac adaptation,
deals with hypertrophy and dilatation and
another with interactions between the heart and
lungs. In six chapters, a variety of acquired
heart diseases and the pathologic features of
the aging heart are considered. The separation
of “ cardiac lacerations” into a chapter seemed
artificial to me. The lesions illustrated could
have been included in other sections.
O f the chapters devoted to congenital heart
diseases, the anatomy of heart chambers and
of vessels leaving the heart, allowing their
recognition, is defined in one chapter, which
also contains a discussion of chamber relation
ships to permit definition of anomalies and to
provide a basis for diagnosing congenital heart
disease. The lesions so defined are dealt with
in subsequent chapters. A non-expert, on first
reading, might have difficulty in understand
ing the text, but persistence is rewarding.
The illustrations are, for the most part,
superb. The quality of reproduction of Fig.
1.11 and some of the low-power photomicro
graphs was poor in my copy. Most photo
graphs are in colour. Many are complemented
by explanatory line drawings. They and the dia
grams, which are simple and pleasingly
presented, are most useful. The text is succinct,
emphasizing the functional, and has pertinent,
if sometimes wonderfully selective, references.

I enjoyed the book and would recommend
it to cardiovascular pathologists, cardiologists,
cardiovascular surgeons, pediatricians and all
interested in heart diseases. All pathology and
cardiology department libraries should have a
copy. Even if a reader is not satisfied with the
text, because the book is not intended to be
encyclopedic, it is worth having because it is
a splendid atlas of heart lesions or, as the
authors prefer, “ a work of a rt” .
M a l c o l m D . S il v e r , m d , p h d , f r c p c
Professor and Chairman,
Department of Pathology,
University of Western Ontario,
London, Ont.
N6A 5C1
COLOR ATLAS OF CARDIAC SURGERY.
Acquired Heart Disease. James L. Monro
and Gerald Shore. 165 pp. Illust. AppletonCentury-Crofts, East Norwalk, C onn.,
1982. $110. ISBN 0-8385-1164-3.
This atlas follows commonly performed oper
ations for acquired heart disease step by step.
It covers the gamut of operations, beginning
with median sternotomy and cardiopulmonary
bypass and continuing through the various
valve operations, coronary artery surgery, com
plications of coronary disease such as left ven
tricular aneurysm and acquired ventricular sep
tal defect, and surgery of the intrathoracic
aorta. General principles of cardiac surgery are
well presented but the book reflects the bias
of the authors by specifically pointing out their
continued on page 271
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5. Prophylactic Mastectomy for Precancerous
and High-Risk Lesions of the Breast
The candidates for prophylactic mastec
tomy are those who have a family his
tory of breast cancer, multiple fibrocystic
masses that have been biopsied or are
too numerous to biopsy appropriately, or
patients who previously have had cancer
in one breast. The decision to perform
the subcutaneous mastectomy is one
that must be made by the surgeons
involved, in consultation with the patient
and her husband. The data from sub
cutaneous mastectomies appear promis
ing and the technical results have
improved as experience has been gained.
However, 5 to 10 more years are neces
sary to determine whether this procedure
decreases the incidence of breast cancer
in these high-risk patients.
Les candidates a une mastectomie
prophylactique sont les patientes qui ont
des antecedents familiaux de cancer du
sein, celles qui ont des masses fibrokystiques multiples qui ont ete biopsiees ou
qui sont trop nombreuses pour I'etre, ou
les patientes qui ont deja eu un cancer
du sein. La decision de proceder a une
mastectomie sous-cutanee doit etre prise
par le chirurgien en consultation avec la
patiente et son conjoint. Les resultats de
la mastectomie sous-cutanee semblent
prometteurs et les resultats techniques
se sont ameliores avec ('experience.
Toutefois, il faudra de 5 a 10 ans pour
determiner si cette operation reduit la
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Surgeons, the Canadian Oncology Society
and the Canadian Society o f Plastic Sur
geons, Montreal, PQ, Sept. 11, 1984

In the mind of the public, breast recon
struction is often a matter of surgery sad
dled with myths. (Many patients have a
great interest in the subject, and to advise
them properly on the action to take, we
need to re-evaluate the entire area.) To
manage patients who undergo mammaplasty with the sympathy and the
empathy that they deserve requires an
understanding of the multiple and com
plex meanings of the breast to these
patients. I shall try to cover this area first,
to provide background for the decision
making process and advice to the patients.
Understanding the Patient

It is in the field of breast augmentation
that we can gain an understanding of the
importance of this organ to women. Con
trary to popular belief, the average
woman seeking breast augmentation is
not a young single woman who wishes to
become a show girl, or a divorcee who is
trying to have the operation to help find
a new boyfriend or husband. It is usually
an educated, upper middle-class, happily
married mother with children who has
considered the surgery for many years
and wants the operation for her own
needs. The husband is usually indifferent,
although quite supportive of the wishes
of his spouse.
The earliest reports on this subject were
by Edgerton and colleagues.I>2 They

reported that the woman seeking breast
enlargement had feelings of inadequacy
about her small breasts and a lower self
esteem and self-confidence than other
women. Druss3 and Baker and associates4
reported that following augmentation, the
patients had more self-confidence, a bet
ter image and self-esteem, had ready iden
tification of the implant as part of their
body and had a very high level of satis
faction.
However, not until 1977 was a con
trolled study on the psychological and
psychiatric aspects of the patients seek
ing augmentation reported, by Shipley
and associates.5 They selected first a
group of 28 patients who had sought aug
mentation mammaplasty. Then they
selected two separate control groups for
comparison from a gynecologic practice,
selected by a gynecologist who was not
involved in the evaluation of the patients.
The first control group comprised 28
women who, in the opinion of the gyne
cologist, had breasts of average size; these
patients served to evaluate the effect of
differing breast size. The second control
was composed of 28 women selected at
random who, in the opinion of the gyne
cologist, had small breasts but who were
not seeking augmentation; these patients
served to evaluate the effect of differing
motivation. Table I shows that these
patients had similar basic characteristics.
In the evaluation of the Ziller Social Self
esteem Test, the authors found that
women in the augmentation group (AUG)
scored higher but admitted to greater selfconsciousness about their bodies than the

Table 1-Comparison of Patients Seeking Augmentation and Control Groups*
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Medicine, 116 FMB, PO Box 3333, New
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frequence du cancer du sein chez les
patientes a risque.

Seeking
augmentation
(n - 28)
31
64
2.7
16 000

Background
Average age, yr
Married, %
Mean no. of children
Income, $
"After Shipley and associates.5
tTo evaluate effect of differing breast size.
+To evaluate effect of differing motivation.

Control groups
Average breastt
(n - 28)
39
61
2.9
16 000

Small breastf
in - 28)
33
57
2.7
17 000
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average-breast control (ABC) patients
and the small-breast control (SBC)
women. This was in agreement with the
previous reports by Edgerton1,2 in that
those in the AUG group were generally
attractive and aware of their attractive
ness, but nevertheless were self-conscious
about the small size of their breasts. More

Fig. la

Fig. lb
FIG. 1—(a) Patient with multiple fibro
cystic masses referred by general surgeon
for removal of breasts, (b) Using transverse
incisions over dome, total mastectomy was per
formed in subcutaneous plane leaving very thin
layer of skin and subcutaneous tissue. Prosthe
sis was placed underneath pectoralis major
muscle in large pocket that included dissection
under serratus anterior muscle.

FIG. 2—“ Hemispheric dome” deformity
seen when fibrous tissues of healed surgical
plane contracted around breast prosthesis
placed in subcutaneous pocket.

im portantly, however, the Attitude
Towards Women Scores and the Califor
nia Psychological Inventory Scores indi
cated that patients in the AUG and ABC
groups had similar personalities, whereas
the SBC patients were more liberal,
“ feminist” , independent, cognitively
resourceful and intellectually oriented.
The authors concluded that “ In contrast
to the previous uncontrolled studies. . .
mammaplasty women scored as psycho
logically healthy and they were compara
ble to the average breast size controls with
whom they seek physical identifica
tio n .” 5'T he SBC group was statistically
the most different.
In a later study, Hetter6 found that
women seeking augmentation mam
maplasty identified with “ feminine
women” , had a positive body image and
a greater interest in styles and fashion
than the average woman. Marcia Goin7
pointed out in her book that “ the breast,
while consciously representing sexuality
and womanly attractiveness to adults,
unconsciously really represents the
m other” . This statement is based on the
work of Sigmund Freud8 in which he
pointed out that the mother’s breast is the
first “ object” that the infant experiences
in the awareness of the existence of
others; as the infant grows emotionally
and psychologically, the breast, which
was only a part of the mother, is now
completed into the “ total person” of the
mother. All this and the importance that
our society has placed on the beautifica
tion of the breast in art and advertising
have led to the prominence of the breast
in representing womanliness and femi
ninity.

cancer. Characteristically, these patients
have breast cancer of early onset (i.e., in
the third or fourth decade of life). Lynch
and associates used several of these
patients, whose families were in various
stages of the cancer genetic evaluation, to
illustrate a hypothetical cancer pedigree
that was compatible with what was cus
tom arily observed in families with
autosomal dominant, inherited disorders.
They postulated that the early onset of
breast cancer in these cases may be a
genetic mutation; approximately one half
of the female descendants of a gene car
rier may be similarly affected. These types
of genetic evaluation are essential for our
better understanding of the increasingly
frequent occurrence of breast cancers of
early onset. It is also essential that we
have verification, if these findings are
valid, from other centres as well.

Women at High Risk

In general, these patients can be treated
with either a simple mastectomy or a sub
cutaneous mastectomy in which the skin
over the breast is preserved with or
without the nipple areola (Fig. I). The
thinnest possible layer of breast skin is
preserved so that not only is the breast
gland removed but as much of the sub
cutaneous tissue as possible between the
overlying skin and the gland. This is done
because it is very difficult to know where
the breast gland begins or ends since it is
not an encapsulated organ. The mound
is best reconstructed with a Silastic breast
prosthesis. The prosthesis used to be
placed over the pectoralis major muscle
and underneath the skin. However, sub
sequent scarring resulted in capsular con
tracture deformities in approximately
80% of these patients (Fig. 2).
Our experience with breast reconstruc
tions following simple or modified radi
cal mastectomies demonstrated that the
placement of the silicone prosthesis
behind the pectoralis major muscle
decreased the degree of capsular contrac
ture and allowed for a more gradual con
tour on the chest wall that made the result

To paraphrase Dr. Mayo, “ It is the
right of every woman to want to look nor
m al.” To achieve this, we must be able
to advise our patients on the proper med
ical care for diseases and lesions of the
breasts, while at the same time be aware
of the importance of reconstruction. The
previous speakers in this symposium have
already provided the data and docu
mented the number of publications that
have reported lesions and other factors
pointing to the patients who are at high
risk for breast cancer. In general, they are
women who have a particular family his
tory of breast cancer. The patient who has
had cancer in one breast runs a higher risk
of having cancer in the opposite breast
and patients with severe fibrocystic dis
ease also have a higher incidence of breast
cancer than the general population.
The subject of familial breast cancer is
beginning to receive more attention. In
1980, Lynch and colleagues9 found that
approximately 20% of the 75 consecutive
women with breast cancer whom they
evaluated had a family history of breast

Indications for Prophylactic
Mastectomy
Prophylactic mastectomy now appears
to be indicated in patients with lobular
carcinoma in situ, intraductal carcinoma,
cancer of the breast in the immediate
family or chronic fibrocystic disease of
the breast with multiple lesions in a given
patient, or multiple previous biopsies with
persistent breast cysts, or both. The last
group presents a difficult problem for the
general surgeon in trying to determine
which cyst should be biopsied next. Mam
mography becomes very difficult because
of the multiple cysts; thus, one potential
treatment is prophylactic mastectomy.
The Procedure
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infinitely better. For that reason better
cosmetic results are achieved when the
prosthesis is placed behind the pectoralis
major and serratus anterior muscles.
Subcutaneous mastectomy can also be
performed in patients with a strong family
history of breast cancer (Fig. 3). Occa
sionally, patients with very large breasts
seek prophylactic mastectomy and this
presents a greater problem. In these cases,
the operation is often a simple mastec
tomy with reconstruction of the breast
mounds using portions of the breast skin
(Fig. 4). Indeed, the most difficult
patients are those with asymmetry. For
them a combination of subcutaneous
mastectomy and a mastopexy may pro
vide symmetry.
Finally, patients with intraductal car
cinoma can be treated with bilateral sim
ple mastectomy with immediate recon
struction (Fig. 5). The nipple areola
should be removed and reconstructed
with local tissue and skin grafts when the
scar around the prosthesis has matured
and the dome is properly positioned.

tissue remaining “ will take the on
slaught” of the circulating hormones;
however, there is no evidence that this is
the mechanism of the development of
breast cancer. If we are to assume that the
earliest breast cancer that can be detected
weighs 1 g, and 1 g of tissue in the body
contains 109 cells, we can see that it
takes approximately 30 doubling times to
reach this number of cells from one origi
nal malignant cell. Sparks11 has pointed
out that the doubling time of breast
cancer tissue cultures varies tremen
dously: from 23 to 209 days. If this is the
case, it will take between 2 and 17 years
before the 30 doubling times are achieved
to make the earliest detection of a malig
nant tumour at 1 g. This appears to be
the most logical explanation for the
development of breast cancer, and if it is
correct, the performance of subcutaneous
mastectomy should lead to a decreased
incidence. However, only long-term
follow-up of these patients will be able to
tell whether or not this is indeed correct.

Another question is whether the nippleareola complex should be removed with
the gland. In one study by Parry and
associates,12 250 breasts that were
removed because of invasive breast cancer
were thoroughly examined by multiple
sections. Histologic evidence of nipple
involvement was found in 16 cases, 14 of
which were determined clinically before
operation to be involved; only 2 cases
were found histologically without clinical
evidence preoperatively (Table II). It
appears, therefore, that areolar involve
ment is uncommon in the absence of clin
ical manifestation and proximity of the
primary tumour to the nipple areola.

Discussion
An important issue in the discussion of
prophylactic mastectomy is the amount
of breast tissue that is removed. Although
we remove as much of the breast tissue
and subcutaneous fat as we can without
devascularizing the overlying skin, it is
not possible to perform a true complete
mastectomy. Goldman and Goldwyn10
demonstrated in subcutaneous mastecto
mies performed on cadaver specimens
that samples of the fat taken from the
breast skin occasionally showed micro
scopic areas of breast tissue remaining.
We estimate that at best we remove
90% to 95% of the breast tissue.
However, even in a simple mastectomy,
it is unlikely that the mastectomy is com
plete. Microscopic amounts of breast tis
sue are left behind in the infraclavicular
area as well as in the axillary tail of
Spence; perhaps at best 95% to 98% of
the breast tissue is removed with this tech
nique. Even with a radical mastectomy
where the chest skin is removed and may
require a skin graft, at best 98% to 99%
is being removed. The issue at hand is not
whether 98% is better than 95% which
is better than 90%, but whether or not the
microscopic tissue that is left behind will
undergo transformation to malignant
tissue.
I contend that breast cancer develops
from within the gland, and grows to the
surface to involve the overlying skin only
in advanced cases, rather than beginning
as cancer in the breast tissue underlying
the subcutaneous layer of the skin. If that
is correct, then it is unlikely that cancer
will develop in the remnant microscopic
breast tissue. The opposite could also
be true: that the small amount of breast
264

FIG. 4—Postoperative view of breasts of
woman in mid-30s who had multiple fibrocystic
masses of both breasts. Her 48-year-old sister
had undergone mastectomy for invasive cancer.
Patient was treated by bilateral total mastec
tomy, with prostheses placed behind pectoralis
major muscle. Dome of mounds was deepithelialized and skin grafts were used for nip
ple and areolar reconstruction.
^

Fig. 3b
FIG. 3—(a) Preoperative appearance of
breast of married woman, 32 years old with
family history o f breast cancer, who desired
subcutaneous mastectomy because she wished
to have children and was concerned about
effects of hormonal stimulation on her breast
tissue during pregnancy, (b) Appearance 4
years after operation. Patient has had two chil
dren and does not wish to have nipples recon
structed although this has been offered.

FIG. 5—Postoperative appearance of patient
with intraductal carcinoma proven by inci
sional biopsy. She was treated by bilateral sim
ple mastectomy and immediate reconstruction
of mounds. Following maturation of scar tis
sue around operative site, nipples and areolas
were reconstructed using local tissue for nip
ple and thigh skin grafts for areola.
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Nevertheless, if there is any question, the
nipple or areola, or both, should be
removed with the breast since both can
be reconstructed.
Data are now accumulating on patients
treated by subcutaneous mastectomy.
Pennisi and Capozzi13 in 1975 reported
on 1385 patients treated by 50 surgeons;
they reported 82 cases of occult carci
noma (6% incidental finding o f malig
nant cells within the breast tissue). They
also reported that carcinoma developed
subsequently in 0.5% of 4179 patients. In
1979, Pennisi14 reported an incidence of
0.1 % among 1000 subcutaneous mastec
tomies and in 1983 W oods15 reported a
0.2% rate among 900 patients.
Subcutaneous mastectomy has been
criticized by those who believe it is not
“ prophylaxis” . The severest critic has
been Louren J. Humphrey who wrote in
an editorial16 that standards o f surgical
care “must. . . be developed from
knowledge o f numbers, from critical
analyses o f studies, and not from argu
ments based on opinions or some quix
otic use o f invalid data” . Nevertheless,
he based the strength of his argument on
a personal communication with Dr. Jer
ome Urban who related his experience on
a panel discussion on prophylactic
mastectomy held in New York City in
1982 by the American Society o f Plastic
and Reconstructive Surgeons. Report
edly, Dr. Urban had asked for a show of
hands of surgeons in the audience who
had experienced the appearance of cancer
in a patient who had previously under
gone subcutaneous mastectomy, and that
Dr. Urban told him that “ at least 90 to
100 hands were raised (personal commu
nication)” .16 Unfortunately, Dr. Hum
phrey’s arguments are also not based on
numbers.
Indeed, it will take an experience o f 10
to 20 years to be able to determine
whether or not the incidence o f breast
cancer following subcutaneous mastec
tomy is reduced in comparison with that
in the normal population. Currently, the
likelihood o f a young woman suffering
from breast cancer in her lifetime is
9%.17 Women who undergo subcutaneous
mastectomy are those who are considered
to run a greater than 9% risk of having
breast cancer. The reported data to date,
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Nipple involvement
Clinical observation preop
Ulceration
Retraction
Fixation
Negative
‘ From Parry, Cochran and Wolfort.12
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Chairman’s Comments

Two types of data have been discussed in
this symposium. First, scientific observa
tions on the incidence and definition of
these diseases have been presented and
second, there has been discussion about
the interpretation of some of these
statistics.
It seems clear from the discussions of
Drs. Schechter and Wolmark that some
lesions can be categorized pathologically
with respect to risk of frank carcinoma
developing. These data, when compared
to the established statistical risk for the
average woman, give us a yardstick by
which to make judgements. When we
move to the area of intervention, we leave
the security of statistical reliability and
enter the uncertainty of interpretation,
opinion and bias.
Dr. Ariyan has demonstrated the feasi
bility of reconstructive surgery following
mastectomy. The technique seems to be
established for prophylactic or therapeu
tic mastectomy and for the subcutaneous
or total versions. However, the interven
tion has been extended to women with
ordinary fibrocystic disease — a type not
normally associated with higher cancer
risk; it is even suggested in some cases for
women with multiple simple cysts whose
management is difficult in terms of recur
rence. Do all these clinical problems
require a solution that seems to be
radical?
When all these statistics and opinions
are presented to an experienced clinical
surgeon, it becomes very difficult to for

NO TICES
continued from page 255

Cardiovascular Surgery will be held Nov.
17-21, 1985, in Bangkok, Thailand. The
meeting is sponsored by the Association
of Thoracic and Cardiovascular Surgeons
of Asia, hosted by the Society of Thoracic
and Cardiovascular Surgeons of Thailand
and supported by the Royal College of
Surgeons of Thailand, the Heart Associ
ation of Thailand and Chulalongkorn
University. English will be the official lan
guage for the congress, which will include
guest speakers, plenary sessions, sympo
sia, scientific films and exhibits.
Information concerning the congress
and travel arrangements can be obtained
from Interport, Ltd., PO Box 338, Sun

mulate concrete proposals. Dr. Ketcham
(see editorial in this issue, pages 194 and
195) prefers to allow the patient a key role
in the decision. He thinks that sufficient
evidence is lacking to conclude that any
of these lesions are precancerous, and he
would like to obtain more scientific infor
mation through follow-up, in order to
acquire a better base for decision-making
in the absence of reliable information. We
cannot expect patients to make better
medical decisions than doctors, so that,
for the present, the patient’s decisions
become choices based on personal prefer
ence rather than scientific conclusions.
The essence of the problem for clini
cians is that little clinical information
exists. The large number of cases com
piled by Pennisi and Woods (cited by
Ariyan) are a pot-pourri of diagnoses
ranging from minimal cancer and precan
cerous lesions to benign fibrocystic dis
ease, painful cystic change, family histo
ries of uncertain risk and even cancer
phobia. Without an adequate definition
of the denominator, one cannot expect
the numerator to give a reliable indica
tion of the probability of cancer being
prevented. Thus, the fact that few cancers
appear in the follow-up years doesn’t
necessarily mean that the operation is
preventing cancer. We don’t know how
many of those patients would have in
vasive cancer without the operation.
This symposium has indicated that
women with intraductal cancer, and to a
certain extent those with lobular carci

noma in situ, run an increased risk of hav
ing invasive cancer. Applying other risk
factors can help define subgroups of
patients who are at yet higher risk for
future cancer development. Dr. Schechter
suggests that this technique may help
identify a smaller subgroup of patients in
whom 80% of the potential cancers will
occur. For the present, this seems to be
the best lead we have towards a rational
application of this procedure.
Although it can be assumed that total
bilateral mastectomy can prevent cancer,
it is not yet possible to predict which
women are at high enough risk and we
cannot achieve consensus on recommend
ing this operation. There is even more
uncertainty about relying on subcutane
ous mastectomies instead of total mastec
tomies. Finally, there is an unresolved
controversy about the need to consider,
for prevention, surgery that is more
extreme than one would actually recom
mend for treatment of invasive ductal
cancer. Although prospective controlled
studies would obviously contribute to our
understanding, none are at present on the
horizon.

set Beach, CA 90742; (213) 592-4446;
Telex 910-380-5385 (Interport SSBH).

University of Minnesota, Box 293, 420
Delaware St. SE, Minneapolis, MN
55455; (612) 373-8012.

R ichard G. Margolese,

md, frcsc

Symposium chairman
Department of Surgery,
Sir Mortimer B. DavisJewish General Hospital,
Montreal, PQ
H3T 1E2

Breast and Endocrine Surgery
The Department of Surgery of the
University of Minnesota Medical School
is holding its 49th Annual Surgery Course,
June 24-26, 1985, at Willey Hall, Univer
sity of Minnesota, Minneapolis, Minn.
The major topic of the course will be
breast and endocrine surgery. The regis
tration fee is $400 (1200 for residents)
and accreditation will be 22 hours in
AMA Category 1.
For more information contact: the
Office of Continuing Medical Education,

American Association
for Hand Surgery
The 15th annual meeting of the Ameri
can Association for Hand Surgery will be
held Oct. 24-27, 1985 at the Vista Inter
national Hotel, Kansas City, Missouri.
For further information contact: Myra
Josephson, Central Office Manager,
American Association for Hand Surgery,
Ste. 218, 2934 Fish Hatchery Rd., Madi
son, WI 53713; (608) 272-8940.
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Splenic Abscess
Abscess of the spleen is a rare entity. It
may develop after generalized infection,
hematologic disorders and trauma. The
authors report the case of a 7-year-old
boy who presented with a 2-month his
tory of spiking fever, anorexia, fatigue
and weight loss. He had left subcostal
tenderness and a palpable spleen. He
had a history of trauma to the left flank
5 months before admission but a splenic
scan obtained at that time appeared nor
mal. A splenic abscess was diagnosed
by gallium scanning, computerized
tomography and ultrasonography.
Although splenectomy has been advo
cated as the treatment of choice for
splenic abscess, this patient was treated
successfully with appropriate antibiotics
and simple drainage, preserving the
spleen. Cultures grew Staphylococcus
aureus. Of all the diagnostic methods
available, ultrasonography is the least
invasive study that will make the diagno
sis and is less expensive than some
methods.
L'abces splenique est rare. II peut survenir a la suite d'une infection generalisee,
d'un probleme hematologique ou d'un
traumatisme. Les auteurs decrivent le
cas d'un garcon de 7 ans qui fut hospita
lise souffrant des clochers thermiques,
d'anorexie, de fatigue et de perte de
poids. II presentait une douleur souscostale gauche et sa rate etait palpable.
On relevait des antecedents de contusion
au cote gauche subi 5 mois avant
I'entree a I'hopital mais une scintigraphie
splenique pratiquee a ce moment avait
semble normale. Un abces splenique fut
diagnostique par scintigraphie au gallium.

From the *Department o f Surgery and
t Department o f Radiology, Children’s
Hospital o f Eastern Ontario, Ottawa, Ont.
Accepted fo r publication July 27, 1984
Reprint requests to: Dr. G. Stringel,
Department o f Surgery, Children’s Hospital
o f Eastern Ontario, 401 Smyth Rd.,
Ottawa, Ont. K1H 8LI

tomographie axiale par ordinateur et
echographie ultrasonique.
Bien que la splenectomie ait ete preconisee comme traitement de choix de
l'abces splenique, le patient fut traite
avec succes par antibiotherapie approppriee et simple drainage, avec conserva
tion de la rate. Les cultures revelerent du
Staphylococcus aureus. De tous les
moyens diagnostiques disponibles,
I'echographie ultrasonique est le moins
envahissant et il est moins couteux que
certaines methodes.

Splenic abscess, although it has long been
recognized, is a rare condition. It may
develop after generalized infection,
hematologic disorders or trauma.1-3 The
overall mortality is about 39%, ranging
from 15% to 100%.1-3
We report the case of a child with a
splenic abscess, accurately diagnosed by
gallium scanning, computerized tomo
graphy and ultrasonography, who was
successfully treated by drainage and anti
biotic therapy, thereby preserving the
spleen.
Case Report
A 7-year-old boy was admitted with a
2-month history of spiking fever, anorexia,
fatigue and weight loss of 1.4 kg. Two days
before admission a cough developed associat
ed with vomiting. He appeared chronically ill,
pale and tired. His temperature was 39.4°C
and pulse 124 beats/min. He had moderate left
subcostal tenderness and a palpable spleen.
He had been born with a cervical menin
gocele, which was successfully repaired but
required a ventriculoperitoneal shunt. At 1 year
of age, he had a Staphylococcus aureus infec
tion of the shunt, requiring removal and antibi
otic treatment; reinsertion of the shunt was not
necessary. Five months before admission he
injured his left side in a fall. He suffered left
shoulder-tip pain, which subsided rapidly. He
was examined at the hospital but no other
problem was found. Because of splenomegaly,
splenic scanning was done. This did not show
rupture; he was thought to have a “ mononucle
osis-like illness” , although his mononucleo

sis spot test gave negative results. He remained
asymptomatic for 2 months.
On admission, his leukocyte count was 19.5
x 109/L with 83% polymorphonuclear leu
kocytes. The hemoglobin level was 97 g/L , the
erythrocyte sedimentation rate was 58 m m /h
and mononucleosis spot test gave negative
results. The bone marrow was very active and
cellular with increased plasma cells. Serum elec
trolyte levels and results of liver function tests
were normal; protein electrophoresis showed
elevated levels of «] and cxi globulins; the
immunoglobulin A level was also elevated.
Blood and urine cultures did not grow any
organisms. Haemophilus influenzae was iso
lated from the tracheal aspirate and beta hemo
lytic streptococcus from a throat swab.
The chest roentgenogram showed an
infiltrate in the lower lobe of the left lung; plain
abdominal films were not helpful.
Liver-spleen scanning showed splenomegaly
(Fig. 1). Gallium scanning demonstrated
intense focal uptake in the spleen (Fig. 2), and
computerized tom ography (Fig. 3) and
ultrasonography (Fig. 4) showed a collection
of fluid with solid elements along the superior
medial aspect of the spleen that was considered
to be subcapsular.
A large splenic abscess was drained of 200
mL of pus through a left subcostal incision.
Because the abscess was confined to the left
upper quadrant of the abdomen and sealed by
omentum, care was taken not to contaminate
the peritoneal cavity; two large Penrose drains
were inserted. Cultures grew S. aureus resis
tant to ampicillin and penicillin but sensitive
to cloxacillin, cefamandole and clindamycin.

FIG. 1—Liver and spleen scanning with
technetium 99m (left posterior view) shows
splenomegaly and displacement of spleen.
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Preoperatively the boy was treated with
ampicillin and clindamycin. Postoperatively he
received cefamandole intravenously for 2 weeks
and subsequently cloxacillin orally for 2 more
weeks. The Penrose drains were gradually
removed over a period of 5 days, starting 5
days after his operation.
Postoperatively the boy remained afebrile.
His recovery was smooth and he returned home
2 weeks after operation. Ultrasonography 2
weeks and 6 weeks after operation showed
gradual resolution of the splenic defect, and
a final examination at 3 months gave normal
findings. At follow-up 6 months after opera
tion he was asymptomatic.

Discussion

Splenic abscess is a rare condition and
most cases occur in adults. In a recent
report by Chun and associates,1 only 27
of 153 patients were under 19 years of age
and only 9 were children under 10 years
old.
The spleen is a critical line of defence
when the host is invaded by blood-borne
bacteria; the unique, sophisticated splenic
filter, which receives 5% of the blood
volume per minute, traps bacteria and
particles larger than 2.5 /un which are
subsequently eliminated by various
mechanisms. The spleen is the main site
of clearance of microorganisms when the
host has little or no pre-existing antibody
and it is where specific immunoglobulin
M (IgM antibody) is initially synthe
sized.1,4,5
Although the spleen is frequently in
contact with blood-borne bacteria, it
rarely becomes infected. This is supported
by the rarity of splenic abscesses in clini
cal practice and the low frequency of
splenic abscesses in autopsy series.1
Bacteremia is the first requisite for
splenic abscess and most likely a func
tional or anatomical defect is present for
the abscess to develop. Several predispos
ing factors have been recognized, such as

infarcts, trauma with hematoma forma
tion and hemoglobinopathies. Another
rare cause of splenic abscess is the direct
extension of infection from contiguous
organs.1
In our case, trauma was documented
5 months before admission and although
splenic rupture was considered, this was
not demonstrated by scanning done 1
week after injury. It is possible that the
splenic laceration was too small to be
detected by this examination.
The child had also had an S. aureus
infection in a ventriculoperitoneal shunt
at 1 year of age; we are not sure whether
this infection played a role in the develop
ment of the splenic abscess.
The most common signs and symptoms
associated with splenic abscess are fever,
abdominal pain, pleuritic chest pain,
abdominal tenderness in the left upper
quadrant, splenomegaly or a mass palpa
ble in the left subcostal area and leukocy
tosis. Other common symptoms and signs
are weakness, nausea, vomiting, ano
rexia, cough, diaphoresis, weight loss and
altered bowel habit. Auscultatory abnor
malities may be present on the left lower
side of the chest as well as signs of pleural
effusion or consolidation.13
Chest roentgenography may show a left
pleural effusion and consolidation or
pneumonic infiltration in the left lower
lobe. Plain abdominal films may show a

FIG. 3—Computerized tomogram of upper
abdomen reveals subcapsular collection of fluid
in spleen. A = abscess.

mass in the left upper quadrant or dis
placement of the gastric shadow, but
these findings are not specific.
Ultrasonography, computerized tomo
graphy, gallium and " mTc liver-spleen
scanning and arteriography are specific
studies to recognize splenic abscesses.1'3
In our case, the best of these methods
were ultrasonography (Fig. 4) and com
puterized tomography (Fig. 3). Both
studies demonstrated the abscess and its
subcapsular location. Gallium scanning
(Fig. 2) showed intense uptake in the area
of the spleen but this was not specific for
splenic abscess. Liver-spleen scanning
(Fig. 1) did not contribute to the diagno
sis except to exclude splenic rupture and
liver involvement. Arteriography was not
done. Our findings confirmed the
experience of others2 who recommended
ultrasonography as the least-invasive
study that will make the diagnosis and is
also one of the less expensive methods.
Streptococcus is the most common
organism in splenic abscess followed
closely by S. aureus (as in our patient),
Salmonella sp. and other gram-negative
bacilli; the presence of pus with sterile cul
ture has also been reported.1,3
Splenectomy has been advocated as the
treatment of choice for splenic abscess;1,3
our patient was successfully treated with
appropriate antibiotics and simple
drainage. We recommend this approach
as the initial treatment of choice, espe
cially in children in whom preservation of
the spleen is vital, to avoid the dangers
of overwhelming postsplenectomy infec
tion that is associated with 50% mor
tality.6 Care must be taken not to
contaminate the peritoneal cavity. Broadspectrum antibiotics should be given
before operation until the final culture
and sensitivity results are obtained.
Antibiotics should be continued intra
venously for 2 weeks then orally for 2
more weeks. Follow-up ultrasonography
should be done at intervals until the defect
has resolved.
With the current emphasis on preserv
ing the spleen in blunt abdominal trauma,
we should see fewer overwhelming post
splenectomy infections, but the frequency
of splenic abscess may increase.
References
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FIG. 4—Transverse ultrasonogram of spleen
also demonstrates subcapsular collection of
fluid. A = abscess, L = left side.
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techniques, which in many instances differ
from those of other institutions around the
world.
Only 165 pages long, the book can easily be
read in a single evening. The quality of the
colour photographs is excellent and the under
lying legends are helpful.
A perusal of this book by junior residents
in cardiovascular surgery early in their train
ing program would be very appropriate. This
book, therefore, should be in libraries of insti
tutions concerned with training residents in
cardiac surgery.
E lliot T. G elfa n d , m d ,
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C O M PL IC A T IO N S OF FRAC TURE
MANAGEMENT. Edited by Harry R.
Gossling and Stephen L. Pillsbury. 565 pp.
Illust. J.B. Lippincott Company, Philadel
phia, 1984. $67.50 (US). ISBN 0-39750584-1.

In the foreword to this book, the point is made
that complications of fractures are to be
expected given the nature of trauma (e.g., highvelocity injuries), old age, patient’s poor state
of health and variations of early treatment.
Also, complications will arise from treatment
or failure of definitive treatment; these com
plications are avoidable. Generally, this book
is directed to those responsible for tertiary care
of injured patients.
Andrew Bassett describes in detail current
concepts of the physiology of fracture healing,
including its bioelectric aspects. This serves as
a basis for a general description of his recom
mended electrical management of ununited
fractures. The chapter on management of softtissue complications associated with fractures
stresses the close mutual relationship now
necessary between orthopedic and plastic sur
geons, especially since the advent of microsur
gery and use of free flaps.
Peter Trafton’s thoughtful and beautifully
written chapter on infected fractures should be
read frequently by orthopedic trainees and at
least once a year by every orthopedic surgeon.
There is a scholarly study of the theoretical
aspects of shock and a detailed discussion of
the modern methods of management of shock
with no fewer than 263 references.
Neurologic, vascular and pulmonary com
plications of fractures are adequately discussed
in separate chapters. Injury to abdominal
organs, and metabolic and gastrointestinal
complications receive considered attention.
Finally, a chapter on the general complications
of fracture management constitutes one third
of the book.
Based on an obviously extensive experience
with metastatic bone disease, Harrington, in
his chapter on the management of pathologic
fractures, provides detailed information on
the timing and effective use of internal fixa
tion and methylmethacrylate. Salter’s clearly
written and illustrated chapter on epiphyseal
plate injuries reflects the author’s extensive
knowledge and experience in pediatric ortho
pedic surgery.

The last 13 chapters are concerned with
regions and limb areas. Complications of cer
vical spine injuries are well detailed with illus
trative case reports and excellent roentgeno
grams. Complications of fractures of the
thoracic and lumbar spine are completely dis
cussed, with special reference to the physiol
ogy of patients with spinal cord injuries.
Stabilization of these fractures with rods and
sublaminar wire fixation is surprisingly omit
ted. Hemorrhagic and urologic complications
of sacral and pelvic fractures rightly take prece
dence over the management of complex pel
vic and acetabular fractures by internal or
external skeletal fixation. The 10 chapters on
fractures affecting specific limb areas are
detailed, well edited and contain very few poor
reproductions of roentgenograms. The biblio
graphy includes the relevant modern publica
tions and the index is sufficiently detailed to
allow this book to be used efficiently as a refer
ence text in orthopedic training centres and by
orthopedic and trauma surgeons.
J.P . M o r ea u ,

m d , facs , frcsc

Chief of Orthopedic Surgery,
Edmonton General Hospital,
Edmonton, Alta.
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AN INTRODUCTION TO NEUROSUR
GERY. 4th ed. Bryan Jennett and Sam Gal
braith. 360 pp. Illust. William Heinemann
Medical Books Ltd., London; Year Book
Medical Publishers, Inc., Chicago, 1983.
$49.95. ISBN 0-8151-4869-0.

This small-format text was first published in
1964. The 360 pages of the fourth edition are
divided into six sections: intracranial spaceoccupying lesions, particular intracranial
lesions, head injuries, spinal lesions, congeni
tal conditions and lesion-making in the nervous
system.
As in past editions, the text is not compre
hensive, but rather a “ primer” designed to
inform the nonspecialist about the recognition,
diagnosis and management principles applica
ble to neurosurgical conditions. Each chapter
comprises an orderly progression from the neu
rologic examination, through differential diag
nosis and diagnostic tests to management prin
ciples. All these are illustrated by clear, easily
comprehensible line drawings and sketches.
Suggestions for further reading are included
at the end of each chapter. Topical subjects
such as brain death, herpetic encephalitis and
the management of pain are placed in their
proper context. Minor omissions, such as
chemonucleolysis, and a personal bias against
surgery for brachial neuropathies associated
with cervical spondylosis, may be forgiven.
This text is highly recommended for senior
medical students, residents rotating on neu
rosurgical services, neuroscience nurses, and
those surgeons located away from neurosur
gical centres, who may be called upon occa
sionally to intervene in neurosurgical cases.
B rien G. B e n o it ,

m d , facs , frcsc

Chief, Division of Neurosurgery,
Ottawa Civic Hospital,
1053 Carling Ave.,
Ottawa, Ont.
K1Y 4E9
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Pneumatosis Cystoides Intestinalis Simulating
Malignant Colonic Obstruction
Pneumatosis cystoides intestinalis is an
uncommon condition in which pockets of
gas occur intramurally in the gastrointes
tinal tract. The authors describe the case
of a 76-year-old man in whom this con
dition caused low colonic obstruction,
simulating a rectal carcinoma. The
patient was successfully treated with
high-flow oxygen therapy. This form of
therapy has not previously been reported
in obstructing lesions, but in this case it
successfully relieved the obstruction and
thus avoided a colostomy that might
have been necessary.
La pneumatose kystique de I'intestin est
une maladie rare au cours de laquelle des
poches de gaz se forment dans la paroi
des voies gastro-intestinales. Les auteurs
decrivent le cas d'un homme de 76 ans
chez qui cette affection causa une obs
truction colique basse simulant un cancer
du rectum. Le patient a repondu a un
traitement d’oxygenotherapie a haut
debit. Cette forme de traitement n'avait
pas encore ete signalee dans les lesions
obstructives mais, dans le present cas,
elle a permis de soulager I'obstruction et,
en consequence, d'eviter une colostomie
qui aurait pu s'averer necessaire.

Pneumatosis cystoides intestinalis is a
relatively rare condition characterized by
the presence o f multiple intramural
pockets o f gas in any portion o f the gas
trointestinal tract and occasionally in the
mesenteric attachments.1 It has been
classified as primary (idiopathic) or
secondary (coexisting lesion o f the gas
trointestinal tract) (Table I). About 15%
o f cases are considered primary; most of
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these occur in adults and involve the
colon, giving rise to the term we have used
— pneumatosis coli.
Currently, the pathogenesis of pneuma
tosis coli is thought to be either mechan
ical or bacterial.1-4 The usual clinical
presentation is of mild to moderate symp
toms of diarrhea, cramping, discharge o f
mucus and occasional constipation.
Hematochezia may occur, and occasion
ally, be alarming.5 The findings on
abdominal examination are usually
unremarkable, although at times the cys
tic colon may be palpable.5,6
We present the case o f a patient who
had low colonic obstruction that was ini
tially thought to be due to a rectal carci
noma, but proved to be pneumatosis coli.

Case Report
A 76-year-old man, known to have chronic
obstructive pulmonary disease, was admitted
with a low colonic obstruction. A benign polyp
26 years previously had been managed by a
colotomy and polypectomy, and 8 years previ
ously sigmoidoscopic polypectomy was done.
Follow-up colonoscopic examination 6 years
before revealed no colonic abnormality. His
presenting symptoms consisted of 5 days of
increasing abdominal distension, generalized
abdominal discomfort, absence of bowel move

Table I—Gastrointestinal Conditions
Associated With Pneumatosis Cystoides
Intestinalis*
Peptic ulcer disease
Intestinal obstruction
Postsurgical bowel anastomosis
Mesenteric vascular occlusion
Acute necrotizing enterocolitis
Chronic inflammatory disease (e.g., regional
enteritis, ulcerative colitis, tuberculosis)
Perforated diverticula
Collagen disorders (especially scleroderma!
Whipple's disease
Abdominal trauma
Ingestion of caustic agents
Intestinal parasites
Intestinal lymphosarcoma
Intestinal instrumentation
‘ Modified from Sleisenger and Fordtran.6

ments and very little flatus. Before this he
noted a decrease in the calibre of his stool for
about 2 weeks. There was no history of diar
rhea, mucous discharge, tenesmus or rectal
bleeding. He was not a known diabetic. He had
recently had an exacerbation of his chronic
obstructive pulmonary disease for which his
prednisone dosage had been increased from 5
mg twice daily to 60 mg once a day, then
decreased to 20 mg daily.
He was a slightly obese, afebrile, mildly
dehydrated man with a blood pressure of
140/80 mm Hg, pulse 76 beats/m in and regu
lar. There was no adenopathy, pallor, cyano
sis or icterus. The chest was increased in the
anteroposterior diameter and he had bilateral
expiratory wheezing. There was no jugular
venous distension or abnormal heart sounds.
The abdomen was distended, soft and non
tender with increased bowel sounds. Rectal
examination revealed an enlarged prostate as
well as a separate mass situated anteriorly
about 8 cm from the anal verge. This mass was
nodular, firm and covered two thirds of the
rectal circumference at its palpable lower
margin.
Laboratory findings were as follows:
hemoglobin 116 g/L , hematocrit 35.4%, leu
kocyte count 10.4x 109/L , serum sodium 138
mmol/L, potassium 4.4 mmol/L, chloride 103
mmol/L and bicarbonate 20.1 mmol/L, blood
urea nitrogen 125 mmol/L urea and blood glu
cose 12.7 mmol/L. Results of arterial blood
gas studies on room air were: pH 7.40, partial
pressure of oxygen 71.3 mm Hg and partial
pressure of carbon dioxide 32.5 mm Hg.
Plain films of the abdomen showed a dis
tended colon, with air and stool from sigmoid
to cecum but no gas in the rectum. Parts of
the sigmoid colon showed linear streaks of gas
within the wall. Roentgenograms after barium
enema revealed an area of marked narrowing
with shouldering and nodularity and nearly
total retrograde obstruction (Fig. 1). We
believed that this represented a carcinoma of
the rectum with pneumatosis coli proximally.
Clinically, we thought this man had an
obstructing malignant rectal carcinoma. Dur
ing sigmoidoscopic examination, pale grey
grape-like clusters were seen projecting circum
ferentially into the rectal lumen. The diagno
sis of pneumatosis coli was made at the time
of biopsy when these lesions were seen to col
lapse. Histologically, there were dilated sub
mucosal spaces showing no evidence of malig
nant change.
The patient was treated with nasogastric tube
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suction, intravenous infusion of crystalloids
and 50% oxygen by venturi-mask for 48 hours.
Twenty-four hours after initiation of oxygen
therapy, he was passing gas and had a small
bowel movement. All colonic symptoms
resolved and a follow-up roentgenogram after
barium enema obtained 6 days later showed
resolution of the obstructing cysts (Fig. 2). He
was well at 15 months after discharge.

Discussion
This case appeared to fall into the
category of primary pneumatosis cystoides intestinalis in that no associated
gastrointestinal lesions were noted clini
cally or pathologically. The rectal biopsy
specimens showed dilated submucosal
spaces without any recognizable cellular
lining, which is the usual histologic
appearance of this entity.1,6
The association between pneumatosis
cystoides intestinalis and chronic obstruc
tive pulmonary disease has often been
reported. A suggested mechanism7-9

FIG. 1—Roentgenogram after barium
enema shows obstructing lesion of distal rec
tum simulating carcinoma. Proximal gas-filled
cysts can be seen.

FIG. 2—After treatment with oxygen,
obstructing cysts in distal rectum have resolved.

begins with rupture of pulmonary blebs
into the subpulmonary space; the air then
makes its way through the mediastinum
and retroperitoneum, eventually reaching
the bowel wall via its mesenteric attach
ments. Our patient had chronic obstruc
tive pulmonary disease, so he may fall
into this category.
Important complications of pneumato
sis cystoides intestinalis are quite unusual.
They include pneumoperitoneum,2,10-15
pneumopericardium,15 malabsorption16
and extensive hemorrhage.5 In addition,
obstruction has been associated with
pneumatosis cystoides intestinalis in two
contexts. The more common is when this
condition is secondary to obstructing gas
trointestinal lesions such as pyloroduodenal disease,2,11,17-20 carcinoma,21 anas
tomotic stricture,22 volvulus2,3,14,18-20,23,24
and intussusception.15 The proposed
mechanism here is that of increased
intraluminal pressure secondary to the
obstruction, in combination with some
form of mucosal disruption, allowing gas
to penetrate the intestinal wall and dis
sect the tissue planes.2
The less common occurrence is that of
pneumatosis coli causing colonic obstruc
tion as in our case. Meikle10 reported a
case of pneumatosis coli resulting in
obstruction, stercoral ulceration and per
foration that led to laparotomy. Gillon
and associates3 described two patients in
whom they believed pneumatosis coli led
to sigmoid volvulus that required opera
tive intervention. Jones and Cole4 and
Paris and Fraire25 reported cases of
small-bowel obstruction secondary to gas
cysts involving the small intestine.
High-flow oxygen therapy has been
used in the treatment of pneumatosis cys
toides intestinalis since 197326-28 on the
premise that raising arterial oxygen ten
sion to between 200 and 300 mm Hg
results in subatmospheric nitrogen pres
sures in the end-capillary and venous
blood, as the oxygen (which displaces
much of the nitrogen) is readily utilized
by the colonic tissues. The resultant
nitrogen-pressure gradient between the
cystic spaces and the venous blood pro
motes collapse of the cysts. High-flow
oxygen treatment appears to be widely
accepted as being beneficial. It may be
required for up to 6 days.26,27
The use of oxygen therapy in obstruct
ing lesions due to pneumatosis coli has
not previously been reported. Since there
is no immediate danger of vascular com
promise from the obstructing process,
laparotomy is not thought necessary and
release of the obstruction should occur
when oxygen at a high flow rate is given,
as happened in our case. The colonic
obstruction was caused by a benign
process so oxygen therapy avoided a
colostomy that would have been neces
sary if the obstruction had not resolved
otherwise.
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Cyclosporine in Heart and Heart-Lung Transplantation
A t S ta n fo rd U n ive rsity M edical Center
fro m J a n u a ry 1 9 6 8 u ntil January 1 9 8 4,
2 8 8 p a tie n ts received 3 1 3 heart tra n s
pla n ts. The im m unosuppressive regimen
before Decem ber 1 9 8 0 co n sisted o f
a za thio p rin e and prednisone, w ith or
w ith o u t ra b b it a n tith y m o c y te globulin.
A fte r th a t tim e cyclo sp o rin e replaced
a za thioprine. In 9 2 recipients o f 9 5 heart
a llo g ra fts , th e 1- and 3 -year survival
rates w e re 8 2 % and 6 5 % to 7 0 %
res p e c tiv e ly . In th e 3 years fro m M arch
1981 to M arch 1 9 8 4 , su cce ssful heartlung tra n s p la n ta tio n w as accom plished in
13 o f 19 recip ie n ts, using cyclosporinebased im m unosuppression. Survival
ranged fro m 1 to 38 m onths.
W h ile it is tru e th a t cyclo sp o rin e has
im p ro ve d su rviva l in heart tran sp la n t
re cip ie n ts, has a llow ed su cce ssful heartlung tra n s p la n ta tio n to be perform ed, has
sh o rte n e d inte nsive care u n it and to ta l
ho sp ita l s ta ys and th e re fo re hospital
co s ts , and has a llow ed easier m anage
m ent o f reje ctio n and in fe c tio n , several
d is c o n c e rtin g problem s have n o t yet
been resolved. These include h yp e rte n 
sion th a t is d iffic u lt to c o n tro l and renal
d y s fu n c tio n in all patients, and the fa c t
th a t c e llu la r and hum oral rejection still
occu rs, as m anifested by g ra ft a th ero 
scle ro sis, b ro n ch io litis obliterans and
classic a cu te rejection. B etter under
sta n din g and application o f cyclosporine
im m u n o su pp re ssio n w ill u n d ou b te d ly
m inim ize b o th cyclosporine- and n o n 
c y c lo sp o rin e -re la ted p o stop e ra tive co m 
p lic a tio n s and w ill im prove survival even
fu rth e r.

De ja n v ie r 1 9 6 8 a janvier 1 9 8 4 , 2 8 8
p a tie n ts o n t recu 3 1 3 g re ffe s cardiaques
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au S ta n fo rd U n ive rsity M edical Center.
A v a n t decem bre 1 9 8 0 , le traitem ent
im m unosuppresseur e ta it com pose d'azathio prin e e t de prednisone, associees ou
non a de I'im m u n o g lo b u lin e antith y m o c y ta ire de lapin. Par la suite, la
cyclo sp o rin e est venue remplacee I'azath ioprine. La survie a 1 e t 3 ans chez 92
receveurs de 9 5 a llogreffes cardiaques
fu t de 8 2 % e t de 6 5 % a 7 0 % respectivem ent. A u cours des 3 annees qui se
s o n t ecoulees entre m ars 1981 et mars
1 9 8 4 , grace a la cyclosporine, des g re f
fe s coeurs-poum ons o n t ete reussies
chez 13 des 19 receveurs. La survie va
de 1 a 3 8 m ois.
M em e s 'il est vrai que la cyclosporine
a ameliore la survie des greffes cardia
ques, rendu possible le succes des g re f
fe s coeurs-poum ons, reduit le sejour aux
soins in te n sifs, la duree d'ho sp ita lisa tio n
e t, par consequent, les co u ts, et, finalem ent, perm is d 'a ffro n te r plus facilem ent
les rejets e t les in fe ctio n s, il reste bon
nom bre de problem es deroutants a
resoudre. Parmi ces com plications, on
n o te une hyp e rte n sio n d iffic ile a tra ite r et
une in su ffisa n ce renale a ffe c ta n t tous les
patients, e t le fa it que surviennent
encore des reactions de rejet a m edia
tio n s cellulaire et hum orale qui se manife s te n t par de I'atherosclerose du greffo n , une b ro n ch io lite o b literante et le
rejet aigu classique. Une meilleure co m 
prehension de I'im m unosuppression a la
cyclo sp o rin e e t une m eilleure utilisation
de ce m edicam ent p e rm e ttro n t sans nul
d o u te de m inim iser les com plications
p o stop e ra toire s reliees ou non a la
cyclo sp o rin e , et d'am e lio re r encore la
survie.

The introduction in December 1980 at
Stanford Medical Center of cyclosporine
to suppress the immune response and the
gradually improving survival rates of
preceding years (Fig. 1) have contributed
to the current revival of cardiac transplan
tation around the world (Fig. 2) and have
allowed successful heart-lung transplan
tation to be performed, with long-term
survival.1,2 To define the current advan
tages and disadvantages of cyclosporine

use, the clinical data from all patients
who had transplants and cyclosporine
immunosuppression at Stanford Univer
sity Medical Center between December
1980 and January 1984 are reviewed and
compared with the data generated from
earlier transplantations when immuno
suppression was based on the use of
azathioprine, prednisone and antithymo
cyte globulin of rabbit origin.
Cyclosporine in Heart Transplantation

From Jan. 1, 1968 to Dec. 31, 1983,
313 heart transplantations were per
formed in 288 patients. At the time of
writing, the total number of 1-year sur
vivors was 155 and 121 patients were alive

YEAR

FIG. 1—Progressive improvement in 1-year
survival rates of heart transplant recipients at
Stanford University Medical Center.

FIG. 2—Total number of heart transplants
performed by year. Open circles indicate proce
dures carried out at Stanford University Medi
cal Center, closed circles are those performed
world wide.
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1 week to 14 years after transplantation.
Nearly 90% of these patients were fully
rehabilitated. From December 1980, 92
patients (74 male, 18 female) who received
cyclosporine for immunosuppression had
95 transplants. These patients ranged in
age from 13 to 52 years. There were six
retransplantations.
The preoperative diagnoses included
coronary artery disease (36 patients), idi
opathic cardiomyopathy (40), viral or
familial cardiomyopathy (11), congenital
heart disease (3) and others (2).
Survival
To understand best the effect that
cyclosporine has had on survival of heart
recipients, one can contrast the survival
curve generated in these patients with that
of two previous immunosuppressive eras
and of patients who did not have a trans
plant (Fig. 3). Of patients selected
for transplantation for whom a suitable
donor was not available, all died in the
first year (mean survival 44 days). From
January 1969 until December 1973, the
immunosuppressive regimen consisted of
azathioprine and prednisone. One- and
5-year survival rates were 42% and 15%
respectively. With the introduction of
prophylactic rabbit antithymocyte globu
lin, given in the first few days after trans
plantation, the 1- and 5-year survival rates
increased to 62% and 42% respectively.
From December 1980 until December
1983, cyclosporine supplanted azathio
prine, resulting in improved graft survival
rates to 82% at 1 year and nearly 70% at
3 years. Twenty patients who had
cyclosporine for immunosuppression died
for the following reasons: rejection 3,
infection 8, malignant disease 3, coronary
artery disease 2, pulmonary hypertension
1, acute graft failure 1, cerebrovascular
accident 1 and cerebral edema 1.
Immunosuppressive Regimen
Immunosuppression consisted of the

YEAR

FIG . 3—Survival of patients in three
immunosuppressive eras compared with that of
patients who did not undergo transplantation.
(Open squares = Jan. 1981 to Dec. 1983, open
circles = Jan. 1974 to Dec. 1980, black circles
= Jan. 1968 to Dec. 1973, black squares = not
transplanted.)

administration of cyclosporine, 12 to 18
mg/kg, orally, 6 hours before operation.
Intraoperatively, after cardiopulmonary
bypass was discontinued, 500 mg of
methylprednisolone sodium succinate was
administered intravenously. Postoperatively, 15 mg of methylprednisolone
sodium succinate was given (three doses
at 8-hour intervals) and cyclosporine, 12
to 18 mg/kg daily (in equal divided doses
every 12 hours). The dose of cyclosporine
was tapered gradually over several days
to several weeks according to blood levels
which were maintained between 100 and
300 ng/mL. On day 1 postoperatively,
following the third dose of methylpred
nisolone, prednisone was begun at a rate
of 1 mg/kg daily (in equal divided doses
every 12 hours), along with the cyclospo
rine. The prednisone dose was tapered to
0.8 mg/kg daily by 2 weeks, 0.5 m g/kg
by 4 weeks and 0.2 mg/kg by 8 weeks.
Rabbit antithymocyte globulin (2.5
mg/kg, intramuscularly, preoperatively
and on postoperative days 1 and 2) was
given prophylactically to the first 27
patients, but not to the subsequent 65
patients.
Rejection
Diagnosis. —With conventional immu
nosuppression based on the use of
azathioprine, antithymocyte globulin and
prednisone, rejection could be suspected
by noting a 20% or more decrease in the
cumulative voltage of the electrocardio
gram (leads I, II, III, V5 and V6).34
Similarly, in the face of a markedly short
ened half-life of circulating rabbit globu
lin, or in the presence of a large volume
of circulating T lymphocytes, rejection
was likely occurring or was imminent.3
Clinical signs indicative of graft dysfunc
tion were those of congestive heart failure
and were late findings. Definite diagno
sis could be achieved only with endo
cardial biopsy when rejection was sus
pected, using the previously described
criteria.3,4
Unfortunately, with cyclosporine, the
electrocardiogram is not a reliable indi
cator, circulating T-cell levels are unrelia
ble and clinical findings are absent.
Therefore, endocardial biopsy is the only
currently reliable means o f diagnosing
rejection in most instances. Surveillance
biopsies, therefore, must be performed
weekly for the first 2 to 3 months, then
bimonthly up to 6 months and every 3 to
4 months thereafter. The endocardial
bioptome is passed percutaneously by the
Seldinger technique through the right
internal jugular vein and under fluoro
scopic control is positioned within the
right ventricle; usually three biopsy speci
mens are taken from the interventricular
septum. More than 5000 biopsies have
been performed at Stanford University
Medical Center with no deaths and only

three perforations that required explo
ration.
Differences in histologic findings be
tween azathioprine- and cyclosporinetreated patients appear to correlate with
differences in clinical findings. Fig. 4
illustrates normal myocardium in a biopsy
specimen. Acute severe rejection in a
patient immunosuppressed with azathio
prine and prednisone uniformly is mani
fested by myocardial edema and lympho
cytic infiltration (Fig. 5); this leads to a
decrease in electrocardiographic voltage
and a decrease in diastolic compliance
with the ultimate appearance of S3 or S4
gallop sounds;3 atrial arrhythmias and
variable degrees of heart block often
ensue. Congestive heart failure and death
secondary to cardiogenic shock rapidly
follow if treatment of the rejection is not
optimal.
With cyclosporine, severe allograft
rejection is not associated with myocardial
edema (Fig. 6), hence the re 
jection is nearly always clinically silent.
Recently, two patients who died of acute
rejection presented with a low-grade
fever, myalgia and weakness. In the first
patient, rejection was not suspected, and
a biopsy was not performed before his
sudden cardiac arrest from which he
could not be resuscitated. In the second
patient, the severity of rejection seen in
the biopsy specimen was not fully
appreciated; the patient was undertreated.
Although all rejection episodes that
occurred in patients during their initial
hospital stay were treated ’with intra
venous Solu-Medrol, once patients were
discharged subsequent rejection episodes
were treated by increasing the prednisone
dosage to 100 mg/d for 3 days, then
tapering the dosage schedule by 10 mg
every other day until the dosage was
approximately 10% above the previous
maintenance dosage. Currently, for
patients who have been discharged from
hospital, important rejection episodes
associated with cardiac dysfunction or
echocardiographic evidence of rejection5
or important clinical findings are treated
with intravenous Solu-Medrol. It is
peculiar that the mononuclear infiltrate
in patients immunosuppressed with
cyclosporine may persist for weeks or
months following treatment. In the
absence of myocyte necrosis, one can only
speculate as to the biologic nature of these
cells.
Nearly 25% of patients in the cyclospo
rine group were free of rejection by
postoperative day 60 as opposed to
approximately 18% in the azathioprine
group.6 Although this difference was not
statistically significant, the severity, as
reflected by cardiac dysfunction and
death from rejection, was significantly
less in patients receiving cyclosporine.7
This was further reflected by decreased
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time spent in the intensive care unit and
an overall shorter hospital stay.
Treatment.— Acute rejection during
the initial hospital stay is treated with
1000 mg of methylprednisolone sodium
succinate, administered intravenously
daily for 3 days. The prednisone reduc
tion is interrupted and the dose is held
constant. If serum levels of cyclosporine
are below the targeted therapeutic range,
the oral dose of cyclosporine is increased.
Rabbit antithymocyte globulin is used
only if extensive myocyte necrosis is noted
in the very first cardiac biopsy specimen
on postoperative day 7, if rejection with
myocyte necrosis is still present follow
ing two courses of methylprednisolone
sodium succinate and in the presence of
life-threatening acute rejection in patients
in cardiogenic shock.
Infection
Infection accounted for 40% of all
deaths in the cyclosporine-treated trans
plant recipients as opposed to 66% of the
deaths in the azathioprine group. The
total number of infectious episodes,
however, did not appear to be signifi
cantly less than in the azathioprine group
in the first 3 years after transplantation
(Fig. 7). A trend towards fewer bacterial,
fungal and protozoal infections is
balanced by an increase in viral infections
(mainly trivial mucocutaneous lesions)
when cyclosporine is used. As with rejec
tion, the infectious episodes are easier to
treat and the hospital stay is shortened;
overall, it is likely that a decrease in the
severity of infectious episodes with
cyclosporine and improved diagnosis and
management have contributed to an
improvement in survival.

Malignant Disease
In patients at risk more than 3 years
after transplantation who received aza
thioprine, prednisone and antithymocyte
globulin for immunosuppression, 10 lym
phomas developed, of which 6 followed
primary transplantation in 124 patients
(5%) and 4 followed retransplantation in
10 patients (40%). The higher incidence
following retransplantation likely re
flected the longer period of immunosup
pression. Leukemia occurred once after
primary transplantation.
From December 1980 until January
1982 the cyclosporine and prednisone
immunosuppression was combined with
a short prophylactic course of antithymo
cyte globulin. Five lymphomas occurred
after primary transplantation in 27
patients for an incidence of 19%. The
apparently synergistic oncogenic effect of
antithymocyte globulin and cyclosporine
was also noted in primates. Accordingly,
from Jan. 1, 1982, the routine prophylac
tic use of rabbit antithymocyte globulin
has been stopped. In 67 patients, only one
lymphoma occurred, a rate of 1.5%. Of
the six patients with lymphomas, two are
alive following local excision and radi
otherapy. One patient also received acy
clovir. Epstein-Barr virus has been impli
cated in the pathogenesis of this
lymphoproliferative disorder.8' 10

100%.3 The generation of graft athero
sclerosis was thought to be related to
immunologically mediated intimal and
endothelial injury, with subsequent depo
sition of platelets followed by myointimal
proliferation. Accordingly, antiplatelet
agents combined with warfarin were
administered prophylactically. This
resulted in a 50% reduction in graft
atherosclerosis at 3 years. Since 1979,
dipyridamole alone has been used,
because, in a subset of patients in whom
warfarin could not be administered, the
incidence of graft atherosclerosis was the
same as in those who had received both
warfarin and dipyridamole. One of the
purported mechanisms of action of
cyclosporine is to inhibit T-cell dependent
antibody formation, and it was hoped
early on that graft atherosclerosis might
be markedly reduced or even eliminated.
While the former may still be true, two
patients have died of severe graft athero
sclerosis and myocardial infarction and a
third patient is currently awaiting re-

Coronary Artery Disease
That graft atherosclerosis might be a
problem was not recognized initially. The
incidence, however, at 3 years was

FIG. 6— M yocardial biopsy specimen
demonstrates acute severe rejection with myo
cyte necrosis and mononuclear infiltration but
distinct absence of myocardial edema in patient
given cyclosporine for immunosuppression
(hemotoxylin and eosin, reduced by 53% from
x 400).

FIG. 4— Normal myocardial biopsy speci
men (hematoxylin and eosin, reduced by 53%
from x 400).
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FIG. 5— M yocardial biopsy specimen
demonstrates acute severe rejection with
marked myocardial edema and mononuclear
infiltration in patient given azathioprine and
prednisone for immunosuppression (hematox
ylin and eosin, reduced by 53% from x 400).

FIG. 7—Total number of infectious episodes
is similar in cyclosporine (open circles) and
azathioprine (closed circles) groups.
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transplantation because of serious
myocardial infarction.
Complications Related to the
Use o f Cyclosporine
Hypertension.—Hypertension in pa
tients immunosuppressed with azathioprine and prednisone was infrequent and
tended to occur in older patients with
atherosclerotic heart disease. However,
with cyclosporine, severe hypertension
was invariably present early after opera
tion and required large doses of nitroprusside frequently in combination with
trimethaphan and occasionally even
boluses of hydralazine. This hypertension
is reflected by severe headaches that often
develop as the blood pressure increases,
and which, therefore, could be controlled
by decreasing the blood pressure. Wellands (personal communication, 1983)
has reported intracerebral hemorrhage
early after operation as a result of uncon
trolled hypertension. The mechanism of
this hypertension is unclear, but nearly all
patients are hypertensive within 2 or 3
months of operation and require a vari
ety of antihypertensive drugs or combi
nation of drugs for its control. There is
no single drug or combination, however,
that is consistently effective for all
patients.
Renal dysfunction.—This has occurred
in most patients. There is a gradual
increase in the serum creatinine level with
time, with an associated time-related
decrease in creatinine clearance. The rela
tion between systemic hypertension and
renal dysfunction is not yet clear.
To evaluate renal dysfunction further,
47 patients who underwent transplanta
tion before December 1980 and were
given azathioprine and prednisone for
immunosuppression were compared with
32 recipients who received cyclosporine
and prednisone.11 An adverse effect on
kidney function of long-term cyclosporine
therapy is suggested by the divergent plot
of the reciprocal of the serum creatinine
level in the two populations (Fig. 8).
Glomerular filtration rate in the azathio
prine group was significantly (p < 0.005,
unpaired two-tailed f-test) higher at all
times after the first post-transplant
month.
To define the renal injury associated
with long-term cyclosporine therapy,
detailed physiologic studies were per
formed in 17 consecutive 1-year survivors
receiving.cyclosporine. For comparison,
the same studies were performed in 13
unselected, long-term, azathioprinetreated control patients." Inulin clear
ance was determined as a precise meas
ure of glomerular filtration rate in the two
groups. Fig. 9 demonstrates that inulin
clearance in azathioprine controls was
usually normal and always exceeded 70
mL/min. By contrast, inulin clearance in

cyclosporine recipients was invariably
below normal, sometimes severely so.
There was almost no overlap between the
two populations, with the average
glomerular filtration rate in cyclosporine
recipients reduced to only 51 m L/m in
versus 92 mL/min after 1 year of therapy.
To examine tubular function, the paraamino hippurate extraction ratio was
measured by sampling renal venous blood
during the catheterization of the right side
of the heart. Although not significantly
different from azathioprine controls,
para-amino hippurate extraction was
depressed to a subnormal value of 72%
in patients receiving cyclosporine. The
patients’ ability to excrete a dilute urine
was determined after giving 1.5 L of
water orally during a 90-minute period.
Both groups were able to lower urinary
osm olarity below that in plasm a.
However, the free water clearance was
appreciably reduced in cyclosporinetreated patients to 3 mL/min compared
with 5.1 mL/min in azathioprine-treated
patients. Thus, there was both proximal
and distal tubular dysfunction in
cyclosporine-treated patients.
To elucidate the cause of the reduced
glomerular filtration rate associated with
long-term cyclosporine therapy, several
hemodynamic parameters were evaluated.
Cardiac output was similar in the two
groups, averaging just under 6 L/m in.
Cyclosporine-treated recipients differed,
however, in that arterial hypertension was
prevalent and renal blood flow, measured
by the clearance and extraction of paraamino hippurate, was appreciably de
pressed to 501 mL/min compared with
836 mL/min. Dividing the renal pressure
drop by blood flow showed that renal vas
cular resistance more than doubled in
cyclosporine-treated patients.
To determine whether the cyclosporineinduced reduction in glomerular filtration
rate was hemodynamically mediated or
whether alterations in the glomerular cell
wall were responsible, the fractional clear
ance of neutral dextrans of graded size
was examined. It did not differ signifi
cantly between the two groups. However,
for the first 24 to 34 angstrom intervals
in patients receiving cyclosporine, the
fractional clearance profile tended to be
depressed below that in the azathioprine
group. If one compares the predicted
effects of a selective reduction in renal
perfusion, where all determinants of
glomerular filtration, except renal blood
flow, have been held constant, then a
selective fall in blood flow should uni
formly enhance, and not depress, the
fractional dextran clearance. Thus, the
fall in renal blood flow from 836 to 501
m L/m in in the cyclosporine group can
not wholly account for the dextranclearance profile. Accordingly, the frac
tional clearances of dextran in each group
were subjected to a theoretical analysis of

solute transport through an isoporous
membrane. From this, two membrane
parameters were derived: first, the mean
radius of functional pores perforating the
glomerular capillary wall was determined
to approximate 61 A in each group, a
value similar to that found previously in
normal subjects; second, the ratio of total
pore surface area to pore length may be
equated with the total number of pores
occupying the membrane to provide the
pore “ density” . It was reduced from a
normal value of 22 in azathioprine con
trols to only 15 in cyclosporine recipients.
The disparity in pore density is compara
ble to the difference in glomerular filtra
tion rate between the two groups, suggest
ing that the loss of surface area for
filtration may be the mechanism by which
long-term cyclosporine therapy lowers the
glomerular filtration rate. To explore fur
ther the structural correlates of this find
ing, five cyclosporine-treated patients in
whom the glomerular filtration rate was
substantially reduced underwent renal

FIG. 8—Renal function in heart transplan
tation. Aza = azathioprine group, CyA =
cyclosporine group.

FIG. 9—Mean glomerular filtration (GFR)
rate at 1 year in cyclosporine-treated patients
(CyA) was invariably below normal and nearly
always less than that in unselected control
patients treated on long-term basis with
azathioprine (Aza).
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biopsy. Light microscopy revealed tubu
Tremor.—A fine resting tremor is
lar atrophy and a remarkable fibrosis in occasionally present for the first few
the interstitium. Electron microscopy weeks after transplantation, but it also
showed that the basement membrane of resolves with time.
tubular cells was thickened and there was
Hepatic dysfunction.—Transient eleva
a variable loss of the brush border. Con tion of liver enzymes and total bilirubin
voluted tubule cells revealed diffuse loss levels occur in most patients early after
o f organelles and nuclear swelling alter transplantation, but both usually return
nating with nuclear pyknosis and loss of to baseline levels within 2 to 4 weeks after
cytosol. Thus, growing evidence impli transplantation.
cates cyclosporine as a tubular cell toxin.
Interaction with rifampin.—Rifampin
Although these findings are striking, the has been demonstrated to induce produc
apparent deterioration in renal function tion of liver microsomal enzymes13 and
over the first year after transplantation enhance the metabolic effect of predni
does not appear to be progressive over the sone.14 In two patients with Aspergillus
subsequent 1 to 2 years. Therefore, we are fum igatus pulmonary infection, in-vitro
guardedly optimistic about the stabiliza synergy studies demonstrated a potential
tion o f renal dysfunction in patients who benefit for them with amphotericin B
received cyclosporine after heart trans combined with rifampin. In both patients,
plantation. We have not yet discounted the requirements for cyclosporine in
the prospect of using cyclosporine in the creased three to fivefold within several
first 2 to 3 months after transplantation, days of beginning rifampin therapy.15 In
and then switching to azathioprine, but one patient, it was difficult to maintain
further long-term data are required before satisfactory cyclosporine levels, and acute
we implement this strategy.
rejection occurred. Despite several treat
Measures that we believe useful to ment courses, the rejection never satisfac
minimize postoperative renal dysfunction torily resolved and the patient ultimately
include: (a) use of less than 18 mg/kg of died of acute and chronic rejection. In the
cyclosporine preoperatively and postoper- second patient, the infection appeared to
atively in the presence of renal dysfunc resolve and it was anticipated that renal
tion; (b) daily monitoring of serum dysfunction would ensue if the rifampin
cyclosporine levels for at least 1 week was discontinued without first lowering
postoperatively, aiming for levels of 150 the cyclosporine dosage. Accordingly, the
to 250 ng/m L; (c) use of mannitol dur cyclosporine was returned to the original
ing cardiopulmonary bypass and then maintenance dosage at the same time that
postoperatively with each dose of the rifampin was discontinued. Neverthe
cyclosporine during the initial hospitali less, the serum creatinine level doubled
zation; (d) maintenance of an optimal and the creatinine clearance decreased to
cardiac filling pressure; (e) use of renal one half of its baseline value for several
effective doses of dopamine and (f) use days before recovery. Others14 have also
of diuretics to maintain an hourly urine reported a marked increase in cyclospo
rine requirements in renal transplant
output of at least 1 mL/kg.
Myocardial fibrosis.—As in the kidney, recipients who have required rifampin
a fine interstitial myocardial fibrosis starts therapy.
within several weeks of treatment with
cyclosporine.12 At least 10 patients at 6 Comparative Costs fo r
months, 18 at 1 year and 2 at 2 years have Heart Transplantation
been assessed for evidence of myocardial
As of March 1983, the average cost per
restriction, both before and after volume
loading with 0.9% saline. Although the patient for cardiac transplantation in 48
long-term results of this fibrosis are not patients treated with cyclosporine was
known, there is no evidence that it leads nearly $30 000 less than in 97 patients
to myocardial damage of physiologic given azathioprine. This difference was
also reflected in the median cost of
importance.
$63 000 as opposed to $91 000.
Headaches.—Although headaches are
common early on in the course of Cyclosporine in Heart-Lung
cyclosporine therapy, they are generally Transplantation
thought to be due to a hyperdynamic cir
culation, hypertension and perhaps cere
Historically, the results of human
bral edema. In general, headaches can be heart-lung transplantation and lung trans
controlled with antihypertensive therapy plantation have been disappointing. In
and analgesics. Usually within 1 to 3 three heart-lung transplantations done in
weeks after transplantation, headaches 1968, 1969 and 1971, no patient survived
are no longer a problem.
beyond 23 days and each died from
Hirsutism.—Hair growth may be strik respiratory complications.16' 18 Similarly,
ing with a general increase in body and of 39 patients who have undergone lung
scalp hair that becomes darker, thicker transplantation, only 2 have survived
and wavier. This may be of concern to beyond 2 months (6 and 10 months).19
women, cosmetically.
Use of steroid immunosuppression con
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tributed importantly to each patient’s
death of pneumonia or tracheobronchial
disruption, by preventing anastomotic
healing. With the successful introduction
of cyclosporine in animal cardiac trans
plantation20-22 and human renal trans
plantation,23 the elimination or reduc
tion of the requirements for steroids in
solid-organ transplantation became a pos
sibility. Experiments begun in 1979 using
cyclosporine in primate heart-lung trans
plantation by Reitz and associates24 at
Stanford strongly supported a move
towards clinical application of the proce
dure. Two primates are still alive and well
at 4.5 and 5 years after transplantation.
Stimulated by the primate experience and
the success with cyclosporine in human
heart transplantation, a program in
human heart-lung transplantation was
begun in March 1981.25
Recipient Selection
From March 1981 until May 1984, 19
heart-lung transplantations were per
formed in 13 men and 6 women ranging
in age from 22 to 45 years (Table I).
Twelve had congenital heart disease with
secondary pulmonary hypertension, and
7 patients had primary pulmonary hyper
tension. Although a large group of
patients with chronic obstructive pulmo
nary disease, pulmonary fibrosis or cys
tic fibrosis are conceivably suitable can
didates, none in this group have yet
undergone transplantation at Stanford
University.
Operative Technique and
Postoperative Management
The details of operative technique and
postoperative management of heart-lung
transplantations have been reported
previously.26 The operative technique
has been modified in the last 13 patients
so that: the lungs are cooled with modi
fied Collins II solution; the heart and
both lungs in the recipient are removed
separately so that visualization of the
bronchial arteries and of both the vagal
and phrenic nerves is better; the back wall
of the left pulmonary artery is left intact
thereby minimizing the likelihood of
injuring the recurrent laryngeal nerve
and, during implantation, both lungs are
bathed with cold (4°C) Physiosol (bal
anced salt) rather than Collins II (bal
anced salt, high in potassium) solution,
to prevent undesirable potassium absorp
tion and hyperkalemia. Modification of
the operative technique, however, has not
alleviated the problem of bleeding requir
ing re-exploration (nine patients). All
patients received antibiotics (cefamandole, nafcillin and erythromycin) perioperatively.
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Immunosuppression
The immunosuppressive regimen used
in all patients consisted of cyclosporine,
14 to 18 mg/kg, orally 6 hours before
transplantation, and then postoperatively
in divided doses according to targeted
serum levels between 100 and 300 ng/mL.
Three doses of antithymocyte globulin of
rabbit origin (2.5 mg/kg) were given
intramuscularly to each patient, immedi
ately following induction of anesthesia,
then on postoperative days 1 and 2. The
determining factor for the second
postoperative dose of rabbit antithymo
cyte globulin was an absolute T-rosette
level exceeding 100/mm3 the day after
the first postoperative dose. Methylprednisolone sodium succinate, 500 mg intra
venously, was given after cardiopulmo
nary bypass, then 125 mg intravenously
every 8 hours for three doses. No further

Patient
no.

Age,
Diagnosis
PPH

steroids were given in the subsequent 2
weeks, during which azathioprine, 1 to 2
mg/kg orally, was given daily if the leu
kocyte count was greater than 4 x 109/L .
After 2 weeks, prednisone was begun at
0.2 to 0.3 m g/kg daily and the azathio
prine was discontinued. Rejection epi
sodes were diagnosed by endocardial
biopsy.
Results
Of the 19 patients transplanted, as of
March 1984, 13 survived the operation
(operative mortality defined as death
within 30 days of transplantation) (Table
I) and were fully rehabilitated; 12 were
still alive.
Of the six operative deaths, two
patients died of multisystem organ
failure, one of lung failure manifested,
immediately following attempts to discon

Table I—Clinical Summary of the Heart-Lung Transplant Recipients
Treated rejection
episodes,
Form of
rejection
Infection
postop. day
Herpes (cutaneous)
11, 25, 45
Cardiac cellular
infiltrate, MN
Cardiac cellular
CMV (systemic)
235, 1041
infiltrate, MN
(pulmonary infiltrate,
pulmonary HPT,
cardiac graft
atherosclerosis)
X
X
Recurrent lung infection
Cardiac cellular
86
(bronchiectasis)
infiltrate, MN
—
21, 52
Cardiac cellular
infiltrate, MN
X
X
X
X
X
X
—
—
Bacteroides (blood and
lung), CMV (systemic)
Enterococcus (lung)
15, 22, 211
Cardiac cellular
infiltrate, MN,
pulmonary infiltrate
—
Cardiac cellular
23, 29, 56, 443
infiltrate, MN,
cardiac graft athero
sclerosis, myocardial
infarction

1

45

Sex
F

2

30

M

E

3
4

29
40

F
M

E
E

5

37

F

PPH

6
7
8

29
22
40

F
M
M

PPH
E
E

9

22

M

E

10

28

M

E

11
12

38
32

M
M

E
E

—

—

—

—

13

33

M

E

14

14
15

28
42

F
M

PPH
E

X
X

Cardiac cellular
infiltrate, MN
X
X

yr

tinue cardiopulmonary bypass, as a severe
loss of alveolar-capillary integrity and
massive pulmonary edema, two o f pul
monary insufficiency on postoperative
days 16 and 33 from undetermined causes
(implantation response and rejection or
infection, or both?) and one patient died
of a myocardial infarction 15 months
after transplantation.
Fourteen episodes of cardiac rejection
have been diagnosed by cardiac biopsy,
demonstrating a mononuclear cellular
infiltrate with myocyte necrosis on histo
logic examination. Thirteen of the epi
sodes occurred within 90 days of trans
plantation. Each episode was treated
successfully with three 1-g/d pulses of
methylprednisolone sodium succinate.
Until recently, we believed that both
pulmonary and cardiac rejection were
accurately reflected in all cases by
endocardial biopsy. We also assumed that

—

CMV (systemic),
Klebsiella (pulmonary),
recurrent lung infec
tion (bronchiectasis)
Serratia (pulmonary),
CMV (systemic)
Candida (pulmonary)
Legionella (pulmonary),

Initial
hospital
discharge, d
85

Survival,
d
1146

46

1090

4
46

4
961

64

881

23
0
40

23
0
542

38

538

39

443

38
46

476
347

51

344

16
33

16
33

49

177

63

150

Serratia, Enterococcus
(pulmonary)
16
17

22
37

M

M

PPH
PPH

29
—

Cardiac cellular
infiltrate, MN
—

Serratia, Hafnia alvei
(pulmonary)

Enterobacter, Serratia,
Staphylococcus

(pulmonary)
PPH
F
18
33
In hospital--------------------------M
E
40
19
PPH - primary pulmonary hypertension, E - Eisenmenger's syndrome, MN - myocyte necrosis, HPT - hypertension, CMV - cytomegalovirus, X = not
applicable.
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pathologic lung rejection would invaria
bly demonstrate a classic cellular pattern.
Although in general these two assump
tions hold true, it appears that, with
cyclosporine immunosuppression, neither
is entirely accurate. Primate heart-lung
transplantation studies have demon
strated that severe cellular lung rejection
may occur without appreciable heart
rejection.27 Furthermore, two patients
(cases 2 and 9) suffered late pulmonary
infiltration on lung biopsy but no cardiac
rejection. Over the previous 4 months,
both had had serum cyclosporine levels
below 150 ng/mL and in patient no. 9 a
restrictive pattern that had developed
along with the infiltration partially
resolved with a return towards normal
lung volumes, compliance and roentgenographic appearance following steroid
therapy; in patient no. 2, severe coronary
atherosclerosis and pulmonary hyperten
sion were documented shortly after the
development of the lung infiltration. A
third patient who had cyclosporine levels
below 150 ng/mL for 7 months died sud
denly and was found to have an extensive
myocardial infarction and graft athero
sclerosis. The occurrence of pulmonary
hypertension and graft atherosclerosis
and perhaps even the late pulmonary
infiltration may represent a less-common
form of vascular rejection, perhaps
immorally mediated. That the pulmonary
changes and graft atherosclerosis oc
curred only in these three patients follow
ing a 4- to 6-month period with low
cyclosporine levels (less than 150 ng/mL)
suggests, but does not prove, cause and
effect. Nevertheless, stimulated by these
findings, our current recommendation is
to aim for serum trough cyclosporine
levels of 200 to 300 ng/m L, rather than
our previous range of 100 to 300 ng/m L.
A similar degree of renal dysfunction
(elevated creatinine and blood urea nitro
gen levels) and hypertension requiring
therapy occurred in heart-lung recipients
as in the heart recipients.
Perhaps the most unusual complication
following heart-lung transplantation was
the development of the “ implantation”
response in the lungs of 9 of the 13 long
term survivors. This reponse, which has
been described previously,28 is character
ized by perihilar infiltration that may
become confluent and must be distin
guished from infection and rejection.
These changes generally occur and resolve
between 7 and 28 days after transplanta
tion, and are associated with hypoxemia
and decreased lung compliance. Factors
exclusive of rejection and infection that
have been considered possible in the
pathogenesis include lymphatic, bronchial
arterial or neural interruption, or both,
mechanical trauma from handling of
lungs, and the perfusate used to cool the
lungs. The etiology of this pulmonary
response, however, is unclear since no
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patients or primates have yet had a diag
nostic lung biopsy. In fact, rejection or
immune complex disease could still be a
factor since all patients appear to improve
when azathioprine is discontinued and use
of prednisone is started on postoperative
day 14; one patient has been documented
as having elevated levels of circulating
immune complexes and decreased serum
complement (unpublished data).
Infection during the initial hospitaliza
tion has been of grave concern, particu
larly in recipients who had an implanta
tion response. Table I documents only a
modest number of non-fatal infectious
episodes. Scrupulous donor selection,
vigorous investigation and surveillance
for infection, use of antibiotics prophylactically and in many instances, pro
longed use of broad-spectrum antibiotics
during the implantation response likely
contributed to the relatively low fre
quency of infectious episodes. Localized
bronchiectasis with recurrent episodes of
pneumonia have developed in two long
term survivors but no malignant process
has been found.
Summary

In summary, 13 of 19 patients are alive
1 to 38 months after heart-lung transplan
tation. Notwithstanding the important
efforts by the many investigators involved
with the heart-lung transplantation pro
gram, none of this would be possible were
it not for the unique immunosuppressive
properties of cyclosporine.
Experience with the use of cyclosporine
in both heart and heart-lung transplan
tation indicates that when used in com
bination with low doses of prednisone,
important improvement in allograft sur
vival can be achieved. That both early and
late rejection (cellular and humoral) and
infection still occur in both groups of
patients, along with hypertension and
renal dysfunction secondary to cyclospo
rine use, demands that we continue our
efforts to control the immune system and
eliminate unwanted drug side effects.
Addendum
As of January 1985, 352 heart allografts had
been placed in 325 recipients, and 24 patients
had received 25 heart-lung transplants.
Conclusions based on data generated as of
January and March 1984 for the two groups
respectively, with regard to survival and
complications, still applied and they support
the continued use of cyclosporine, with the
guidelines suggested to minimize toxicity. In
some patients with declining renal function,
azathioprine may have to replace cyclosporine
for immunosuppression.
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Prescribing Information

Marcaine*

(bupivacaine hydrochloride injection U.S.P.).
In d ic atio n s:

Peripheral nerve block including retrobulbar block, infiltration, sympa
thetic blockade, caudal, epidural, and pudendal blocks.
C o n tra in d ic a tio n s :

Bupivacaine is contraindicated in persons with known sensitivity to
local anesthetics o f the amide type.
The use of bupivacaine is contraindicated in the presence of sepsis
near the site of proposed injection, in severe shock and in heart block.
W arnings:

Usage in Pregnancy: There are no adequate and well-controlled studies
in pregnant w omen o f the effect of bupivacaine on the developing
fetus. Decreased pup survival in rats and an embryocidal effect in rab
bits have been observed when bupivacaine hydrochloride was adminis
tered to these species in doses comparable to nine and five times
respectively the m axim um recommended daily human dose (400 mg).
Bupivacaine h ydrochloride should be used during pregnancy only if the
potential benefit justifies the potential risk to the fetus. This does not
exclude the use of Marcaine 0.25% or 0.50% at term fo r obstetrical
anesthesia or analgesia.
Obstetrics: The highest (0.75%) concentration is not recommended for
obstetrical anesthesia. There have been reports of cardiac arrest with
difficult resuscitation o r death following its use for epidural anesthesia
in obstetrical patients.
Due to the high risk to the fetus, paracervical block is no longer recom 
mended.
The obstetrician is warned that severe persistent hypertension may
occur after adm inistration of certain oxytocic drugs, if vasopressors
have already been used during labor (e.g. in the local anesthetic solu
tion or to correct hypotension).
Until further experience is gained in children younger than 12 years,
administration of bupivacaine in this age group is not recommended.
P re c a u tio n s :

Marcaine (bupivacaine) should be used cautiously in persons with
known drug allergies o r sensitivities, particularly to the amide-type local
anesthetics.
Caution is advised in administration of repeat doses of bupivacaine to
patients with severe liver disease.
The lowest dosage th a t gives effective anesthesia should be used, to
avoid high plasma levels and serious systemic side effects. Injection of
repeated doses o f bupivacaine may cause a significant increase in
blood levels due to accumulation of the drug or its metabolites or slow
metabolic degradation.
Tolerance varies w ith th e status of the patient. Debilitated, elderly and
acutely ill patients m ay require reduced doses commensurate with age
and physical condition.
It should be rem em bered that solutions containing a vasopressor
agent, e.g. epinephrine, should be used with caution, if at all, in patients
who are receiving m onoam ine oxidase inhibitors or anti-depressants
o f the triptyline or im ipram m e type, because severe, prolonged hyper
tension may result. Dose-related cardiac arrhythmias may occur if
preparations containing epinephrine are employed in patients during or
immediately follow ing the administration of chloroform, halothane,
cyclopropane, trichloroethylene or other related agents. In deciding
whether to use these products concurrently in the same patient,
the combined action o f both agents upon the myocardium, the concen
tration and volum e o f vasoconstrictor used, and the tim e since injec
tion, when applicable, should be taken into account.
The decision to use a local anesthetic containing a vasoconstrictor in
areas with a lim ited blood supply or in patients with peripheral vascular
disease, will depend on th e physician’s appraisal of the relative advan
tages and risks.
Local anesthetics which contain preservatives, i.e. those supplied in mul
tiple dose vials, should not be used for caudal or epidural anesthesia.
Epidural Use: It is advised that a test dose, generally 2-3 mL of 0.5%
bupivacaine (or other am ide anesthetic) containing 1:200,000 epine
phrine (10-15 m icrogram s) be administered to check that the spinal
canal or a blood vessel has not been entered while locating the epidural
needle or catheter.
In the event of spinal injection clinical signs of spinal block would
become evident in a few minutes.
In the event of intravascular injection a transient increase in pulse rate
and possibly m om entary increase in systolic blood pressure are
usually detectable w ith a monitor. The other symptoms and signs of
"epinephrine response” are less dependable. The effects of other m edi
cation the patient has received may m odify this response.
When reinforcing doses are required the te st dose should be used
again to check the catheter location.
Use in Ophthalmic Surgery: When Marcaine 0.75% is used for retrobulbar block, com plete corneal anesthesia usually precedes onset of clini
cally acceptable external ocular muscle akinesia. Therefore, presence
of akinesia rather than anesthesia alone should determine readiness of
the patient fo r surgery.

nervous system and the cardiovascular system. The central nervous
system effects are characterized by excitation or depression. The first
manifestation may be nervousness, dizziness, blurred vision, or tre 
mors, followed by drowsiness, convulsions, unconsciousness, and pos
sibly respiratory arrest. Since excitement may be transient o r absent,
the first manifestation may be drowsiness, sometimes m erging into
unconsciousness and respiratory arrest.
Other central nervous system effects may be nausea, vomiting, chills,
constriction of the pupils, or tinnitus. The cardiovascular m anifesta
tions of excessive plasma levels may include depression of the myocardium, blood pressure changes (usually hypotension), and cardiac
arrest. Recent clinical reports and animal studies suggest this may be
m ore likely to occur with the long acting amide local anesthetics such
as bupivacaine.
Allergic reactions are characterized by cutaneous lesions (e.g. urticaria,
edema) and other manifestations of allergy.
Reactions following epidural or caudal anesthesia may include: high or
total spinal block, urinary retention; fecal incontinence, loss o f perineal
sensation and sexual function; persistent analgesia, paresthesia, and
paralysis of the lower extremities; headache and backache; and slow
ing o f labor and increased incidence of forceps delivery.
It should be noted that reactions due to systemic absorption may be
slow o r rapid in onset. Those of rapid onset include respiratory depres
sion, cardiovascular collapse and cardiac arrest. This type of reaction
necessitates a high degree of preparedness since it can occur with little
warning.
In co-ordinated studies o f 3 200 procedures carried out by 15 investiga
tors, there were 2 severe systemic reactions. Both patients experienced
convulsions as a result of inadvertent vascular injection.
Fetal bradycardia has been observed with the use of bupivacaine. Most
cases, including a few fatalities, occurred when the paracervical route
was used (see "Warnings").
In some subjects bupivacaine may produce marked peripheral vaso
constriction in unanesthetized areas which may last for several hours.
T r e a tm e n t o f O ve rd o se an d S e v e re R eac tions:

Toxic effects of local anesthetics require symptomatic treatm ent; there
is no specific cure. The physician should be prepared to maintain an
airway and to support ventilation with oxygen and assisted or con
trolled respiration as required. Supportive treatment of the cardiovas
cular system includes intravenous fluids and, when appropriate, vaso
pressors (preferably those that stimulate the myocardium).
Convulsions may be controlled with oxygen and intravenous adm inis
tration, in small increments, o f a barbiturate or muscle relaxant, as
follows: preferably, an ultra short-acting barbiturate such as thiopental
or thiamylal; if this is not available, a short-acting barbiturate (e.g. seco
barbital or pentobarbital) or a short-acting muscle relaxant (succinylcholme). Intravenous muscle relaxants and barbiturates should only be
administered by those familiar with their use.
D o s a g e an d A d m in is tra tio n :

The duration of anesthesia with bupivacaine is such that, fo r m ost p ro 
cedures, a single dose is sufficient. Maximum dosage limit m ust be indi
vidualized in each case after evaluating the size and physical status of
the patient, as well as the usual rate of systemic absorption from a par
ticular injection site. Most experience to date is with single doses of
bupivacaine up to 225 mg with epinephrine 1:200,000, and 175 mg
w ithout epinephrine; more o r less drug may be used depending on indi
vidualization of each case.
At present there is insufficient clinical evidence with multiple dosage or
interm ittent dose techniques to perm it precise recommendations for
such procedures to be given. However, limited clinical experience in this
area o f use indicates that bupivacaine may be repeated in 3 to 6 hours
up to a maximum dose o f 4 00 mg in 24 hours. In most cases the dura
tion o f anesthetic effect is prolonged by the addition of epinephrine.
The following doses have generally proved satisfactory for the average
adult. They may require adjustment in relation to age and the physical
condition of the patient.
Local infiltration: up to a maximum dosage of 0.25% solution.
Peripheral n e r\^ block: 5 to 30 mL of 0.50% or 5 to 60 mL of 0.25%
solution.
Sympathetic: 20 to 50 mL o f a 0.25% solution,
r pldural: 10 to 20 mL of a 0.25%, 0.50%, or 0.75% t solution.
Caudal: 15 to 30 mL of a 0.25% or 0.50% solution,
tO .75% not recommended for obstetric use.
S u p p lie d :

Each 2 0 mL single dose vial contains: bupivacaine 0.25%, 0.50% or
0 . 7 5 . with or without epinephrine 1:200,000. Boxes of 5 vials.
Each 50 mL multiple dose vial contains: bupivacaine 0.25% or 0.50%.
Boxes o f 1 vial.
Note: Bupivacaine solutions without epinephrine may be autoclaved.
Product Monograph available on request.
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A d v e rs e R e a c tio n s :

Reactions to bupivacaine are characteristic o f those associated with
amide-type local anesthetics. A major cause of adverse reactions to
this group o f drugs is excessive plasma levels, which may be due to
jv e r dosage, inadvertent intravascular injection, or slow metabolic
degradation. Other causes o f reactions to these local anesthetics may
be hypersensitivity, idiosyncrasy, or diminished tolerance.
..xcessive plasma levels cause systemic reactions involving the central
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Cost of Coronary Artery Bypass Surgery: a Pilot Study
The increasing concern about the high
cost of health care led the authors to
conduct a pilot study on the overall cost
and cost variability for patients who
underwent coronary artery bypass graft
ing. They reviewed the charts of 50 ran
domly selected patients to determine
actual costs of catheterization and
bypass grafting. Four patients had singlevessel disease, 12 double- and 34 triple
vessel disease and 13 had moderate to
severe impairment of ventricular func
tion. The length of hospital stay ranged
from 8 to 43 days (mean 16.5 days).
The duration of stay in the recovery
room and intensive care unit ranged from
21 to 356 hours (mean 91 .6 hours).
Operative time ranged from 2 to 6.5
hours (mean 3.9 5 hours). Using several
accepted cost-allocation methods, the
authors developed a valid, complete
breakdown of clinical and nonclinical
costs. Total cost was directly related to
the length of hospital stay, left ventricu
lar function, secondary diagnosis and
number of diseased vessels. Further
studies will address clinical factors
related to cost and cost effectiveness of
coronary artery bypass grafting as
opposed to other forms of treatment for
coronary artery disease.
Les couts eleves des soins de sante font
I'objet d'un souci croissant. Les auteurs
ont done mene une etude pilote des
couts globaux et de leur variation chez
des patients soumis a un pontage aortocoronarien. Its ont etudie les dossiers de
50 patients choisis au hasard afin d'etablir les couts d'un catheterisme et d'un
pontage. L'oblit6ration coronarienne etait
simple chez 4 patients, double chez 12
et triple chez 34; 13 malades presen-
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taient une insuffisance ventriculaire
moyenne a severe. La duree d'hospitalisation a varie de 8 a 43 jours (16.5 jours
en moyenne). Le sejour en salle de reveil
et aux soins intensifs a dure de 21 a
356 heures (moyenne de 9 1 .6 heures).
L'operation a dure de 2 a 6 .5 heures
(moyenne de 3.95 heures). A I'aide de
plusieurs methodes de facturation reconnue, les auteurs ont etabli une repartition
complete et acceptable des couts cliniques et non cliniques. Le cout total etait
directement relie a la duree du sejour a
I'hopital. a I'etat de la fonction ventricu
laire gauche, aux diagnostics secondaires
et au nombre de pontages requis. Des
etudes subsequentes s'interesseront aux
facteurs cliniques relies aux couts et au
rapport couts/benefices du pontage
aorto-coronarien par rapport a d'autres
formes de traitement de la maladie coro
narienne.

The high cost of health care is causing
increasing concern to the public, govern
ment and health-care professionals. Coro
nary artery disease, particularly its sur
gical treatment, places an enormous
burden on all. The University of Ottawa
Heart Institute, in conjunction with the
Health Administration Program of the
Faculty of Administration, University of
Ottawa, has embarked on studies to
determine the cost and cost effectiveness
of coronary artery bypass grafting. The
first step has been a pilot study to deter
mine the overall cost and cost variability
for patients who undergo bypass grafting.
The question of the cost of heart surgery
is of interest in Canada because we lack
the basic data for public decision-making
about funding for increases or changes,
or both, in this area. The lack of data is
common to the health-care system in all
provinces and has specific impact on
cardiovascular disease, Canada’s number
one health-care problem. It is well recog
nized how widely costs vary among
health-care institutions, even among those
providing a similar type or range of serv
ices. While such institutions may face
identical market prices for their goods
and services, the degree of efficiency in

the use of resources will ultimately deter
mine the net cost of care. Identifying and
measuring the many interrelated input
factors and tracing the connection
between them and specific medical serv
ices require a tailored approach in each
health-care facility. To complicate cost
analysis further, and this is especially true
of hospitals, management systems are not
designed to provide the requisite informa
tion. Accounting procedures typically
aggregate costs, so that it is difficult to
determine the relation between resource
consumption and production of those
resources. Cost analysis must often start
at the bottom and work up, adapting the
methodology to the obstacles of incom
plete, invalid or inaccurate primary data.

Methodology
The University of Ottawa Heart Insti
tute at the Ottawa Civic Hospital is a free
standing structure devoted to the preven
tion, investigation, treatment — both
medical and surgical — and the rehabili
tation of patients with cardiovascular dis
ease. It has 125 set-up beds, including
8 surgical and 8 medical intensive-care
beds with an additional 6 recovery room
beds, 8 day-care and 4 emergency resus
citation beds. We perform more than
1000 operative procedures annually of
which 750 are bypass grafting.
Cost for the services provided for
patients who undergo coronary artery
bypass grafting were determined accord
ing to accepted disease-costing methodol
ogy.1 The first step was to design a costcentre matrix that integrated six arbitrary
stages of the patient’s hospital stay into
admission, preoperative, ward, operating
room, recovery room and surgical inten
sive care, and postoperative ward and dis
charge. With the hospital cost centres
defined in previous research at the Ottawa
Civic Hospital,2 these cost centres were
divided into three categories: support
departments, diagnostic and therapeutic
departments and patient-care depart
ments. All hospital operating costs and
treatment elements applicable to the
procedure were identified and classified
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as direct, indirect or overhead. Costs were
assigned to an individual patient and
aggregated to obtain the cost of an epi
sode of illness for coronary artery bypass
grafting (Fig. I).3 The cost of labour on
the wards before and after operation was
determined using a work-sampling ratio
delay study over a 7-day period.4'5 The
hospital charts of 50 randomly selected
patients who underwent coronary artery
bypass were reviewed in detail to deter
mine the actual cost of admission for
catheterization or separate admission for
operation, or both. Professional fees were
determined by recording the actual
amounts reimbursed by the provincial
government plans to the medical staff
involved in the treatment: surgeons,
anesthetists, surgical assistants, cardiol
ogists and radiologists.
Clinical Profile o f Patients
We reviewed the charts of 50 patients
(42 men, 8 women) who underwent coro
nary artery bypass grafting between April

and September 1983, excluding patients
who underwent reoperation or who died
in hospital. The mean age of the patients
was 55.3 years (ranging from 39 to 73
years). This is representative of the male
to female ratio and age range of our total
patient population. Four patients had
single-vessel, 12 double-vessel and 34
triple-vessel disease. Seven had been oper
ated upon urgently and 43 electively.
Thirteen had poor ventricular function
(class III or IV6) and the remaining 37
had normal function or mild impairment.
Seven patients underwent additional
procedures: coronary endarterectomy in
six and left ventricular aneurysm resec
tion in one; two patients required intra
aortic balloon pump assistance early
postoperatively. The total length of hospi
tal stay including the stay for cardiac
catheterization averaged 16.5 days (rang
ing from 8 to 43 days).
Total Episode Cost
An episode of illness for this costing

study is defined as a stay in hospital for
the surgical procedure and separate
admission for cardiac catheterization.
Twenty-five patients underwent catheteri
zation during the admission for opera
tion, three had catheterization as outpa
tients and one at a different hospital (that
single procedure was not costed). The epi
sode costs are the total costs for all treat
ment elements during the hospital stay.
The total costs varied from $6387. to
$18 415. (Canadian 1983 dollars) with an
average cost of $9595. This total com
prises two parts: professional fees and
hospital costs.
The hospital costs were broken down
into five categories: cardiac catheteriza
tion; laboratory, radiologic and phar
maceutical expenses; surgical ward
(including preoperative coronary care
unit); operative procedure; recovery room
and surgical intensive care unit. The mini
mum, maximum and mean costs in each
of these subcategories are summarized in
Table I.
The total episode cost, not surprisingly,
was directly related to length of hospital
stay (Table II). It was also directly related
to the number of diseased vessels, secon
dary diagnoses, left ventricular dysfunc
tion and age (Table III). It was not related
to sex, emergency category of a patient,
number of bypass grafts placed or aux
iliary procedures performed.
Discussion

FIG- 1—Direct method of cost allocation. CABG = coronary artery bypass grafting.

T a b le
C a te g o ry

— H o s p it a l C o s ts
M in im u m , $

M a x im u m , $

_

_

C a t h e t e r iz a tio n
L a b o r a t o r y , r a d io lo g y , p h a rm a c y
S u r g ic a l w a r d in c lu d in g c o ro n a r y c a re u n it
C o r o n a r y c a re u n it a lo n e , p re o p

349
1 205
474

M ean, $
409*
555

1 621
11 8 2 8
9 006

2 750

8 894

3 629
1 817

1 828

O p e ra tio n a n d r e c o v e r y ro o m
- s u r g i c a l in t e n s iv e c a re u n it
O p e ra tio n a lon e

2 332
1 700

1 943

* 0 n e c h a rg e o n ly .

T a b le II— E p iso d e C o s t V e r s u s L e n g th o f H o s p it a l S t a y
L e n g th o f
s ta y , d
9
1 0 -1 2
1 4 16
1 7 -1 9
2 0 -2 9
3 0 -4 3
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No.
5
15
6
7
10
3

6
6
8
7

Range, $

M ean, $

389- 8
9 4 9 -1 6
4 5 8 -1 0
5 6 8 -1 0

7
9
9
9
13

143
183
363
804

8 9 3 1 -1 8 4 1 5
10 8 7 2 - 1 4 9 9 7

584
319
702
126
067

13 159

Establishing a firm estimate for the sur
gical cost of treatment for coronary artery
disease is the first step in analysing cost
effectiveness. We carried out a detailed
study of the cost of treating 50 patients
who underwent coronary artery bypass
grafting. Fig. 2 shows the distribution of
total costs ranging from the lowest to the
highest for each patient. For the first time
we know the actual costs of treating a
group of patients who had heart surgery
in Canada. We studied the treatment
process for patients who underwent coro
nary artery bypass grafting, carrying out
a detailed cost analysis in every depart
ment of the hospital participating in their
treatment. We studied their cost patterns
and developed unit costs for every iden
tifiable component of patient care as it
appeared on the patient’s medical chart
and others such as administrative, over
head and capital equipment costs that
were not recorded on the charts. We
covered all direct and indirect aspects of
care. These costs were then used together
with a detailed chart review to develop an
accounting for each patient.
In two other detailed costing studies
done in the United States, the method of
costing and reimbursement for patients’
services was different from our own.7'8
However, a broad comparison is possi
ble after adding an annual inflationary
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factor (10%) and converting American to
1983 Canadian dollars (25%). Although
the institutions and the methodology were
different, professional fees remain at a
fairly constant percentage of the total
hospital cost (Table IV), with professional
fees representing 20% to 30% and hospi
tal charges 70% to 80% of total costs.
Stoney and colleagues,8 reporting from
Vanderbilt University School of Medicine
in Nashville, showed a considerable
difference in hospital costs when they
were subdivided. Most notably, nursing
costs on the ward were half our costs,
operating room expenses twice, catheteri
zation procedures three times and blood
16 times our costs. It must be noted,
however, that the cost of $21 per patient
for blood in our institute refers only to
the charges for cross-matching since the
blood itself is free of charge. In a more
recent A m erican study, Jang and
colleagues9 compared the cost of surgery
for single-vessel disease as opposed to per
cutaneous transluminal coronary angio
plasty and quoted a cost for coronary
artery bypass grafting of $15 580 in 1983
US dollars. There are no published Cana
dian costing studies in this area.

This pilot study is our first step towards
dealing with disease costing and analysis
of cost effectiveness at the University of
Ottawa Heart Institute. We expect to
refine further the costing components of
care and to develop a patient care infor
mation system that will generate data for
medical peer review. This will be of use
in discussions of both the medical and
economic aspects and will eventually lead
to a study of the cost effectiveness of
alternative forms of treatment for coro
nary artery disease.
H ospital inform ation systems in
Canada are in their infancy in the area of
clinical patient information systems. With
the development of cost data, not only
will physicians and surgeons be able to
present their cases from the clinical point
of view, but they will also have the pre
cise cost data with which to judge the eco
nomic implications of their decisions to
use one form of investigation and treat
ment as opposed to another. An exam
ple of the potential for such knowledge
is the development of a system for
estimating the day of discharge, focusing
on expeditious treatment and discharge of
patients and thus reducing unnecessarily

Table III—Variables Affecting Episode Cost
Range of cost, $
No.

Variable
Age, yr
37-49
50-59
60-73
No. of diseased vessels
1
2
3
Left ventricular function
Poor
Good
Secondary diagnoses
Diabetes
Hypertension
Peripheral vascular disease
Transient ischemic attacks
Chronic obstructive pulmonary disease
Total secondary diagnosis
Coronary artery disease alone

Mean cost, $

15
17
18

6 387-16 183
7 329-16 224
7 317-18 415

8 616
9 603
10 404

4
12
34

6 387- 8 143
7 329-18 415
6 949-16 224

7 624
9319
9 702

13
37

7 341-14 998
6 387-18 415

10 196
9 383

6
5
5
2
2
20
30

6 387-13 174
7 979-14 999
7 317- 8 885
8 303- 9 154
16 225-18 415
6 387-18 415
6 949-16 412

11 059
10 599
7 905
8 728
17 320
10 549
8 495

Table IV —Comparison of Hospital Costs (1983 Canadian Dollars)
Loma Linda,*9 $
Ottawa, $
Birmingham,7 $
Nashville,8 $
—
2
749
1
268
Ward
—
474
684
Intensive care unit/d
—
46
254
Electrocardiogram
3 600
1 800
—
3 729
Operating room
—
—
408
1 151
Catheterization
21
—
324
Blood
—
—
117
160
Radiology
144(1.5%)
800 (4.4%)
Pharmacy
6 130(31%)
2 254 (23.5%)
3 860 (20.6%)
6 344(30%)
Professional fees
13 350(69%)
7 345 (76.5%)
14 104(75%)
14 983(70%)
Total in hospital
19 480
9 595
18 764
21 332
Total/episode
‘ Combined national study.

lengthy stays to which cost is directly
related. This frees up beds to allow flexi
bility in the flow of patients. Other alter
natives to investigate are the performance
of cardiac catheterizations on an outpa
tient basis and the provision of lessexpensive hostel-type inpatient care for
patients from out of town or for those
with minor complications who do not
require the resources of the normal inpa
tient facilities.
One area of continuing concern is
whether particular courses of treatment
have long-term cost benefits for the
individual patient and for society as a
whole. So far, we have simply addressed
ourselves to the cost of one mode of treat
ment. However, the proposed research
will encompass the broader questions.
The objective is to continue to treat
patients as effectively, but also as eco
nomically, as possible. The added bonus
of a clinical information system would be
for administrative use in planning patient
load and workloads in each department
and institution as well as in budgeting and
forecasting.
The days of open-ended financial atti
tudes on planning health care have
passed. Improvements must come from
within the system and be initiated by the
physicians and surgeons concerned and
must not be imposed by the funding bod
ies. Accurate and responsible disease cost
ing studies are a prerequisite to this intel
ligent planning.
We thank Jann Darlington, David Kay,
John MacIntyre, Janie Reed and Melissa Sonberg, master’s degree students in the Health
Administration Program, and Mrs. Katrin
Smith, Research Assistant, University of
Ottawa Heart Institute, for their assistance in
this study.

Cost

FIG. 2—Variability of costs of coronary
artery bypass grafting for each of 50 patients.
1 = cost of coronary angiography (+ separate
stay), 2 = laboratory, radiologic and phar
maceutical costs, 3 = surgical ward nursing,
4 = cost in coronary care unit preoperatively,
5 = recovery room and surgical intensive care
unit costs, 6 = professional fees.
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Liver Transplantation: the Initial Experience
of a Canadian Centre
At the University Hospital in London,
Ont., 19 patients have received 24 liver
transplants. The commonest indications
for transplantation were primary biliary
cirrhosis and cirrhosis from chronic
active hepatitis. The first three patients
in the series died of infectious complica
tions. Eleven of the subsequent 16
recipients are alive from 5 months to
years after transplantation. Eight
patients who are alive more than 1 year
after the operation have an excellent
quality of life. Cyclosporine and steroids
in combination are used for immunosup
pression.
With current surgical techniques,
modern immunosuppression and good
patient selection, the restoration of
patients with advanced irreversible liver
disease to good health by liver transplan
tation is a realistic goal. Much effort and
considerable resources are required to
run a liver transplant program.

2'h

A I'Hospitalier Universitaire de London,
Ont., 24 transplantations de foie ont ete
executees dans 19 beneficiaires. Les
indications les plus communes pour la

transplantation etaient le cirrhose biliaire
primaire et le cirrhose resultant de
I'hepatite active chronique. Les trois pre
miers patients de la serie moururent de
complications infectieuses. Onze des 16
destinataires ulterieurs sont actuellement
vivants apres des periodes d'entre 5
mois et 2 'A ans apres la transplanta
tion. Huit patients sont vivants apr&s
plus d'un an, et la qualite de leur vie est
excellente. L'immunosuppression em
ployee actuellement est une combinaison
de cyclosporine et de steroides.
A cause des techniques actuelles de
chirurgie, et de l'immunosuppression
moderne, ainsi que d'une selection particuli&rement efficace de patients, le retablissement a la bonne sante des patients
souffrant de maladies de foie irreversibles par la transplantation de foie est un
but realiste. L'effort et les ressources
necessaires a mettre sur pied un pro
gramme de transplantation sont en effet
importants.

transplantation at University Hospital in
London, Ont., that now includes trans
plantations of heart, heart-lung and pan
creas.3-4 This report details our
experience to date in transplantation of
the liver.
Patients

Twenty-four orthotopic liver trans
plants have been performed in 19 patients
(13 females, 6 males) (Table I). Three
patients received two transplants and one
patient received three. The recipients
ranged in age from 14 to 58 years. The
majority had primary biliary cirrhosis or
cirrhosis from chronic active hepatitis
(surface antigen negative) (Tables II and
III). Recipients with a chronic liver
condition had advanced disease with
uncontrolled ascites, hypoalbuminemia,
malnutrition, increasing jaundice, coagu
lopathy and encephalopathy in spite of
ideal medical therapy. Two patients had
previously undergone portacaval shunt
ing for bleeding esophageal varices. Six
teen of the 19 recipients were hospitalized
while awaiting transplantation because
they were too sick to be managed at
home. Transplantation was not recom
mended to patients with chronic liver dis
ease until it seemed that life expectancy
was measured in months or less. Three
patients had acute liver failure from
extensive liver necrosis and were trans-

Almost 1000 human liver transplants have
been performed since Starzl’s first report
more than 20 years ago.1 The early
procedures were plagued by technical
complications, uncontrollable bleeding,
From the *Department o f Surgery,
infection and poor organ preservation, all
t Department o f Medicine and XDepartment
of
which resulted in high operative mor
o f Anesthesia, University Hospital, Univer
tality
and morbidity. Recently, however,
sity o f Western Ontario, London, Ont.
results have improved substantially and
Supported in part by grant M230A1 from
1-year survival rates following liver trans
the Medical Research Council o f Canada
plantation
now approximate 70% in
and the Richard and Jean Ivey Fund
experienced hands.2 The main reasons
for the improved results have been bet
Presented at the annual meeting o f the
Canadian Transplantation Society, Mon
ter immunosuppression and more critical
treal, PQ, Sept. 13, 1984, held in conjunc
selection of recipients.
tion with the 53rd annual meeting o f the
In the late 1970s we became convinced
Royal College o f Physicians and Surgeons
that some individuals with certain types
o f Canada
of liver disease could benefit from liver
Accepted for publication Jan. 29, 1985
transplantation. We believed that there
was a need for this service in our area and
Reprint requests to: Dr. William J. Wall,
that the results justified starting a pro
Department o f Surgery, University Hospi
tal, PO Box 5339, Station A, London,
gram.
This was an expansion of an
Ont. N6A 5A5
already established program in renal
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T a b le 1— L iv e r T r a n s p l a n t s

Year

N o. of

N o. of

r e c ip ie n t s

s u rv iv o rs

1977

1

1978

1

0

1981

1

0

0

1982

1

1

1983

4

3

1984

11

7

T o t a ls

19

11

planted when they were in grade 4 liver
coma, were ventilator-dependent, and
had associated renal failure. The patients
with acute liver failure were deemed to be
dying and would not survive without a
transplant. Important considerations in
selecting patients were a stable psychoso
cial background and the absence of car
diopulmonary disease. Only one patient
with malignant disease received a trans
plant. She had a multifocal, fibrolamellar hepatoma that was shown grossly to
be confined to the liver.
Donor Operation

Livers were removed from donors in
whom brain death had occurred as a
result of head trauma or spontaneous
intracranial hemorrhage. In 17 cases the
donors were in hospitals outside London
and the transplant team travelled to the
donor hospital to remove the liver. The
round-trip distances travelled by the
donor team ranged from 290 to 3520 km.
Livers were preserved in ice-cold Collins
solution, using the in-situ flush technique
and hypothermic storage.5 The preserva
tion times of the donor livers ranged from
1 h 51 min to 5 h 21 min (average 3 h 54
min). With one exception the kidneys
were also removed from each liver donor
for transplantation and in five of the
donors the heart was also used for trans
plantation. The liver donors were bloodgroup compatible with the recipients but
no other tissue matching was attempted.
Recipient Operation

doses were aimed at maintaining serum
trough levels of 150 to 200 ng/mL in the
immediate postoperative period. Several
months after transplantation, main
tenance levels of 80 to 150 ng/mL were
accepted. Serum levels were monitored by
radioimmunoassay. Recently, concurrent
high-pressure liquid chromatography
(HPLC) assay has been used as a better
indicator of parent compound only.6
Methylprednisolone, 500 mg, was given
intraoperatively after revascularization of
the liver. Post operatively, prednisone, 1
mg/kg daily, was given, tapering to 0.2
mg/kg daily by the fourth or fifth week.
Rejection episodes were treated by bolus
steroid therapy consisting of 250 to 500
mg of methylprednisolone daily for 3
days. Steroid-resistant rejection was
treated with Minnesota equine antilym
phocyte globulin (15 to 20 mg/kg daily)
for 7 to 10 days, aiming to keep the blood

T a b le I I — D a ta o n 1 1
P a t ie n t

lymphocyte count at 100 to 200 cells/mL.
Rejection was diagnosed by a sudden
increase in serum bilirubin and amino
transferase levels, accompanied by posi
tive immunologic responses in the
recipient.7 Liver biopsies were performed
selectively in patients whose rejection was
difficult or impossible to reverse.
Results

The first three patients in the series died
of overwhelming fungal infections
between 1 and 3 months after transplan
tation. Two of them (nos. 1 and 3) had
bacterial infections following transplan
tation and required prolonged antibiotic
therapy which resulted in fatal oppor
tunistic Candida infections. The third
patient (no. 2) had an undiagnosed cryptococcal meningitis before transplanta
tion, complicating her liver coma; the

S u r v iv o r s o f L iv e r T r a n s p la n t a t io n

Age,
Com m ent

D is e a s e

no.

yr

S ex

4

26

F

C h ro n ic a c t iv e h e p a t i t is

A liv e a n d w e ll a t 3 0 m o , a t w o r k

5

29

F

C h r o n ic a c t iv e h e p a t i t is

A liv e a n d w e l l a t 2 6 m o , a t w o r k ( n u r s e ),

6

30

F

B ilia ry h y p o p la s ia a n d c irrh o s is

A liv e a n d w e l l a t 2 2 m o , a t w o r k

( r a d io g r a p h e r ), n o r m a l liv e r f u n c t i o n
n o r m a l liv e r f u n c t io n
(s a le s c le r k a n d h o u s e w i f e ) , n o r m a l liv e r
f u n c t io n
7

39

M

P o s t n e c r o t ic c ir r h o s is

A liv e a n d w e ll a t 1 8 m o , a t w o r k

9

56

M

P r im a r y b ilia ry c ir r h o s is

A liv e a n d w e l l a t 1 5 m o , a t w o r k

( r e s t a u r a n t m a n a g e r ) , n o rm a l liv e r f u n c tio n
( a c c o u n t a n t ) , d e v e lo p e d h e p a t i t is B 6 m o
a f t e r t r a n s p la n t , m ild ja u n d ic e
10

50

M

P r im a r y b ilia ry c ir r h o s is

A liv e a t 1 3 m o , a t h o m e , r e c e iv e d t w o
m o re t r a n s p la n t s b e c a u s e o f r e je c t io n .

The diseased recipient liver was
removed and the donor organ placed in
the orthotopic position. No pumping or
venous bypass was used. The vascular
anastomoses were performed in the fol
lowing sequence: suprahepatic vena cava,
portal vein, infrahepatic vena cava and
hepatic artery. The bile duct was
anastomosed end-to-end without a stent
in all cases but one. One patient (no. 6)
had a duct-to-Roux loop as a primary
procedure. A fine polyethylene catheter
was left in the common duct or gallblad
der, or both, for postoperative cholan
giography. The recipient anesthesia time
ranged from 5 h 55 min to 10 h 55 min
(average 7 h 24 min).
Immunosuppression

The first two patients in the series
received Imuran and steroids for
immunosuppression. All subsequent
recipients received cyclosporine and
steroids. Cyclosporine was given
intravenously (2 to 3 mg/kg daily) after
operation until the recipients could take
it by mouth (10 to 15 mg/kg daily) in two
divided doses, usually at the end of the
first week after operation. Cyclosporine

Now

5 m o a f t e r t h ir d t r a n s p la n t w i t h

n o r m a l liv e r f u n c t io n
11

44

M

S c le r o s in g c h o la n g itis

A liv e a t 1 2 m o , a t w o r k ( e n g in e e r ) ,
r e t r a n s p la n t e d b e c a u s e o f r e je c t io n ,
n o r m a l liv e r f u n c t io n

14

14

M

C h ro n ic a c t iv e h e p a t i t is

A liv e a t 1 2 m o , a t s c h o o l, n o r m a l liv e r

16

34

F

P r im a r y b ilia r y c ir r h o s is

A liv e a t 8 m o , a t h o m e , c h r o n ic r e je c t io n

17

19

F

H e p a to m a

A liv e a t 7 m o , a t h o m e , n o r m a l liv e r f u n c 

19

48

F

P r im a r y b ilia ry c ir r h o s is

A liv e a t 5 m o , a t h o m e

P a t ie n t

Age,

no.

Vt

f u n c t io n
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infection disseminated following the oper a satisfactory recovery at home 5 months four recipients in the early postoperative
ation.
after receiving his third transplant.
period but eventually resolved. Three
Eleven of the subsequent 16 recipients
Biliary tract complications developed patients had mucocutaneous herpes infec
are currently alive (Table II). Of these 11,
in three patients (Table IV): a biliary tions and one patient had a cytomegalovi
7 have returned to work or school and 4 fistula in one and strictures and obstruc rus infection. Three of the four patients
are convalescing at home (1 has chronic tion at the site of the duct-to-duct anasto who had viral infections required antilym
rejection). The patients who have re mosis in two. In each of these patients the phocyte globulin as part of their immu
turned to their previous occupation are biliary drainage was revised to a Roux- nosuppressive therapy. Hirsutism deve
well and have excellent quality of life. The en-Y choledochojejunostomy.
loped in five patients in the cyclosporine
period of convalescence before patients
Six episodes of acute irreversible rejec group and two patients had isolated sei
returned to work or school was usually tion occurred in five patients. Three of zures in the immediate post-transplant
between 4 and 6 months but was as short these patients had another transplant and period. Patient no. 9 suffered from
as 8 weeks after transplantation.
two are alive. Two patients (nos. 8 and cyclosporine nephrotoxicity and hyper
Four patients received more than one
18) died of rejection and liver failure tension so the cyclosporine was replaced
transplant. Patient no. 4, who is alive
before another transplant could be done. by Imuran 4 months after transplan
2 Vi years after operation, required a
The overall incidence of irreversible rejec tation.
second emergency transplant 9 days after tion in cyclosporine-treated patients was
The length of stay in hospital follow
the first because thrombosis of the hepatic 30% (six livers lost from rejection in 20 ing operation is shown in Fig. 1. The
artery and liver infarction occurred. She transplants placed in 17 patients).
mean (± SD) postoperative stay was
is well at present and has normal liver
There have been no long-term survivors 52.3 ± 20.3 days with an average of
function. Two patients (nos. 11 and 12) in the patients transplanted for acute liver
16.6 ± 18 days in the intensive care unit.
required a second transplant because of failure from extensive liver necrosis (nos. Excluding the first three patients in the
rejection. One of them (no. 12) was in
1, 12 and 15). These patients were mori series, the average length of stay after
extremis at the time of the second trans bund when transplanted and although operation was 50.6 ± 20.4 days, with an
plant and died within 24 hours of the each of them had immediate recovery average of 11.6 ± 8.0 days in the inten
operation. The other patient made a good with resolution of coma, correction of sive care unit. The average volume of
recovery following the second procedure;
coagulopathy and reversal of renal blood transfused during surgery was
he remains well and has returned to work.
failure, they died 9, 58 and 102 days after
19.6 ± 19 units. Excluding the two
Patient no. 10 had to be retransplanted
transplantation (Table III). Patient no.
patients with the largest and smallest
‘twice because of rejection; he is making
15, who was transplanted for fulminant,
number of transfusions, the average was
non-A, non-B, viral hepatitis, died when
16.8 ± 8.9 units.
acute massive necrosis and failure of the
Of the 19 recipients, 9 required one or
transplanted liver occurred suddenly 7 more operations in addition to the trans
T a b le IV — S u r g ic a l C o m p lic a tio n s
days after transplantation. Clinically and
plant procedure during the same hospi
in 1 9 L iv e r R e c ip ie n t s
histologically, the injury in the grafted
tal admission.
No. of
liver was similar to that of her original
C o m p lic a t io n
p a t ie n t s
diseased liver.
Discussion
B ilia r y f is t u la
1
Serious bacterial infections have been
B ilia r y s t r ic t u r e
2
infrequent since cyclosporine was intro
The object of liver transplantation is to
W o u n d d e h is c e n c e
2
duced for immunosuppression. Two pa
restore patients with advanced irreversi
P o s t o p e r a t iv e b le e d in g re q u irin g
tients (nos. 3 and 13) in the cyclosporineble liver disease to good health and return
la p a r o t o m y
2
treated group had severe bacterial infec
them to a productive life in the commu
T h r o m b o s is o f h e p a tic a r t e r y
1
tions that eventually proved fatal.
nity. Our experience has shown that this
Troublesome viral infections occurred in
is possible for the majority of such
patients. Indeed, if this were not possi
ble, the value of liver transplantation
would be questionable. The vigour and
well-being these patients have enjoyed
several months after a successful trans
plant has been very encouraging. Because
we have concentrated our efforts on
patients with nonmalignant liver disease,
it is anticipated that those who are alive
1 year after transplantation can look for
ward to many years of worthwhile and
trouble-free survival. Unfortunately,
most patients who have received a liver
transplant for a malignant condition have
had recurrent or metastatic disease, and
cure is unusual.8-9 We are not enthusias
tic about this indication for transplanta
tion, but some patients with welldifferentiated hepatomas appear to be
exceptions and may be considered candi
dates.10
Liver transplantation has its major
therapeutic role in the management of
children with biliary atresia and adults
FKT 1—Postoperative duration of hospitalization for each of 19 liver recipients. Hatched
area indicates time spent in intensive care unit. * = transplanted twice during same admission,
with nonalcoholic cirrhosis, although
* - third liver transplant for this patient, • = second liver transplant for this patient, + = died.
patients with liver disease in many other
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categories may benefit by transplanta
tion.2,11 In general, candidates should be
less than 50 years of age. The timing of
transplantation is particularly crucial in
patients with cirrhosis. Transplantation
needs to be performed before patients
reach a terminal stage when severe mal
nutrition and profound coagulopathy
make them unacceptably high operative
risks. In hindsight, two of our first three
patients were probably too ill to undergo
the procedure. On the other hand, the
operation should not be recommended
too early, when the patient’s quality of
life and prognosis are still relatively good.
Patients with primary biliary cirrhosis are
perhaps the best candidates in this respect
because clinical deterioration is more
progressive and predictable, and choos
ing a time to intervene can be done more
precisely than in some other forms of liver
disease. Patients dying of acute liver
failure are formidable operative risks for
transplantation. The patient and family
need to be clearly informed about the
risks and benefits of the procedure. It is
important for the patient to have a posi
tive attitude and strong self-motivation.
Transplantation for alcoholic cirrhosis
may be considered in those rare individ
uals who have shown their rehabilitation
potential and who abstain from alcohol
for 6 to 12 months but continue to deteri
orate from progression of their liver
disease.
The presence of hepatitis B antigenemia is regarded as a contraindication to
liver transplantation because of reinfec
tion of the grafted liver.12,13 The one
patient in this series in whom fatal hepa
titis developed following transplantation
for non-A non-B hepatitis suggests this
too should be a contraindication to trans
plantation.
The time, effort, resources and com
mitment to run a liver transplant program
are substantial. The operation is long,
technically demanding and allows little
margin for error. Most of the operations
are done during off hours so that regular
operating-room schedules are minimally
disrupted. Operative management is
difficult because of the debilitated state
of the patient’s health and the complex
ity of metabolic and hemodynamic alter
ations inherent in the operation. Post
operative care requires balancing the
intricacies of immunosuppressive therapy
against rejection in patients who are
already at special risk of infection.
Postoperative complications are frequent.
Approximately half the recipients in this
series required additional surgery in the
postoperative period, an experience simi
lar to that reported by Starzl’s group.14
Long distances may need to be travelled
to retrieve donor organs. Patients can
expect to spend 6 to 10 weeks in hospital
following transplantation, although much
of this time is spent in monitoring liver

function and adjusting immunosuppres
sion. The blood bank has to be able to
respond to sudden and unpredictable
demands. An aggressive policy of retran
splantation is necessary when irreversible
rejection occurs. In spite of these factors
and the problems they create, the suc
cesses obtained in liver transplantation are
extremely gratifying. In patients who have
made a good recovery by the time of their
discharge from hospital, follow-up care
is neither extensive nor a burden and the
lifestyle enjoyed by the patients is essen
tially normal.
Cyclosporine has been a major advance
in organ transplantation.1517 We have
used it in combination with steroids,
tapering the steroid dose quickly to low
maintenance doses. The selective immu
nosuppressive effect of cyclosporine on
T lymphocytes appears functionally to
permit control of rejection without seri
ously predisposing to bacterial infection.
This has special importance for liver
recipients who are at high risk of bacterial
infections in the early postoperative
period. In White’s experience18and ours,
cyclosporine is not an easy drug to use
immediately after liver transplantation
when hepatic function is stabilizing but
abnormal. Absorption, metabolism and
excretion of the drug are variable during
this period and calculations of the amount
of drug needed to maintain therapeutic
levels are difficult. Daily adjustment of
the dose is required according to serum
levels. Levels of recirculating metabolites
(detected by radioimmunoassay) can be
high and may not correlate with levels of
the parent compound (as measured by
HPLC assay).6 The 30% incidence of
irreversible rejection in this series reflects
these difficulties. In some of the patients
immunosuppression was undoubtedly
inadequate. We are currently focussing
our attention on the HPLC assay of
cyclosporine in an attempt to provide
ideal immunosuppressive levels of the
drug in liver recipients.
In summary, liver transplantation has
been used to treat patients with advanced
nonalcoholic liver disease. Of 19 patients
transplanted, 11 are alive at 5 months to
2Vi years after the operation. Three
patients required a second and one a third
transplant. Rejection is the commonest
cause of graft failure and remains a
problem despite the use of cyclosporine.
In those who survive, the quality of life
is excellent.

We are grateful to the many residents,
interns, nurses, physiotherapists and other
health-care personnel who participated in the
care of these patients. The liver transplants
could not have been performed without the
superb cooperation provided by the staff of the
donor hospitals. The technical assistance
provided by K. Rycroft, M. Bloch and A. Hellstrom is acknowledged.
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Correction
In the January 1985 issue of the Journal,
in the article “ Head injuries: a prospective,
computerized study” by D. Parkinson, S.
Stephensen and S. Phillips, two references,
not cited in the text, were omitted from the
reference list. On page 80, right-hand
column, under the section “A ge”, the final
sentence that begins “ In children younger
than 9 years...” should read “ Head inju
ries due to traffic accidents occurred most
frequently in pedestrians under 9 years of
age (54. 2%) and over 70 years (52.4%).”
This statement is supported by the follow
ing two references: D o w n s A R , B u r n s
CM: Manitoba accident investigation and
accident health care project. Department
of Surgery, Faculty of Medicine, Univer
sity of Manitoba, February 1980, and
K a l s b e e k WD, M c L a u r i n R L , H a r r i s BS
h i . M i l l e r JD: The National Head and
Spinal Cord Injury Survey: major findings.
J Neurosurg 1980; 53 (suppl): SI9-31.
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BOOK REVIEW S
continued fro m page 271
NEW APPROACHES TO THE STUDY OF
BENIGN PROSTATIC HYPERPLASIA.
Proceedings of the Ninth Brook Lodge
Workshop on Problems in Reproductive
Physiology, held in Augusta, Michigan,
September 26-27, 1983. Edited by Frances
A. Kimball, Allen E. Buhl and Donald B.
Carter. 394 pp. Illust. Alan R. Liss, Inc.,
New Y ork, 1984. $56 (U S). ISBN
0-8451-0145-5.

This book represents the proceedings of a
workshop on problems in reproductive phys
iology held in 1983. Its contents reflect the
varied background of the participants and,
although o f potential interest to a wide
audience, its appeal to the clinician is only
modest. The initial chapters on the etiology,
anatomy and morphogenesis of benign
prostatic hypertrophy are of utmost interest
and are replete with new information relevant
to individuals dealing with this problem. In
addition, the discussion at the end of each
chapter is crisp, direct and helpful in under
standing the concepts expressed by the authors.
The remaining two thirds o f the book are
devoted to results of basic research into
prostatic hyperplasia in vitro and in animal
models. These chapters are highly specialized
and are directed towards individuals with
expertise in biochemistry and endocrinology.
The main interest for the clinical urologist lies
in the compilation of current knowledge on the
basic aspects o f benign prostatic hyperplasia
and the assurance that a great deal of interest
exists in the elucidation of an aging process,
which, according to one of the contributors,
may start during puberty! For the basic scien
tist, on the other hand, there is a wealth of
information that updates the present under
standing of the pathophysiologic mechanisms
involved in the development of benign prostatic
hyperplasia that may be manipulated to stop
or reverse this process. The inescapable con
clusion is that although we have a better under
standing of prostate physiology, the means and
ways to control the development of prostatic
hyperplasia are not yet within our reach.
This volume deserves a place in academic
libraries but its usefulness to the clinician is
limited.
A . M o r a les , m d , f a c s , fr csc
Department of Urology,
Queen’s University,
Kingston, Ont.
K7L 2V7
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ORTHOPAEDICS. Principles and Their
Application. 2 vols. 4th ed. Samuel L.
Turek. 1756 pp. Illust. J.B. Lippincott
Company, Philadelphia, 1984. $125 (US).
ISBN 0-397-50604-X.

The fourth edition of this well-known book on
orthopedic surgery is most welcome. Its pub
lication in two volumes, rather than the one
volume of the previous edition, allows the use
o f larger print and thus easier reading. The
author has updated it consistent with current
knowledge.
Chapter three now includes a discussion of
the progenitor cell principle, with discussion

of the autoradiographic studies of DNA and
RNA. The section on delayed union and
nonunion and the use of electric stimulation
has been well written. Included here is a con
sideration of homogeneous and autogenous
transplantation. The section on osteonecrosis
is also well written. The chapter on collagen
pays particular attention to details and the
references are complete. The chapter dealing
with the blood supply of long bones is new;
this is a most important subject and is well
covered. Chapter eight has a pertinent addi
tion concerning the biophysical properties of
bone and cartilage.
I believe that the short paragraph in chap
ter 11 on the treatment of old subluxation of
the hip should be removed. The new addition
on proximal femoral focal deficiency is per
tinent.
The chapter on rheumatoid arthritis is well
done and informative and has been updated
with regard to the use of nonsteroidal anti
inflammatory drugs and immunosuppressive
agents. Of extreme value is the inclusion in
chapter 14 of the section on compression of
the ulnar nerve at the wrist. The material on
tumours of bone has been revised to a great
extent, with a discussion of new techniques that
adds substance to the chapter. Unfortunately,
computerized axial tomography as an investiga
tive tool was not considered.
I welcome the addition on the surgical treat
ment of Paget’s disease, discussing the prob
lems of surgical intervention and management.
The author has presented valuable and rele
vant material on the small blood vessel supply
of the upper end of the femur. The section on
idiopathic avascular necrosis o f the femoral
head has been expanded. The chapter dealing
with knee ligaments is well documented and has
been expanded, giving a description of the
methods of assessment and reconstruction of
specific ligaments. The section on total knee
arthroplasty has also been updated.
I strongly recommend this textbook to the
orthopedic surgeon in training and in practice.
It is well written and illustrated and it main
tains the high standard of the previous editions.
L eo n H e l l e r , m d , fr csc
Department of Orthopedic Surgery,
The Sir Mortimer B. DavisJewish General Hospital,
Montreal, PQ
H3T 1E2
TEXTBOOK OF DISORDERS AND INJU
RIES OF THE MUSCULOSKELETAL
SYSTEM. An Introduction to Orthopae
dics, Fractures and Joint Injuries, Rheuma
tology, Metabolic Bone Disease and Re
habilitation. 2nd ed. Robert Bruce Salter.
578 pp. Illust. Williams & Wilkins, Balti
more, 1983, $39.75 (US). ISBN 0-68307500-4.

The second edition of Professor Salter’s text
is as welcome to this decade of undergraduate
students and their teachers as was the original
edition. In the foreword, Dr. Paul Curtiss, Edi
tor of the American Journal o f Bone and Joint
Surgery, lists some of the scientific and tech
nical advances that have occurred since the first
edition was published 13 years ago. These
continued page 292
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